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Abstract 
Glycosides are complex carbohydrates that are involved in essential cellular and 
molecular biological processes within all living organisms. In addition, certain 
glycosides have anti-cancer, antioxidant, anti-inflammatory, antibacterial, antiviral, 
antiparasitic and antifungal activities. The functions of glycosides in biological 
processes and in biomedicine have led to a high demand for these organic 
molecules. However, the study of glycosides is hindered by the practical challenges 
in generating these compounds synthetically. This is even more true in the case of 
glycosides bound by means of α-glycosidic bonds, as most of the available synthetic 
methods promote the formation of β-glycosides. Methods that form α-glycosides are 
either low yielding or also promotes β-glycoside formation, resulting in the formation 
of mixtures that are challenging to separate. During the course of this study novel α-
thioglycoligases derived from a CAZy family GH89 α-N-acetylglucosaminidase were 
prepared and characterized for their ability to form α-glycosides through 
biotransformation. The utility of the new biocatalysts was showcased by preparing 
several α-GlcNAc-based glycosides of biomedical and chemical interest. The 
products were purified or modified further through chemical transformations (such as 
“Click”-cycloaddition) and subsequently tested as potential small molecules 
chaperones for the treatment of Sanfilippo syndrome and/or as alternative substrates 
for the MshB, a mycothiol biosynthetic enzyme that has been identified as a potential 
target for development of new antituberculosis agents. Through the discovery of 
these molecules and the development of a new continuous deacetylase enzyme 
assay the findings of this study will significantly strengthen our ability to mobilise α-
GlcNAc-based glycosides as part of ongoing research efforts in these fields. 
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Opsomming 
Glikosiede is komplekse koolhidrate wat betrokke is by noodsaaklike sellulêre en 
molekulêre biologiese prosesse binne alle lewende organismes. Daarbenewens het 
sommige glikosiede ook anti-kanker, anti-oksidant, anti-inflammatoriese, 
antibakteriële, antivirale, antiparasitiese en antifungale aktiwiteite. Die funksies van 
glikosiede in biologiese prosesse en in die biomediese vakgebied het gelei tot 'n 
groot aanvraag vir hierdie organiese molekules. Die studie van glikosiede word egter 
verhinder deur die praktiese uitdagings om hierdie verbindings sinteties te berei. Dit 
is selfs meer waar in die geval van glikosiede gebind deur middel van α-glikosidiese 
bindings, aangesien die meeste van die beskikbare sintetiese metodes die vorming 
van β-glikosiede bevorder. Metodes wat α-glikosiede vorm het óf 'n lae opbrengs óf 
bevorder ook β-glikosied-vorming, wat lei tot die vorming van mengsels wat 
uitdagend is om te skei. Gedurende die verloop van hierdie studie is nuwe α-
tioglikoligases wat afgelei is van 'n CAZy familie GH89 α-N-acetylglucosaminidase 
berei en gekarakteriseer vir hul vermoë om α-glikosiede vorm deur biotransformasie. 
Die nut van die nuwe biokataliste is ten toon gestel deur die voorbereiding verskeie 
α-GlcNAc-gebaseerde glikosiede van biomediese en chemiese belang. Die produkte 
is gesuiwer of verder verander deur chemiese transformasies (soos "Click"-
sikloaddisie reaksies) en daarna getoets as potensiële klein molekule chaperones vir 
die behandeling van Sanfilippo sindroom en/of as alternatiewe substrate vir MshB, 'n 
mikotiol biosintetiese ensiem wat geïdentifiseer is as 'n potensiële teiken vir die 
ontwikkeling van nuwe antituberkulose middels. Deur die ontdekking van hierdie 
molekules en die ontwikkeling van 'n nuwe deurlopende deasetieleringsensiem-essaï 
sal die bevindinge van hierdie studie ons vermoë om α-GlcNAc-gebaseerde 
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Chapter 1: Introduction  
1.1  Introduction 
Glycosides are complex carbohydrates that are comprised of a sugar moiety linked 
either to another sugar moiety or a non-sugar moiety through a glycosidic bond [1-3]. 
The sugar moiety is referred to as a glycone, while the non-sugar part is called an 
aglycone. An example is shown in Figure 1.1. The glycone can comprise a single 
sugar (monosaccharide) or multiple sugars, including disaccharides (di = 2), 
oligosaccharides (oligo = few) or polysaccharides (poly = many). As the names 
indicate, disaccharides contain two monosaccharide units, oligosaccharides consist 
of three to ten units and polysaccharides have more than ten units [1, 4-6]. The 
aglycone moiety can either be an alcohol, aryl group, lipid, protein, nucleic acids etc. 
[2, 4, 7, 8]. 
 
 
Fig. 1.1: A structure of a chromogenic glycoside (2,4-dinitrophenyl-α-D-
glucopyranose) consisting of a glycone (glucopyranose) linked to aglycone (2,4-
dinitrophenol) through an α-O-glycosidic bond 
 
Glycosides have many essential functions within living organisms. These organic 
molecules are classified based on the structures of the glycone moiety (or moieties) 
and the aglycone moiety (chromogenic, cyanogenic, etc.), the configuration of the 
glycosidic bond (α or β) and the atom involved in the glycosidic bond linkage, that is, 
carbon, oxygen, nitrogen and sulphur. It is based on these atoms that glycosides are 
Stellenbosch University  https://scholar.sun.ac.za
2 
referred to as C-, O-, N- or S-glycosides. The most abundant type of glycoside 
linkage both naturally and synthetically is the O-glycosidic bond, which leads to the 
formation of O-glycosides [3]. Glycosides are a very diverse and complicated family 
of compounds owing to the glycone and aglycone moieties and are involved in 
numerous essential biological and biomedicinal functions, as detailed below [9-11]. 
1.2  Function of glycoside 
Glycosides play several essential biological roles within the cellular and molecular 
processes of living organisms [2, 10-16]. The cellular process includes cellular 
transport, adhesion, cell-to-cell recognition and the molecular processes including, 
but not limited to, embryogenesis, fertilisation, neuronal development and 
proliferation of cells. In biomedicine, glycosides are involved in facilitating the mode 
of action of various drugs through stabilization of protein folding and by aiding the 
active transmembrane transport system; or they act as inhibitory compounds [2, 10, 
17-21]. In most of these instances it is the glycone moiety that confers the activity, as 
is the case of daunomycin and erythromycin. In fact, the glycone moiety facilitates 
the physical, chemical and biological properties of its aglycone moiety. In addition, it 
regulates the pharmacokinetic properties of how the drug is absorbed, distributed, 
metabolised and excreted (ADME) by the host system [2, 10, 21]. Certain glycosides 
have anti-cancer, antioxidant, anti-inflammatory, antibacterial, antiviral, antiparasitic 
and antifungal activities [10, 17-19, 21-24]. The ever first effective antibiotic against 
Mycobacterium tuberculosis (M. tuberculosis), the main causative agent of 
Tuberculosis (TB) was Streptomycin (Figure 1.2), an aminoglycoside isolated from a 
soil bacterium, the Actinobacterium Streptomyces griseus [17, 22-24]. Other 
antibiotic glycosides include aminoglycosides such kanamycin, gentamicin, 
bleomycin among others, all of which are used to treat infections by pathogenic 
Gram-negative bacteria such as Pseudomonas and Salmonella species etc. In 
addition, infections by pathogenic Gram-positive bacteria such Staphylococcus 
aureus, Streptococcus pneumonia etc., genetic disorders and human 
immunodeficiency virus infections are also treated by compounds that include 
glycosides [10, 17, 22-26].  
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Fig. 1.2: The structure of Streptomycin 
The essential roles of glycosides in several fundamental biological processes and 
the wide use thereof in biomedicine have led to a high demand for certain 
glycosides, and consequently also the development of various ways to produce them 
synthetically. This is because the extraction of glycosides from plant or soil bacteria 
normally results in low yield due to the number of purification steps required to obtain 
a pure final product. However, the chemical synthesis of glycosides often encounters 
difficulties in generating the bond with the correct anomeric configuration, and linked 
to the correct substituent of the glycone. Therefore, while glycosides can be 
synthesized either chemically and/or enzymatically, the interest in the latter, more 
specific, method has been receiving increasing interest.  
This project focused on the generation of α-N-acetyl-glucosamine (GlcNAc)-based 
glycosides of biomedical and chemical interest through enzymatic synthesis, 
particularly since these glycosides are known to be produced in low yields [8, 27, 
28]. In the next section the methods currently available for the chemical and 
enzymatic synthesis of glycosides are reviewed, the motivation for the generation of 
α-GlcNAc-based glycosides is provided, and the problem of generating such 
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1.3  Synthetic preparation of glycosides 
Glycosides are synthesized through a process known as glycosylation that involves 
the formation of a glycosidic bond [2, 3, 5, 7, 8]. Whether by chemical or enzymatic 
methods, glycosylation has four basic requirements: (1) the use of a glycosyl donor 
that contains a good leaving group (LG) at the anomeric centre; (2) an acceptor 
molecule with a suitable nucleophilic group, which can be either a sugar moiety or a 
non-sugar moiety; (3) controlled environmental conditions and; (4) a suitable 
promoter/catalyst. (Figure 1.3) [7, 9]. The formations of glycosidic bonds by either 




Fig. 1.3: General mechanism of glycoside bond formation between two sugar 
moieties, one acting as donor, and the other acceptor. Glycoside bond formation 
through enzymatic synthesis does not require protecting groups, hence the final de-
protecting step is not needed [3, 9]. 
1.3.1 The chemical synthesis of glycosides 
The groundwork of synthetic carbohydrate chemistry was laid by Emil Fisher in the 
late 1800’s [3, 29-31]. It is reported that the first glycosides chemically synthesized 
were aryl glycosides by Michael in 1879 [2, 7]. This was followed by generation of 
glycosides through acid-catalysed alcoholysis of monosaccharides in 1893 by Fisher 
[2, 7]. In the early 1900s, Koenings and Knorr developed other chemical methods for 
the synthesis of glycosides based on the synthesis of Michael [2, 3, 5, 7]. In modern 
times, Ray Lemieux is considered to be one of the foremost contributors to the 
chemical synthesis of carbohydrates [3, 32]. He was the first person to chemically 
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synthesize sucrose and he developed key glycosylation methods, such as in situ 
anomerisation [3]. Since then, several chemical and enzymatic glycosylation 
methods have been established which are utilised to generate disaccharides, 
oligosaccharides, polysaccharides, glyco-conjugates and glycosaminoglycans 
molecules [5, 9, 33]. 
Chemical formation of a glycosidic bond includes vigilant selection of suitable 
promoter(s), correct protecting groups for both the glycosyl acceptor and donor, 
proper selection of a leaving group at the anomeric centre of the donor in order to 
give rise to the correct regio- and stereoselectivity [3, 5, 7, 9]. In addition, it also 
includes careful removal of the protecting group without destabilizing the final 
product. The general mechanism follows a SN1-like mechanism and SN2-like 
displacement which can occur through different ion intermediates such as 
oxocarbenium ion, acetoxonium ion or oxazoline [3, 8, 9, 13, 34]. It is through these 
intermediates that the glycosidic bond is formed and its anomeric configuration is 
fixed. 
1.3.1.1 The chemical formation of β- and α-glycosides 
Glycosidic bond formation is highly influenced by the choice of the donor and 
acceptor molecules, the promoter/catalyst used, the temperature of the reaction, the 
solvent used and the choice of protecting groups [3, 5, 7, 9, 34-36]. Furthermore, the 
sequence in which the reagents are added could also influence the anomeric 
configuration of the formed glycoside. However, the most prominent influence of the 
anomeric configuration is exerted by the group attached at the second carbon (C2) 
of the gycosyl donor [9, 36]. The first step of glycosidic bond formation involves the 
loss of the LG; this activates the glycosyl donor through formation of an 
oxocarbenium ion intermediate (Figure 1.4) [13]. The departure of the leaving group 
is also assisted by lone pairs of the ring oxygen, which also stabilised the 
oxocarbenium ion intermediate through resonance. This intermediate can 
subsequently be attacked either from the bottom or top by the nucleophile of the 
glycosyl acceptor to form the glycoside bond.  
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Fig. 1.4: The chemical mechanism of glycosidic bond formation. On the left the 
formation of glycosidic bonds from a glycosyl donor without a participating group at 
C2 is shown, while glycoside bond formation from a glycosyl donor with a 
participating group at C2 is shown on the right. R, protecting group; R’, non-
participating groups such benzyl, azido etc. R’’, participating groups such alkyl, aryl 
etc. and R’’’as glycosyl acceptor which can be a sugar moiety or aglycone [3, 9, 34]. 
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The attack of the intermediate, that is either top or bottom, is highly dependent on 
the nature of the group at C2, specifically whether it is a participating or non-
participating group. For example, when a glycosyl donor containing a non-
participating functional group such as azide, benzyl etc. at C2 is used as a donor 
(together with careful selection of other factors), the formation of the α-anomeric 
configuration is promoted over the β-configuration (Figure 1.4). The α-glycosides 
form when the nucleophile of the glycosyl acceptor attacks the oxocarbenium ion 
intermediate from the bottom, while the attack from the top would lead to formation of 
the β-anomer. The attack from the bottom of the oxocarbenium ion intermediate is 
thermodynamically favoured as a result of the anomeric effect at the anomeric 
carbon which stabilizes the formation of α-glycosides since no other group it is 
participating within the oxocarbenium ion intermediate [4, 5, 8, 9]. 
In a situation where a glycosyl donor contains a participating functional group (such 
as alkyl, aryl, acyl, ester groups) at C2, an acyloxonium ion intermediate is 
generated from the oxocarbenium ion intermediate (Figure 1.4) [3, 8, 9, 35]. After the 
activation step the oxocarbenium ion intermediate is stabilised by the carbonyl 
oxygen of the participating group at position C2 which results in the formation of 
acyloxonium ion intermediate. Once the acyloxonium ion intermediate is formed, its 
dioxolane ring is attacked by the nucleophile of the glycosyl acceptor either from the 
top or the bottom to form a β- or α-glycosidic bond, respectively. Acyloxonium ion 
intermediates preferentially promote the formation of β-glycosides over the α-
counterparts due to the effect of the participating group. Attack of the carbocation 
resonance form of the acyloxonium ion by an alcohol nucleophile under basic or 
neutral conditions produces a by-product known as an orthoester. Orthoesters can 
eventually be converted into β-glycosides through isomerization in most, but not all, 
cases [3, 34]. 
In the case of N-acetyl-aminoglycoside synthesis a glycosyl donor with N-acetyl 
group at the C2 is used as either a protecting or permanent functional group. This 
reaction occurs through a different intermediate known as an oxazoline which is also 
formed via the oxocarbenium ion intermediate [8]. The oxazoline intermediate 
(Figure 1.5) is attacked in the same way as the acyloxonium ion by the nucleophilic 
glycosyl acceptor, and consequently they mostly also preferentially promote the 
formation of β-glycosides. However, due to the increased stability of the oxazoline 
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intermediate compared to the acyloxonium ion these reactions usually have long 
reaction times with low yields.  
 
Fig. 1.5: The oxazoline intermediate [8] 
1.3.1.2 Chemical methods used to generate glycosidic bonds 
Chemical glycosylation methods are generally evaluated based on the amount of 
reagents they require, the yield of the product, whether they are stereo-selective and 
whether they allows for large scale production [7]. To date a number of chemical 
methods have been established for the formation of O-glycosidic bonds and some of 
them can also be used to synthesise N-, S- or C-glycosidic bonds. The chemical 
methods for the formation of O-glycosidic bonds include Michael, Fischer, Helferich, 
Koenigs-Knorr, Schmidt/trichloroacetimidates, Sulfure and Armed-Disarmed 
reactions method amongst others [2, 3, 7, 37, 38]. The Michael, Fischer, and 
Koenigs-Knorr methods were the first established glycosylation methods, although 
currently the Koenigs-Knorr, Schmidt/trichloroacetimidates, sulfure and Armed-
Disarmed methods are the most frequently applied chemical glycosylation methods. 
These methods are distinguished based on the nature of the glycosyl donors that are 
used (Figure 1.6).  
 
Fig. 1.6: The structure of the glycosyl donors used in the most popular chemical 
methods for formation of the O-glycosidic bond. Glycosyl halides are used as donor 
during Koenigs-Knorr, while Schmidt/trichloroacetimidates, sulfur and Armed-
Disarmed methods use glycosyl trichloroacetimidates, thioglycosides and n-pentenyl 
glycosides as donors, respectively. 
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Koenigs-Knorr uses glycosyl halides as donor, while Schmidt/trichloroacetimidates, 
sulfur and Armed-Disarmed methods use glycosyl trichloroacetimidates, 
thioglycosides and n-pentenyl glycosides as donors, respectively. In addition, they 
also utilise different promoters, which is a component added to a reaction to increase 
the catalyst reactivity and activity. For example, the Koenigs-Knorr method uses 
silver, mercury and other heavy metal salts as promoters, while the sulphur methods 
use promoters such N-iodosuccinimide or iodinium dicollodine. Koenigs-Knorr is the 
most used method for generation of the O-glycosidic bond and was established in 
1901 by Wilhelm Koenigs and Eduard Knorr [3]. This method mostly promotes the 
formation of the β-glycosidic bond configuration as a result of the donor and 
promoter used. Figure 1.7 provides an example of glycosidic bond formation through 
the Koenigs-Knorr method. Koenigs-Knorr method is also used for the preparation of 
n-pentenyl glycosides which are used as glycosyl donor in the Armed-Disarmed 
method to synthesise large oligosaccharides such pseudo-tetrasaccharide. The 
other methods also occur in the similar way as the Koenigs-Knorr method and also 
result mostly in the formation β-glycosidic bond confirmation. 
 
 
Fig. 1.7: The formation of glycosidic bond through Koenigs-Knorr method with an 
acetylated glycosyl bromide containing a participating group as the donor. The 
Koenigs-Knorr method mostly results in the formation of the β-glycosidic bond 
configuration due to the nature of the glycosyl donor [3, 5, 37]. 
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In addition to these methods, Lemieux and co-workers developed a kinetically 
controlled glycosylation method in 1975 (known as in situ anomerization) for the 
generation of α-glycosidic bonds [39]. In this method, generation of the glycosidic 
bond is highly depended on the anomeric effect at the anomeric centre, which 
destabilises the leaving group of the glycosyl donor. This effect was discovered by 
Raymond Lemieux and is highly influenced by non-participating functional group of 
the C2 and the electronegativity of the anomeric substituent: the more electro-
negative the substituent at the anomeric is, the larger the anomeric effect [3, 5, 6]. 
The anomeric effect occurs as a result of the dipole-dipole interaction next to the 
anomeric centre and stereoelectronic effect at the anomeric centre. Two dipole 
interactions occur near the anomeric centre which influences the anomeric effect. 
The first interaction dipole is that of the two non-bonding electron pairs of the 
endocyclic carbohydrate ring oxygen, which generates a dipole in the exocyclic 
direction. The second dipole occurs as a result of the polarized bond between the 
anomeric carbon atoms and the exocyclic heteatom. The interaction of the two 
dipoles in β-anomers is parallel to each other facing the same direction as the 
anomeric carbon atom exocyclic heteratom bond of which is chemically energetically 
poor and unstable (Figure 1.8a). In the case of α-anomers the dipoles are antiparallel 
facing away from each other resulting in the bond that is stable and chemically 
energetically favoured (Figure 1.8b). Anomeric effect promotes the formation of the 
α-glycosidic bond. The formation of the α-glycosidic bond through in situ 
anomerization method also requires highly controlled and careful selection of 
promoter, solvent, glycosyl donor and leaving group in order to avoid formation β-
glycosidic bond.  
 
Fig. 1.8: The anomeric effect of the β-(A) and α-(B) glycosidic bond formation [3, 6] 
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1.3.1.3 Shortcomings of chemical glycosylation methods 
The biggest shortcoming of the various chemical glycosylation methods that have 
been developed to date is the fact that they nearly all favour the formation of β- over 
α-glycosides. Apart from this, some of the methods also use toxic chemicals to the 
human system. In most cases chemical glycosylation methods also require the 
protection and de-protection of the various substituents in order to get the correct 
regio- and stereo-selectivity. This can lead to multi-step syntheses with low yields.  
The formation of α-glycosidic bonds by chemical methods still remains a big 
challenge. In addition, chemical methods for α-glycosides often also lead to the 
formation of β-glycosides as side-products during the reaction; this in turn creates 
another challenge as the required α-glycoside has to be purified from the mixture. 
The formation of GlcNAc-based glycosides with the α-configuration in particular still 
remains a significant challenge as a result of the acetyl group at C2 which 
participates in the reaction during the glycosidic bond formation, giving rise to the 
preferential formation of β-glycosides over their α-counterparts. As such, new 
chemical methods that will promote the formation of α-GlcNAc glycosides still need 
to be developed.  
1.3.2 The biocatalytic synthesis of glycosides 
Apart from the various chemical methods to prepare glycosides, several enzymes 
have also been applied in the synthesis of these compounds, i.e. through a 
biocatalytic process [3, 5, 40, 41]. For the enzymatic synthesis of glycosides 
enzymes such as glycosyltransferases, glycosidases or glycosidases modified at 
their catalytic residues are usually used. There are various requirements for such 
enzymes to be used in biocatalysis. First, the enzyme in question needs to be able to 
form the desired glycoside, but not hydrolyse or otherwise transform the final 
product. Second, the enzyme must be stable under conditions that may be very 
different from its natural physiological environment, and third, the conditions under 
which the enzyme functions optimally should be known. Lastly, information regarding 
the mechanism of the enzyme that is to be used must be available. This helps to 
know what kind of donors and acceptors can be used. 
The current biocatalytic methods available for the synthesis of glycosides mostly 
promote the formation of the O-glycosidic bonds, although one type of modified 
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glycosidase also promotes S-glycosidic bond formation. The configuration of the 
glycosidic bond (α- or β-) is highly dependent on the type of enzyme used, as well as 
on the glycosyl donor to some extent. Enzymatic glycosylation usually occurs under 
mild conditions without the requirement for protecting groups. In the following 
sections the various enzymes that are used to generate glycosidic bonds through 
biocatalytic methods are briefly discussed.  
1.3.2.1 Glycosyltransferases for biocatalytic glycoside synthesis 
Glycosyltransferases are anabolic enzymes that generate the formation of the O-
glycosidic bond between a sugar moiety and either another sugar moiety or an 
aglycone [42-46]. If the aglycone is a lipid, a glycolipid gets produced while a 
glycoprotein is the product if it is a protein. Glycosyltransferases are classified as 
either inverting or retaining based on the catalytic mechanism they use for the 
glycosidic bond formation, and often can be identified based on their primary 
sequence. In addition, they are also classified into clans depending on their fold: 
glycosyltransferases-A and glycosyltransferases-B. More than 90 families of 
glycosyltransferases have been characterised to date and their information is 
available on the Carbohydrate-Active enZYmes (CAZY) database 
(http://www.cazy.org). These enzymes utilises inverting and retaining mechanism for 
the formation of glycosidic bond [43, 44, 46]. The inverting mechanisms occur in a 
way similar to that of glycosidases, which will be discussed in more detail below. The 
only difference is that the inverting glycosyltransferases-A requires Mn2+ which acts 
as acid catalyst [44, 47]. On the other hand, the catalytic mechanism of retaining 
glycosyltransferases is not yet fully understood [43, 46]. It proposed that some 
retaining glycosyltransferases use a double-displacement mechanism while other 
use a single-displacement mechanism, with the latter one having more support. 
Glycosyltransferases utilise activated donors such as nucleoside mono/di-
phosphosugars and lipid phosphosugars among others for the formation of 
glycosides [41, 48]. More than 60 glycosyltransferases—some of which are 
commercially available—have been characterized for the chemo-enzymatic 
synthesis of glycosides [41]. Nonetheless, the utilisation of such enzymes is 
hindered by the fact that most glycosyltransferases are not stable once out of their 
natural physiological environment, and are subject to feedback inhibition. In addition, 
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the glycosyl donors required by these enzymes are too expensive to allow for their 
use on preparative scale.  
1.3.2.2 Glycosidases for biocatalytic glycoside synthesis 
Glycosidases are hydrolytic enzymes that normally cleave the glycosidic bonds 
found in oligosaccharides, polysaccharides, glycoproteins and glycolipids [49, 50]. 
These enzymes are divided into various families depending on their primary 
sequence, their structural fold and the reaction mechanism they use for hydrolysis of 
the glycosidic bond [51-54]. Glycosidases have many different structures, which is 
believed to be due to the diversity of both their natural substrates and the evolution 
of the active site residues that is used to cleave the bond. More than 100 different 
families have been identified, with their taxonomy regularly being updated at 
http://www.cazy.org. Glycosidases are classified based on the anomeric 
configuration of the bond that they cleave (i.e. as α- or β-glycosidases) and on the 
mechanism used to cleave the bond (i.e. whether they are inverting- or retaining-
glycosidases) [55]. In addition, they are also classified as exo-glycosidases or endo-
glycosidases depending on the position of the bond that is cleaved [49]. Endo-acting 
glycosidases cleave any glycosidic bond except those attaching the terminal 
saccharide units in chains, while exo-acting glycosidases act on the bonds attaching 
these terminal units (Figure 1.9). 
 
  
Fig. 1.9: Exo- and endo-acting glycosidases. The exo-acting enzyme in this example 
gives rise to a monosaccharide and oligosaccharide, while the endo-acting 
glycosidase results in two oligosaccharides: one consisting of three subunits and the 
other of four subunits. 
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Whether glycosidases are inverting or retaining, in both cases the mechanism 
involves an oxocarbenium ion-like transition state and a pair of carboxylic acids 
located on opposite sides of the enzyme’s active site [54, 56, 57]. However, they 
differ in that enzymes with a retaining catalytic mechanism depend on a double 
displacement reaction, while those with an inverting mechanism make use of a 
single displacement. The final product of a retaining glycosidase has the same 
anomeric configuration as the substrate, while the opposite is true for inverting 
enzymes (Figure 1.10). In addition, the distance between the catalytic residues are 
different between the two mechanisms; in the case of inverting enzymes these 
residues are often very far apart from each other, thus giving space for water (or 
other molecule) to intervene in the process. This stands in contrast to enzymes with 
a retaining mechanism, where the catalytic residues are much closer [56]. For 
example, the distance between the residues of an inverting enzyme is 9.0 ± 1.0 and 
9.5 Ȧ for α and β-glycosidases respectively, while for enzymes with a retaining 
mechanism the active site acid and base residues are approximately 4.8 ± 0.5 and 
5.3 ± 0.2 Ȧ apart for α and β-glycosidases respectively.  
During the inverting catalytic mechanism one carboxylic acid from the pair acts as an 
acid, while the second carboxylic acid acts as a base (being in its carboxylate form) 
[54, 56, 57]. The base deprotonates the incoming water molecule allowing it to attack 
the anomeric carbon. This releases the sugar or aglycone moiety attached at this 
centre, thereby facilitating the cleavage of glycosidic bond (Figure 1.10A).  
In contrast, the retaining mechanism occurs through two steps, namely glycosylation 
and deglycosylation (Figure 1.10B). During the glycosylation step, one carboxylic 
acid acts as an acid while the other acts as a nucleophile. The nucleophile attacks 
the anomeric carbon directly to release the sugar or aglycone moiety attached at this 
centre (facilitated by its protonation by the acidic residue), and to form a covalent 
glycosyl-enzyme intermediate. Next the deglycosylation step occurs when the 
residue that had acted as an acid in the first step now acts as a base that 
deprotonates a water molecule to generate a nucleophile that attacks the anomeric 
carbon of the glycosyl-enzyme intermediate. This resolves the substrate-enzyme 
complex and promotes cleavage of the glycosidic bond, leading to formation of the 
final product that has the anomeric configuration as the substrate. 
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Fig. 1.10: Catalytic mechanisms of glycosidase [48]. Panel A, is the inverting 
mechanism and panel B, the retaining mechanism.  
 
Glycosidases are known to not only promote hydrolysis, but to also promote 
glycosidic bond formation under specific conditions [58-60]. Glycosidase-mediated 
glycosidic bond formation occurs by one of two different mechanisms, namely by: 
reverse hydrolysis or by transglycosylation under retaining mechanism. The reverse 
hydrolysis reaction, also referred to as equilibrium control synthesis, depends on 
both concentration of monosaccharides as an acceptor and the presence of water. It 
is promoted by high concentration of monosaccharide acting as an acceptor and 
high concentration of organic solvents (80-90% v/v), such as acetonitrile, tert butanol 
etc. in relation to water [58]. The sugar moiety acting as an acceptor competes with 
water to act as the nucleophile that attacks the enzyme-substrate complex and, as a 
result of a low concentration of water and a high concentration of sugar acceptor, the 
sugar acceptor dominates leading to more glycosylation formation in relation to 
hydrolysis. Several glycosidases from different organisms have been used to 
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biosynthesis glycosides through the reverse hydrolysis reaction [58]. The 
transglycosylation mechanism also known as the kinetically controlled reaction 
depends on the rate activity of the substrate-enzyme complex formation, ratio 
between the rate activity of water concentration and rate activity sugar acceptor 
concentration to hydrolysis the substrate-enzyme complex [58-60]. This mechanism 
requires activated glycosyl donors such as nitrophenyl glycoside in order to promote 
fast and operationally irreversible cleaving of the donor. The reverse rate activity of 
the substrate-enzyme complex formation must be zero, that is, no reverse reaction of 
the substrate-enzyme complex formation. When the rate of attack by the sugar 
acceptor is higher than that by the water, transglycosylation is promoted and vice 
versa if the rate of the forward activity with water as nucleophile is higher than that of 
the acceptor.  
The problem with the reverse hydrolysis or transglycosylation mechanism of 
glycosidase for the glycosidic bond formation is that the product formed in such a 
case also becomes a substrate for the hydrolytic activity of the enzyme; yields of 
glycosides formed in this way are usually low. To overcome this problem Withers 
and co-workers generated a new set of enzymes from glycosidase through mutation 
of one or both of the catalytic active site residues [56, 61]. Specifically, point 
mutation of the nucleophilic residue or the acid/base residue resulted in generation 
of glycosynthase and thioglycoligase enzymes, respectively. Double mutation, that 
is, the inactivation of both active site residues generated thioglycosynthases. More 
information on these non-natural enzymes acting as biocatalysts is provided in the 
next section. 
1.3.2.3 Glycosynthases as biocatalytic enzymes 
Glycosynthases are mutated glycosidases at the nucleophilic catalytic active site, 
wherein the nucleophilic amino acid usually the glutamic acid or aspartic acid residue 
is changed into either a polar uncharged amino acid or non-polar aliphatic amino 
acid [40, 55, 56, 59, 61-63]. These enzymes are classified based on the glycosidase 
that they are generated from, and also on the anomeric configuration of the final 
product. For example, a glycosynthase generated from an exo-acting β-retaining 
glycosidase will be categorised as exo-acting β-glycosynthase. The first reported 
glycosynthase was derived from a retaining β-glucosidase enzyme from 
Agrobacterium sp. family 1 by Withers and co-workers in 1998 [61]. They mutated 
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the Glu345 residue of the β-glucosidase/galactosidase from Agrobacterium sp. into 
the non-polar aliphatic amino acid alanine. To generate the glycosidic bond activated 
α-glycosyl-fluoride was used as donor, with an aryl glycoside used as acceptor. 
Since then, many glycosidase from different families have been engineered using 
this approach to obtain glycosynthases [40, 59]. Nearly all of these employ the 
retaining mechanism, with only two inverting glycosidases having been converted to 
glycosynthases.  
Glycosynthases require an activated glycosyl donor that contains a good leaving 
group (such as fluoride or dinitro-phenol), an external nucleophile (such as sodium 
azide/fluoride to mimic the mutated nucleophilic residue) and a glycosyl acceptor [40, 
55, 56, 59, 61-63]. In addition, a glycosynthase derived from a β-glycosidase can act 
as both an inverting or retaining glycosynthase. In general, glycosynthases produced 
from thermophilic organisms utilises nitrophenyl glycosides as donors such 2-
nitrophenyl-/4-nitrophenyl-N-acetyl--D-glucosaminide (2NP/4NP-GlcNAc) among 
other with either sodium azide or sodium formate as the external nucleophile. For 
glycosidases from mesophilic organisms donors with either fluoride and dinitrophenol 
leaving groups are mostly used, as these are more reactive but generally stable at 
standard reaction temperatures. The mechanisms of glycosynthases are shown in 
Figure 1.11. In the first step the glycosylation reaction occurs between the glycosyl 
donor and the external nucleophile to form a product complex which mimics the 
enzyme-substrate complex of the natural enzyme. This is followed by a 
deglycosylation step which occurs in the same way as it would have with the wild 
type glycosidase, forming a glycosidic bond which has the same anomeric 
configuration as the starting material [40, 55, 56, 59, 61-63]. Consequently, 
configuration of the product is highly dependent on the nature of the glycosyl donor. 
For example, when a glycosyl donor with an anomeric configuration opposite to that 
of the natural substrate of the parent enzyme is used, the glycosynthase forms a 
glycosidic bond that has the same anomeric configuration as that of the natural 
substrate (Figure 1.11A). In such a case, the glycosynthase acts an inverting 
enzyme, with the glycosidic bond formed in the same way as for glycosidases with 
an inverting mechanism. To act as a retaining glycosynthase the enzyme requires a 
glycosyl donor with the same anomeric configuration as that of the natural substrate 
of the parent enzyme (Figure 1.11B).  
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Fig. 1.11: The catalytic mechanism of β-glycosynthases. A) the inverting β-
glycosynthase and B) retaining β-glycosynthase [59].  
Ultimately both inverting and retaining β-glycosynthases generate a product with the 
same anomeric configuration to that of the natural substrate of the wild type enzyme. 
The only difference is that the retaining β-glycosynthase requires an external 
nucleophile and donor with the same anomeric configuration as the natural 
substrate, while the inverting β-glycosynthase needs a donor with an anomeric 
configuration that is opposite to that of the natural substrate.  
1.3.2.4 Thioglycoligases as biocatalytic enzymes 
Thioglycoligases are enzymes wherein acid/base catalytic active site usually the 
glutamic acid or aspartic acid residue is changed into either a polar uncharged amino 
acid or non-polar aliphatic amino acid [40, 49, 55, 59, 64, 65]. They promote the 
formation of S-glycosidic bond that is more resistant to enzymatic hydrolysis than O-
glycosidic bonds. Moreover, thioglycosides have been found to be good inhibitory 
compounds for glycosidase enzymes [40, 65, 66]. Thioglycoligases are classified in 
the same way as glycosynthases. The first thioglycoligase was generated by Withers 
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and co-workers from a retaining β-glucosidase from Agrobacterium sp. [64, 66]. 
Since then several retaining glycosidases have been converted to thioglycoligases, 
only two of these being α-retaining glycosidases [40]. However, to date no 
thioglycoligase with an inverting mechanism has been generated. 
For thioglycoligase activity the enzyme requires a glycosyl donor with a good leaving 
group that has the same anomeric configuration as the substrate of the parent 
enzyme, as well as a thio-compound as acceptor [40, 49, 55, 64, 65]. The reactions 
occur via a double displacement reaction, giving rise to the observed retention 
(Figure 1.12). The first step involves attack from the nucleophilic residue to form the 
enzyme-substrate complex. This complex is broken up when the thiolate of the 
acceptor reacts with the complex giving rise to a product in which the sugar of the 
donor is attached to the thiol acceptor with an S-glycosidic bond.  
 
Fig. 1.12: The retaining catalytic mechanism of α-thioglycoligases 
There is also one example of a thioglycosynthase that has been generated by 
Withers and co-workers from β-glucosidase of Agrobacterium sp. [67]. This is a 
glycosidase enzyme that is mutated at both catalytic residues, i.e. at both the 
acid/base and nucleophile residue sites (Figure 1.13). For this enzyme to function it 
requires a glycosyl fluoride as donor molecule and a thio-compound as an acceptor 
compound.  
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Fig. 1.13: Thioglycosynthase mechanism [67].  
1.3.2.5 Benefits and shortcomings of utilising biocatalysis for glycosidic bond 
formation 
The transformation of glycosidases into either glycosynthases or thioglycoligase has 
great benefit for the production of glycosides. Reactions catalyzed by these enzymes 
give good to excellent final product yields without too much difficulty. In addition, 
mutated glycosidase enzymes are stable, highly soluble and can be used with 
cheaper and a wider range of donors and acceptors. Nevertheless, there are some 
challenges associated with converting glycosidases into either glycosynthases or 
thioglycoligases. Retaining glycosynthases requires an external nucleophile to mimic 
the role of the mutated nucleophilic residue, that is, the glycosyl donor must be 
reactivated by an external nucleophile, and this is not always observed. Additionally, 
enzymes with an inverting mechanism require glycosyl donors that are not available 
commercially, meaning that they must be chemically synthesized. For 
thioglycoligases, a major shortcoming is the need for the chemical synthesis of thio-
sugars that can act as acceptors; this is often not trivial. Currently, only five retaining 
α-glycosynthases have been generated, and only two retaining α-thioglycoligases 
[40], demonstrating the difficulty associated with converting an α-glycosidase into 
either α-glycosynthases or α-thioglycoligases. 
1.4. Project background and rationale 
Pathogenic bacteria such as S. aureus and M. tuberculosis among other bacteria are 
becoming more resistant to the antibacterial drugs that are used to treat infections 
caused by them [68]. For example, S. aureus has developed several resistant strains 
including methicillin-resistant S. aureus (MRSA) and community-associated MRSA 
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(CA-MRSA) [68-70], while M. tuberculosis has developed resistant strains including 
multidrug-resistant tuberculosis (MDR-TB), extensively drug resistant tuberculosis 
(XDR-TB) and total drug resistant tuberculosis [68, 71-75]. This resistance is due to 
several mechanisms, including the reduction of intracellular drug concentration 
through excretion via efflux pumps, the modification of the drugs by enzymes in the 
targeted organism that render them harmless, and the modification of the target site 
to prevent drug binding [17, 23]. In addition, social factors such as non-compliance of 
patients to prescribed antimicrobial treatments, poor health service, poor hygiene 
and poor living conditions also accelerate the process of antibiotic resistance. 
 
The escalation in the numbers of drug-resistant pathogens present a real threat to 
the global public health, as over a million of people die every year due to these 
pathogenic bacteria [68]. Such problems call for urgent action, specifically to develop 
new antibiotics that will be active against these resistant strains. Furthermore, new 
potential targets that are conserved within the pathogen need to be identified and 
studied for their potential for the development of new drugs. Currently a specific 
biosynthetic pathway that is conserved within certain actinomycetes, including the 
pathogen M. tuberculosis and another that is found in S. aureus and certain 
Firmicutes, are being viewed as potential targets for the development of new 
antibacterial drugs against these organisms [76-79]. These pathways are the 
mycothiol (MSH) biosynthetic pathway in actinomycetes and the bacillithiol (BSH) 
biosynthetic pathway in Firmicutes and S. aureus. These pathways are essential 
within the respective organisms for the generation of these essential low molecular 
weight thiols. MSH and BSH consist of a L-cysteinyl-D-glucosamine moiety linked to 
an aglycone through an α-glycosidic bond (Figure 1.14). For MSH the aglycone 
moiety is inositol, while that of BSH is malic acid.  
 
Fig. 1.14: The chemical structures of MSH and BSH. 
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MSH and BSH are biosynthesised in several enzymatic steps that include a glycosyl-
transfer, dephosphorylation, deacetylation, acetyl-transferase and ligation reaction 
with each reaction catalysed by a different enzyme (Figure 1.15) [76, 80-83]. The 
dephosphorylation and acetyl-transferase reactions only occur in the MSH 
biosynthetic pathway. MSH is generated through five enzymatic reactions (Figure 
1.15A) [76, 80, 81]. The first reaction is catalysed by a glycosyltransferase enzyme 
known as MshA which transfers N-acetylglucosamine from uridine diphosphate-N-
acetylglucosamine (UDP-GlcNAc) to 1-L-myo-inositol-1-phosphate (1-L-Ins-1-P) to 
form 3-phospho-1-D-myo-inosityl-2-acetamido-2-deoxy-α-D-glucopyranoside 
(GlcNAc-Ins-3-P) and UDP. This is followed by the removal of the phosphate group 
by means of an uncharacterized phosphatase, MshA2, to produce 1-D-myo-inosityl-
2-acetamido-2-deoxy-α-D-glucopyranoside (GlcNAc-Ins) and phosphate (Pi). The 
third reaction involves an N-deacetylase enzyme known as MshB which cleaves the 
acetyl group from the N-glucosamine moiety to give glucosamine-inositol (GlcN-Ins) 
and acetic acid (AcOH). The free amino group of GlcN-Ins is subsequently joined to 
a cysteine amino acid in the presence of ATP by a ligase enzyme, MshC to yielding 
cysteine-glucosamine-inositol (Cys-GlcN-Ins) and pyrophosphate (PPi). The last 
reaction is the transfer of an acetyl group from acetyl-coenzyme A (AcCoA) to the 
free amino group of Cys in Cys-GlcN-In as catalysed by MshD, generating MSH and 
CoASH.  
 
On the other hand, BSH in generated in three enzymatic steps (Figure 1.15B) [82]. 
The first reaction is catalysed by a glycosyltransferase enzyme known as BshA, 
which transfers N-acetylglucosamine from uridine diphosphate-N-acetylglucosamine 
(UDP-GlcNAc) to L-malate to form N-acetylglucosamine-malate (GlcNAc-Mal). This 
is followed by a reaction catalysed by an N-deacetylase enzyme known as BshB 
which cleaves of the acetyl group from the N-glucosamine moiety of GlcNAc-Mal to 
form glucosamine-malate (GlcN-Mal). The last step is catalysed by BshC, which 
ligates cysteine (through its carboxyl) to the free amino group of GlcN-Mal to form 
BSH.  
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Fig 1.15: The biosynthetic pathways of MSH (A) [76] and BSH (B) [82], respectively. 
See text for a detailed description of each step.  
 
These low molecular weight thiols are essential within these microorganisms for 
several metabolic reactions. They maintain intracellular redox balance in a manner 
similar to glutathione in eukaryotes, act as co-factors and are used by the 
microorganisms for the detoxification of xenobiotics, including antimicrobial agents 
[76, 83-86]. These various processes are facilitated by different MSH and BSH-
dependent enzymes, such as mycothiol disulfide reductase (Mtr), mycothiol-S-
conjugate amidase (Mca), mycothiol-S-nitrosoreductase/-formaldehyde 
dehydrogenase (MscR) in the case of MSH. For BSH, BSH-dependent enzymes 
include bacillithiol S-tranferase (BST) and bacillithiol S-conjugate amidase (Bca). 
Both BSH- and MSH-biosynthetic and -dependent enzymes are being studied to 
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determine their potential as targets for the development of new antibiotics. However, 
such studies are hindered by the lack of the crystal structures of some of the 
enzymes in question, the lack of availability of the substrates of some of the 
enzymes, resulting in poor characterization of their activities and finally, the lack of 
appropriate continuous assays that could facilitate the characterisation of these 
enzymes. In combination, these factors have hampered the development and 
identification of compounds that specifically inhibit these enzymes and that could be 
developed into antimicrobial agents.  
1.5 Problem identification and previous work  
Of the stumbling blocks outlined above that currently hinder the study of MSH- and 
BSH-related enzymes, the lack of substrate availability is probably one of the biggest 
to overcome. This is due to the various synthetic difficulties associated with 
preparing these compounds, one of which is the challenge of generating the α-
anomeric glycosidic linkage. In addition, the lack of continuous kinetic enzymatic 
assays, specifically for the deactylases BshB and MshB that are regarded as targets 
that has excellent potential for antimicrobial development, also contribute to the slow 
progress in development inhibitors that target these pathways. 
 
Previous studies in the Strauss group and in the laboratories of our collaborators had 
identified an α-N-acetylglucosaminidase from Clostridium perfringens (C. 
perfringens) from family 89 (CpGH89) that has a retaining mechanism as a 
candidate for the development of an α-glycosynthase and/or α-thioglycoligase 
catalyst that could be used in the synthesis of MSH and/or BSH biosynthetic 
intermediates, or of analogues of these compounds. In previous work four potential 
α-glycosynthases and four potential α-thioglycoligases were generated by mutation 
of the glycosidase active site at the nucleophile (Glu601) or acid/base (Glu483) 
residues to serine, alanine, glycine or glutamine [87, 88]. Initial characterisation of 
the mutants showed no reactivation by external nucleophiles, while the α-
thioglycoligases were only evaluated for their hydrolytic activity, but not for their 
ability to promote thioglycosylation reactions. This project therefore focused on 
expanding on this initial work by characterisation of the α-retaining thioglycoligases 
prepared from GH89, and applying these in the synthesis of α-GlcNAc-based 
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glycosides that could act as MshB and/or BshB substrates or inhibitors. Additionally, 
a study was launched to develop a general continuous assay that would suitable for 
activity characterization of these two enzymes.  
1.6 Objectives of the project 
The main goal of this project was to characterise and apply the α-thioglycoligase 
enzymes from CpGH89 in the generation α-GlcNAc-based glycosides that can be 
used as potential alternative substrates and/or inhibitors of MshB and/or BshB. A 
secondary goal was to develop a continuous assay for the characterization of these 
enzymes. 
 
Objective 1: Characterisation of the α-thioglycoligases derived from the α-N-
acetylglucosaminidase CpGH89 for the biocatalytic preparation of α-GlcNAc-
based glycosides.  
The first objective involved the full characterisation of the α-thioglycoligases 
generated from CpCH89, including their suitability for use as biocatalysts to prepare 
α-GlcNAc-based glycosides. This also included testing the α-thioglycoligases for 
thioglycoligation activity using various glycosyl donors and different thio-molecules 
as acceptor. Finally, the best enzyme/acceptor/donor combinations were evaluated 
for their ability to produce α-GlcNAc-based glycosides on preparative scale. The 
compounds prepared in this way were subsequently tested for biomedical activity. 
The work pertaining to this objective is described in Chapter 2.  
 
Objective 2: Chemo-enzymatic synthesis and characterization of α-GlcNAc-
based glycosides as alternative substrates or inhibitors of MshB and/or BshB. 
The best α-thioglycoligase/donor combinations as identified in Objective 1 was 
subsequently used to generate more α-GlcNAc-based glycosides, specifically with 
the aim of preparing MshB and/or BshB substrate analogues or inhibitor through 
biocatalysis. Compounds prepared in this manner were tested as alternative 
substrate of MshB and BshB. The application of α-thioglycoligases in such work is 
presented in Chapter 3. 
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Objective 3: Development of a continuous assay suitable for characterization 
of the metallodeacetylases, MshB and BshB. 
The assays that are currently available for characterisation of MshB and BshB are all 
discontinuous assays with the exception of one, which has several limitations. The 
problem with the discontinuous assays are that they use derivatizing reagents, are 
laborious to execute, and do no lend themselves to high-throughput inhibitor 
screening. A continuous assay for MshB that makes use of various coupled enzyme 
reactions was therefore developed. The work executed towards the development of 
such a coupled-enzyme assay is described in Chapter 4.  
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Abstract: We report here on the preparation of
a novel a-thioglycoligase that can be used for the
fast and efficient synthesis of a-N-acetylglucosamine-
based glycosides. Using the a-N-acetyl-glucosamini-
dase from Clostridium perfringens of family GH89
(according to the Carbohydrate Active Enzymes
classification) as starting point, we prepared mutants
in the acid/base residue glutamic acid 483 that were
found to have different synthetic efficiencies (maxi-
mal yields >80% after 24 h) in the presence of an
activated donor and suitable acceptors. The synthetic
potential of the Glu483 alanine mutant as an a-thio-
glycoligase – only the third biocatalyst with this ste-
reospecificity reported to date, and the first selective
for the N-acetylglucosamine moiety – was demon-
strated by producing for the first time N-acetyl-a-d-
glucosaminyl azide and N-acetylglucos ACHTUNGTRENNUNGamine a-thio-
glycosides in high yields. To showcase the application
of such compounds, we show that they offer the
wild-type CpGH89 protection from thermal unfold-
ing, demonstrating their potential as pharmacological
chaperones for the treatment of mucopolysacchari-
dosis IIIB (Sanfilippo syndrome).
Keywords: carbohydrate active enzymes; chemo-en-
zymatic synthesis; glycoside hydrolases; pharmaco-
logical chaperones; reaction mechanism of glycoside
hydrolases
Introduction
The inhibition of glycoside hydrolases (GHs) is
a proven strategy for the study of these interesting en-
zymes, the discovery of GH-binding molecules, and
treatment or study of a variety of metabolic, genetic,
and infective diseases.[1] For example, the drugs migli-
tol and voglibose are used to treat type 2 diabetes
based on their competitive inhibition of the a-glucosi-
dase enzyme responsible for the breakdown of starch
and smaller oligosaccharides to glucose in the small
intestine.[2] However, GH inhibitors can also play
a positive role in pharmacological chaperone therapy
(PCT) used in lysosomal storage disorders (LSDs)
alone or in combination with the enzyme replacement
therapy (ERT), helping to maintain the target
enzyme in its folded, active form.[3]
The use of GH inhibitors as pharmacological chap-
erones has become the main treatment option for
LSDs where ERT is not possible. A case in point is
mucopolysaccharidosis (MPS), a very serious autoso-
mal recessive lysosomal storage disorder caused by
the impaired function of enzymes involved in the deg-
radation of heparan sulphate, leading to accumulation
Adv. Synth. Catal. 0000, 000, 0 – 0  2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim1
These are not the final page numbers! 
FULL PAPERS DOI: 10.1002/adsc.201601091
Stellenbosch University  https://scholar.sun.ac.za
of undegraded glycosaminoglycans in lysosomes. In
particular, defective mutations of the human gene en-
coding for an a-N-acetyl-glucosaminidase (NAGLU)
causes MPS IIIB, or Sanfilippo syndrome, a tragic
rare disease leading to severe neurological disorders.[4]
There are no current treatments for MPS IIIB, as
gene therapy is in its infancy, and ERT cannot be
adopted because the pharmacological enzyme cannot
cross the blood–brain barrier to replace the defective
enzyme in the nervous system. However, small-mole-
cule chaperones can interact with mutant enzymes to
favour their correct conformation and enhance their
stability.[5] In this manner pharmacological chaperone
therapy (PCT) becomes a viable alternative to ERT
in cases where suitable molecules with high affinity
for the target enzyme can be identified.
Whether for use as inhibitors or in PCT, the ability
of small molecules to selectively bind to their respec-
tive targets in the presence of other enzymes with
similar substrates would be highly beneficial from
a therapeutic perspective. One strategy whereby this
can be achieved is by using compounds that have the
same anomeric configuration as the natural substrates
of the targeted enzymes. However, in the case of a-
GHs, this is not easily accomplished. Remarkably, the
chemical synthesis of a-linked glycosides of especially
N-acetyl-glucosamine (GlcNAc) is generally less
tractable than that of their b-counterparts. This has
severely hampered the discovery and the production
in good yields of inhibitors that are selective for a-N-
acetyl-glucosaminidases, and that can serve as leads
for the development of molecules with the potential
for use in a clinical setting. Consequently, those com-
pounds that have been shown to inhibit a-N-acetyl-
glucosaminidase enzymes are in fact repurposed in-
hibitors of b-N-acetyl-glucosaminidases, and do not
show selectivity at the anomeric position.[6] Since such
a lack of specificity is an undesirable pharmacological
feature, the search for a-specific N-acetyl-glucosam-ACHTUNGTRENNUNGinidase inhibitors continues. In this regard the discov-
ery of more efficient methods for the reliable synthe-
sis of a-linked glycosides would be extremely useful,
and would enable the production of new compounds
for testing in such a context.
To address some of the constraints associated with
the chemical synthesis of oligosaccharides, such as
protection/deprotection strategies and selective acti-
vation of the anomeric centre, the use of engineered
retaining GH enzymes (referring to the anomeric con-
figuration of the product relative to the substrate)
was pioneered.[7] This is achieved by mutating either
the active site nucleophile or acid/base residues that
are required for normal GH catalysis (Scheme 1A) to
non-nucleophilic residues, thereby removing the en-
zymes ability to hydrolyse glycosidic bonds. To con-
vert the mutant enzymes into biocatalysts, two ap-
proaches are followed: in the first, which leads to gly-
cosynthases (GSs), mutation of the active site nucleo-
phile is countered by the use of an activated donor
substrate with an appropriate leaving group at the
anomeric position (Scheme 1B). If the leaving group
is in the same anomeric configuration as the substrate
Scheme 1. Mechanisms of a-glycoside hydrolase enzymes
and of the biocatalysts that are derived from them. A :
Mechanism of a retaining a-GH showing the active site resi-
dues acting as nucleophile and acid/base respectively. R can
be a sugar or an alcohol. B : Mechanism of an a-glycosyn-
thase (a-GS) derived from the a-GH shown in panel A
after exchange of its active site nucleophile for a non-nucle-
ophilic residue. Such enzymes can use two types of sub-
strates: if the leaving group is in the a-configuration (–OR1
in green; with R1 usually 2-, 4-nitrophenyl, or 2,4-dinitro-
phenyl), a small external nucleophile (Nu in blue) such as
azide or formate is added to allow the reaction with an ac-
ceptor (R2 can be a sugar or an alcohol) to take place, while
substrates with small leaving groups (green X= fluoride or
azide) in the b-configuration can react directly. In both cases
the product is an a-glycoside. C : Mechanism of an a-thiogly-
coligase (a-TGL) derived from the a-GH shown in panel A
by exchange of its active site acid/base residue for a non-
protic/non-nucleophilic residue. In this case the leaving
group (X in green) can be 2-, 4-nitrophenyl, 2,4-dinitrophen-
yl, fluoride or azide, and a thiolate (in orange) is used as ac-
ceptor, which acts as nucleophile to form an a-thioglycoside
product.
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of the wild-type enzyme an external nucleophile such
as sodium azide or sodium formate is added to chemi-
cally rescue the loss of the active site residue.[8] With
some small leaving groups (e.g., fluoride and azide) in
a configuration opposite to that of the substrate,
chemical rescue is not required (for reviews see
ref.[9]). In either case, the product formed accumulates
due to the impaired hydrolytic activity of the mutated
GH enzyme. In the second approach, which was de-
veloped specifically to produce non-hydrolysable thio-
glycosides, the exchange of the acid/base residue of
GHs is again countered by the use of an activated
donor with the same anomeric configuration as the
substrate but, in this instance, also by an acceptor
containing a thiol serving as nucleophile (Scheme 1C).
The thioglycoside product accumulates in the reac-
tion, as it is resistant toward enzymatic hydrolysis.[10]
Such enzymes are therefore dubbed thioglycoligases
(TGL), and their thioglycoside products usually serve
as GH inhibitors.
Despite the potency of these approaches – which
recently led to an engineered b-hexosaminidase with
improved transglycosidase activity[11] – so far a-GSs
are limited to a-fucosynthases [from families GH29
and GH95 according to the classification of carbohy-
drate active enzymes (CAZy, www.cazy.org[12]] , a-glu-
cosynthases (GH31), and a-galactosynthases
(GH36).[8a,9a,13] In striking contrast, thioglycoligases
are even less common. To the best of our knowledge,
only two a-TGLs have been produced so far, a thio-
glucoligase and a thioxyloligase, both belonging to
family GH31.[14]
Considering the need for selective inhibitors and
molecular chaperones of the medicinally relevant a-
N-acetyl-glucosaminidase enzymes, we decided to
embark on the modification of the catalytic residues
of an a-N-acetyl-glucosaminidase to produce a novel
a-GS and a-TGL able to synthesise a-N-acetyl-gluco-
saminide-containing glycosides. In CAZy, a-N-acetyl-
glucosaminidases (EC 3.2.1.50) are reported only in
family GH89,[12] in which the enzyme from the bacte-
rium Clostridium perfringens (CpGH89) has been
identified as a useful model system of the human
NAGLU. Studies on the 3D-structure of CpGH89
demonstrated that the enzymes belonging to this
family followed the classical retaining reaction mecha-
nism as opposed to b-hexosaminidases from families
GH18, 20, 25, 56, 84, and 85, which hydrolyse sub-
strates containing an N-acetyl (acetamido) or N-gly-
colyl group at the 2-position acting as nucleophile and
forming an oxazolinium ion intermediate.[15] In addi-
tion, mutations giving rise to MPS IIIB were also
identified from a homology model of NAGLU.[6,16] We
show here that CpGH89 mutants in the nucleophile
of the reaction were recalcitrant to act as a-glycosyn-
thases, but that modification of the acid/base with
non-nucleophilic amino acids led to efficient a-thio-
glycoligases capable of producing glycoside analogues
when used with suitable acceptors. The potential of
such compounds as pharmacological chaperones was
subsequently explored by determining the effects of
these novel products on parental CpGH89. Taken to-
gether, these observations demonstrated that the first
a-TGL is capable of efficiently producing a-N-acetyl-
glucosaminide-containing thioglycosides and N-acetyl-
a-d-glucosaminyl azide (a-GlcNAc-N3), a compound
that is not commercially available, yet holds promise
for the use in bio-orthogonal click chemistry reac-
tions. Such compounds can find broad application in
biomedicine for the synthesis of inhibitors and lead
compounds of a-GlcNAc-active enzymes.
Results and Discussion
Preparation of a-N-Acetyl-glucosaminosynthases
CpGH89 was selected for investigation as potential
chassis to produce mutant enzymes able to synthesise
N-acetyl-a-d-glucosaminide (a-GlcNAc) derived
products. The gene encoding for CpGH89 was pro-
duced as a truncated version of the wild type, which
comprised residues 26–916 as reported previously.[6]
The enzyme purified to homogeneity by a single-step
purification by immobilised metal affinity chromatog-
raphy showed the steady state kinetic constants listed
in Table 1. Previous studies demonstrated that the
enzyme followed a double-displacement retaining
mechanism and that the residues glutamic acid 601
(Glu601) and 483 (Glu483) were the nucleophile and
the acid/base of the reaction, respectively, with no evi-
dence of the participation in catalysis of the N-acetyl
group of the substrate (Figure 1A and B).[6] To test if
CpGH89 could be converted into an a-GS by follow-
ing the approach that was demonstrated to be suc-
cessful for GHs from several families[7] the nucleo-
phile Glu601 was exchanged for non-nucleophilic resi-
dues producing the alanine, glycine, and serine mu-
tants (E601A/G/S). These mutant enzymes had no de-
tectable activity on 2-nitrophenyl-N-acetyl-a-d-
glucosaminide (2NP-a-GlcNAc) and 2,4-dinitrophen-
yl-N-acetyl-a-d-glucosaminide (2,4DNP-a-GlcNAc)
as donor substrates. This is in agreement with previ-
ous studies on CpGH89[6] and with the 103-fold reduc-
tion of specific activity observed in other retaining
glycoside hydrolases mutated in the nucleophile of
the reaction.[17] However, remarkably, attempts to
chemically rescue the enzymatic activity of the mu-
tants acting on 2- and 2,4DNP-a-GlcNAc at 25 and
37 8C by using high concentrations (up to 1 M) of ex-
ternal nucleophiles (sodium azide, sodium formate,
sodium chloride and sodium fluoride) were all unsuc-
cessful and remained so even with the use of excess
of enzyme, different reaction temperatures, buffer/pH
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systems, substrate acceptors, and donor/acceptor
ratios (data not shown). In addition, no synthesis was
observed by using N-acetyl-b-d-glucosaminyl azide
(b-GlcNAc-N3) as donor, in an attempt to apply the
same strategy that was successful for other a-GSs
(Scheme 1B).[8a,9a] We confirmed that this lack of ac-
tivity was not due to changes in the stability (Fig-
ure 2A) or structure (Supporting Information, Fig-
ure S1A) of the E601A/G/S mutants. More likely, the
shape of the CpGH89 active site prevents entry and/
or placement of the acceptor substrates in catalytical-
ly relevant positions (Figure 1B). This renders the
enzyme resistant to conversion to an a-GS, as has
been reported for similar cases.[18] We therefore
turned our attention to the conversion of CpGH89
into a novel a-TGL.
Preparation of a-N-Acetyl-thioglycosaminoligases
a-TGLs are mutants in which the general acid/base
catalytic residue of the enzyme has been replaced by
a non-nucleophilic amino acid.[10] The mutant, in the
presence of a sugar donor with an excellent leaving
group and suitable acceptors with a thiol goup, cataly-
ses the formation of S-glycosidic linkages in high
yields. The replacement of the general acid/base of
CpGH89 with non-acidic residues (E483A/S/Q/G)
produced mutants with very low enzymatic activity on
2NP-a-GlcNAc (up to 780-fold less than the wild
type), on 4-nitrophenyl-N-acetyl-a-D-glucosaminide
(4NP-a-GlcNAc, up to 70-fold less) and on 2,4DNP-
a-GlcNAc (up to 30-fold less) (Table 1), confirming
what was previously reported for the CpGH89–
E483A mutant on 4NP-a-GlcNAc as substrate.[6] We
confirmed that this lack of activity is not due to struc-
ture-based defects introduced by the mutation
through circular dichroism (CD) analysis of the pro-
teins secondary structure elements (Supporting Infor-
mation, Figure S1B) which produced mutants with
very low enzymatic activity on 2NP-a-GlcNAc (up to
780-fold less than the wild type), 4-nitrophenyl-N-
acetyl-a-d-glucosaminide and by comparative analysis
of their temperature melting curves (Figure 2B). No
significant differences could be observed, indicating
that the loss of activity can be directly attributed to
the mutation.
Chemical Rescue of the Acid/Base Mutants with
NaN3
To test if the inactivation caused by mutation of the
general acid/base residue could be chemically res-
cued, we used sodium azide (NaN3) as external nucle-
ophile. In an initial test, the rate of the release of 2,4-
dinitrophenolate from the more reactive donor
2,4DNP-a-GlcNAc at 37 8C was measured in the pres-
ence of increasing concentrations of sodium azide as
catalysed by the Glu483 mutants (Figure 3A). The re-
Table 1. Steady-state kinetic parameters of wild type CpGH89 and its Glu483 mutants.
CpGH89 mutant (substrate) KM [mM] kcat [s
1] kcat/KM [s
1 mM1]
2NP-a-GlcNAc 25 8C 37 8C 25 8C 37 8C 25 8C 37 8C
wild type 41656 19010 2.310.11 230.3 5.6 121
E483Q 115 101 0.0330.001 0.0290.001 3.1 2.90
E483A 465 503 0.0760.001 0.0510.001 1.7 1.02
E483S 345 624 0.0640.014 0.0930.002 1.9 1.49
E483G 7914 685 0.0220.001 0.0460.001 0.3 0.67
4NP-a-GlcNAc
wild type 104979 1800300 0.170.01 0.350.01 0.16 0.19
E483Q 23719 20020 0.00620.0001 0.00650.0001 0.026 0.028
E483A 45943 80040 0.01300.0004 0.01460.0002 0.028 0.017
E483S 44325 70070 0.01580.0004 0.02400.0078 0.036 0.035
E483G 820220 60070 0.00270.0002 0.04820.0163 0.003 0.080
2,4DNP-a-GlcNAc
wild type 3.20.3 6.20.6 5.50.1 9.90.2 1718 1596
E483Q nd[a] nd nd nd nd nd
E483A nd nd nd nd nd nd
E483S nd nd nd nd nd nd
E483G nd nd nd nd nd nd
2,4DNP-a-GlcNAc+250 mM NaN3
E483Q 2.40.3 1.30.1 1.50.1 1.60.2 616 1289
E483A 0.70.1 1.80.3 1.10.1 2.31.2 1642 1307
E483S 1.10.2 1.80.2 2.10.1 2.40.7 2191 1326
E483G 1.70.4 3.20.4 1.00.1 1.90.9 582 591
[a] nd=not detectable.
Adv. Synth. Catal. 0000, 000, 0 – 0  2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim4
These are not the final page numbers! 
FULL PAPERS asc.wiley-vch.de
Stellenbosch University  https://scholar.sun.ac.za
sults clearly show that addition of azide restored the
mutants activity, with the CpGH89–E483A and
E483S mutants showing the best performance under
these conditions. This finding was confirmed by deter-
mining the steady-state kinetic constants of the mu-
tants acting on 2,4DNP-a-GlcNAc in the presence of
250 mM sodium azide (Table 1). TLC analysis of
these reactions incubated for 16 h showed that the
donor was converted to a glycoside with a retention
factor (Rf) very similar to that of the control b-
GlcNAc-N3, the closest commercially available ana-
logue of the expected product a-N-acetyl-d-glucosa-
mide azide (a-GlcNAc-N3) (data not shown). These
same conditions were subsequently used to determine
the synthetic efficiency of all the mutants (calculated
as the % products formed from the donor assuming
the amount of GlcNAc available in 2,4DNP-a-
GlcNAc as 100%) by analysis with high performance
anionic exchange chromatography using pulsed am-
perometric detection (HPAEC-PAD). The efficiency
was found to be remarkably high for all the mutants,
Figure 1. CpGH89 catalytic mechanism and active site
structure. A : Mechanism of the initial hydrolytic step cata-
lyced by CpGH89, showing the roles of the active site nucle-
ophile (Glu601) and acid/base (Glu483) residues. B : Sub-
strate binding pocket of CpGH89 shown as a section
through the solvent-accessible surface with GlcNAc (stick
structure with carbon atoms in green) bound. The anomeric
carbon that is the point of initial attack by Glu601 (nucleo-
phile) is indicated by an arrow. Both Glu601 and Glu483 are
shown as stick structures with carbon atoms in grey.
Figure 2. CpGH89 structure-based stability. A : Melting
curves of CpGH89 and its Glu601 mutants measured by fol-
lowing the change in CD absorption at 220 nm by heating
from 25 8C to 85 8C in intervals of 1 8C each minute. B : As
for A, but for the Glu483 mutants.
Adv. Synth. Catal. 0000, 000, 0 – 0  2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim5
These are not the final page numbers! 
FULL PAPERS asc.wiley-vch.de
Stellenbosch University  https://scholar.sun.ac.za
being 70.30.1%, 78.60.1%, 75.01.5% and 81.4
0.8% for E483A/S/Q/G, respectively, while the blank
mixture, containing all the reagents but the enzyme,
revealed only GlcNAc resulting from the spontaneous
hydrolysis of the donor (Supporting Information, Fig-
ure S2).
These high yields prompted us to reinvestigate the
activity of the mutants at either 25 or 37 8C with all
three donors and either low (5 mM) or high
(100 mM) concentrations of NaN3. TLC analysis
showed spots corresponding to a-GlcNAc-N3 for all
the mutants but only when 100 mM NaN3 was used
with either 2NP-a-GlcNAc or 2,4DNP-a-GlcNAc as
donors; we found that no reaction took place with
4NP-a-GlcNAc (Figure 4). Interestingly, the most
productive reactions were found to be those using
either 2NP-a-GlcNAc as donor at 37 8C or 2,4DNP-a-
GlcNAc at 25 8C. The results also show that when
2NP-a-GlcNAc was used as donor at 37 8C or
2,4DNP-a-GlcNAc at either temperature, hydrolysis
(i.e., formation of GlcNAc) was the predominant re-
action being catalysed. These findings show that
donor reactivity (as mediated by the nature of the
leaving group or the reaction temperature) is the pri-
mary consideration for activity. However, when reac-
tivity is too high, or in the absence of sufficient ac-
ceptor (NaN3), donor hydrolysis becomes a significant
problem. Optimised product formation would there-
fore entail finding a balance between donor reactivity
in the presence of a specific acceptor, and hydrolysis.
Taking these results together, we concluded that
the Glu483 mutants were promising candidates for
application as a-TGLs and set out to demonstrate this
using a range of thiol acceptors.
Evaluating a-TGL Activity using Selected Thiol
Acceptors
Encouraged by the chemical rescue of the activity of
the CpGH89 acid/base mutants using sodium azide,
we decided to perform a comparative evaluation of
their a-TGL activity. This was achieved by measuring
their synthetic efficiencies when incubated at 37 8C
using 2NP-a-GlcNAc as donor (the preferred choice,
since it is commercially available and showed high
levels of product formation in the reactions with
NaN3). As acceptors, the thiolated esters methyl or
ethyl thioglycolate were used, since the pKa values of
their thiol groups (~8.08 at 25 8C for methyl thiogly-
colate – from the National Center for Biotechnology
Information. PubChem Compound Database; CID =
16907, https://pubchem.ncbi.nlm.nih.gov/compound/
16907, accessed on August 5, 2016) would ensure that
at least half of the molecules in the reaction mixture
would be in the more nucleophilic thiolate form at
pH 8.0, i.e. , the conditions under which the tests were
performed. Mutants were incubated using >20-fold
molar excess of the donor, and the amount of thiogly-
coside product formed was measured by HPAEC-
PAD analysis of the reaction mixtures after 24 h and
48 h. The yield of converted product in each case was
calculated based on the amount of GlcNAc available
Figure 3. Thioglycoligase activity of CpGH89-derived acid/
base mutants. A : Chemical rescue of the activity of the
CpGH89–Glu483 mutants in the presence of increasing
amounts of sodium azide. The activity was measured at
37 8C using 2,4DNP-a-GlcNAc as donor under standard con-
ditions. B : Synthetic efficiency of the CpGH89–Glu483 mu-
tants using 2NP-a-GlcNAc as donor and either methyl thio-
glycolate (Me) or ethyl thioglycolate (Et) as acceptors. The
reaction mixtures were analysed by HPAEC-PAD after 24
and 48 h to quantify the amount of product formed. The
synthetic efficiency of the mutants was determined assuming
the amount of GlcNAc available in 2NP-a-GlcNAc as
100%. Bars indicate the average value obtained from dupli-
cate experiments; the error bars indicate the standard devia-
tion.
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in 2NP-a-GlcNAc set as 100%. Blanks showed only
unreacted donor (Supporting Information, Figure S3).
The results show that in the case of methyl thioglyco-
late, the CpGH89–E483A mutant is by far the most
efficient a-TGL, with a yield of 81.810.2% after
only 24 h (Figure 3B). With the larger ethyl thioglyco-
late acceptor the efficiency of the mutants was re-
duced, and in this case the E483S mutant gave the
Figure 4. Products of the chemical rescue of CpGH89–E483 mutants from different donors as analysed by thin layer chro-
matography (TLC). b-GlcNAc-N3, GlcNAc, and the respective donor are loaded in the first three lanes of each TLC plate
as references. Three sets of reaction mixtures were analysed in each case, with either no NaN3, or 5 mM or 100 mM NaN3
present, and with each set containing wild-type enzyme (WT), E483Q (Q), E483A (A), E483S (S) mutant, and a blank reac-
tion without enzyme (B). Reaction mixtures were incubated at either 25 8C or 37 8C, as indicated. Spots that were UV-visible
are indicated by dotted circles; other spots were visualised by staining with 10% sulphuric acid in methanol, followed by in-
cubation at 150 8C for 15 min. A : Using 2NP-a-GlcNAc as donor at 25 8C. B : Using 2NP-a-GlcNAc as donor at 37 8C. C :
Using 4NP-a-GlcNAc as donor at 25 8C. D : Using 4NP-a-GlcNAc as donor at 37 8C. E : Using 2,4DNP-a-GlcNAc as donor
at 25 8C. F : Using 2,4DNP-a-GlcNAc as donor at 37 8C.
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best results (64.61.70%, also after only 24 h). The
E483Q mutant was found to show the least efficient
activity, whereas the activity of the E483G mutant
corresponded to those of the alanine and serine mu-
tants with ethyl and methyl thioglycolate, respectively.
In the light of these results, we chose the CpGH89–
E483A and E483S mutants to investigate their activity
as a-TGLs using a variety of thiol acceptors at con-
centrations of between 2.5 mM and 100 mM. Reac-
tions were performed at 37 8C using 5 mM 2NP-a-
GlcNAc as donor in 100 mM sodium phosphate
buffer. Based on previous reports that the pKa of the
thiol group is an important consideration in its ability
to act as acceptor in a thioglycoligase reaction,[19] we
chose the thiols to span a range of pKa values, and
also performed the reactions at various pHs to evalu-
ate if the predominance of the thiolate anion is a pre-
requisite for the TGL reaction to proceed. Reactions
were evaluated by TLC and scored for product for-
mation and hydrolysis as a side-reaction (Table 2).
The results show that a-TGL activity is usually ob-
served with thiols that have pKa values of 8 and
lower, i.e. , thiols that would be at least 50 % ionised
at pH 8.0. We found that promoting the ionisation of
thiols with higher pKa values was not practically pos-
sible, since the hydrolysis of the donor becomes a sig-
nificant side reaction at higher pH values. In fact, al-
though the 2NP-a-GlcNAc donor (as an acetal) is ex-
pected to show enhanced stability at increased pH,
the observed side reaction likely is the result of the
higher concentration of HO by acting as nucleophile
on the enzyme-GlcNAc intermediate. Indeed, we ob-
served that for the thiosugar methyl 4-deoxy-4-thio-
glucoside and for cyclohexanethiol, both of which
have pKa values of 9.5 and above, GlcNAc was the
major product formed. These findings indicated that
the CpGH89–E483A and E483S mutants have excel-
lent a-TGL activity, but only if the thiol acceptor is
carefully chosen.
CpGH89–E483A/S Mutants as Preparative Scale a-
TGL Biocatalysts
The excellent synthetic efficiency of the CpGH89–
E483A mutant motivated us to determine if its a-
TGL activity would also translate to reactions on
a preparative (multimilligram) scale, and allow the
synthesis and purification of a-GlcNAc-N3 (using
NaN3 as external nucleophile) or a-GlcNAc thiogly-
cosides (using thiol acceptors with pKa values of 8 or
lower). Towards this end, we performed biocatalysis
reactions using CpGH89–E483A and/or E483S mu-
tants using ~0.08 mmol 2NP-a-GlcNAc as donor and
a 20-fold molar excess of acceptor at 37 8C. Reaction
progress was monitored by TLC, and once being
judged as complete, the reaction product was purified
by means of four sequential steps that removed the
protein, buffer and nitrophenol side-product, respec-
tively, before the final product was purified by flash
chromatography on silica. The purified products were
analysed by 1H and 13C NMR and HR-MS analysis to
confirm their structures, including the expected a-con-
figuration of the newly-formed glycosidic bond. The
preparative scale yields were also determined based
on the amount of donor used. These values, summar-
ised in Table 2, show that the small scale synthetic ef-
ficiencies were excellent predictors of the mutants
preparative scale abilities, with the CpGH89–E483A
mutant also giving preparative yields in excess of
80%. The lower synthetic yields observed in some
cases are due to less favourable transglycosylation/hy-
drolysis ratios (compare the columns showing donor
hydrolysis and product formation for each enzyme
and substrate in Table 2) and, in some cases to diffi-
culties encountered in the purification of the products.
However, it is worth mentioning that the overall effi-
ciency of the chemo-enzymatic approach shown here
is much better than the classical chemical synthesis
strategy that needs many more steps. Moreover, the
yields obtained for the compounds prepared in this
study are comparable to the overall yield of 35 % re-
ported for one of these compounds (entry 1, Table 2)
prepared in six steps by traditional synthetic meth-
ods.[21] These findings confirm that the CpGH89–
E483A mutant is an excellent a-TGL biocatalyst. In
addition, this mutant also provides a means for the
preparation of a-GlcNAc-N3, a compound that is cur-
rently not commercially available and, according to
the chemical database SciFinder, has never been de-
scribed before. Nevertheless, it yet has multiple po-
tential uses – including as azide substrate in the ex-
ceedingly versatile “click” reactions such as cop-
per(I)-catalysed- and strain-promoted azide–alkyne
cycloadditions (CuAAC and SPAAC).[22] Taken to-
gether, the CpGH89–E483A mutant opens routes to
the facile preparation of a variety of a-linked S-glyco-
sides and triazoles of high potential value that were
previously not synthetically tractable.
Effect of the a-TGL Products on CpGH89
Since GH enzymes cannot hydrolyse the S-glycosidic
bond, we next sought to demonstrate the potential of
the biocatalytically-prepared GlcNAc a-thioglycosides
as inhibitors of N-acyl-glucosaminidases. This was
done by evaluating the ability of the compounds to
bind to and inhibit the GH activity of wild-type
CpGH89. We included in these tests commercially ob-
tained b-GlcNAc-N3 to demonstrate the importance
of the configuration of the glycosidic bond, as well as
GlcNAc-a(1!4)-(methyl 4-deoxy-4-thioglucoside)
[GlcNAc-S-(Me4-thioGlc)], the expected product of
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Table 2. The a-thioglycoligase activity of CpGH89–E483A and E483S with various thiol acceptors or sodium
azide, and 2NP-a-GlcNAc as donor.
[a] Values taken from the National Center for Biotechnology Information (NCBI) PubChem Compound Database
(https://pubchem.ncbi.nlm.nih.gov/), or from ref.[20] The pKa value for methyl 4-deoxy-4-thioglucoside was cal-
culated using ChemAxons pKa predictor.
[b] Relative extent of donor hydrolysis based on the intensity of the spots representing GlcNAc and 2NP-a-
GlcNAc as visualised from the TLC analyses of the reaction mixtures.
[c] Relative extent of product formation based on the intensity of the anticipated product spot (identified by com-
parison with a standard, if available) as visualised from the TLC analyses of the reaction mixtures.
[d] Yield of purified product prepared from preparative scale biocatalytic transformations, based on the amount of
2NP-a-GlcNAc donor used as starting material.
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the TGL reaction with methyl 4-deoxy-4-thiogluco-
side as acceptor. While we were not able to prepare
this compound through biocatalysis, we prepared it by
chemical synthesis to act as standard for the TGL
evaluation tests, and it was therefore available for
testing.
To quantify the inhibitory effect we measured the
specific activity at standard conditions of wild-type
CpGH89 at 600 mM of each compound. This concen-
tration was chosen based on this amount of O-(2-acet-
amido-2-deoxy-d-glucopyranosylidene)amino-N-phe-
nylcarbamate (PUGNAc), a known competitive in-
hibitor of CpGH89.[6] leading to 20% residual activity.
Among the a-TGL products tested, the products of
the reactions with methyl and ethyl thioglycolate
(GlcNAc-S-CH2CO2Me and GlcNAc-S-CH2CO2Et,
respectively) showed the highest inhibition with 79%
and 62% of residual activity, respectively (Figure 5A).
In order to evaluate if the products obtained by
chemical rescue and by the TGL approach could pro-
tect wild-type CpGH89 from unfolding by binding to
the enzyme, we performed differential scanning fluo-
rimetry (DSF) experiments in the 25–94 8C tempera-
ture range and in the presence of 10 mM of each
product, the highest concentration used for allosteric
pharmaceutical chaperones (PCs).[23] As positive con-
trols we used PUGNAc (0.2 mM) and two other
known N-acetylglucosaminidase inhibitors: 2-acetami-
do-1,2-dideoxynojirimycin (2AcDNJ, 0.1 mM) and 6-
acetamido-6-deoxycastanospermine (6AcCAS,
2.8 mM), i.e., at concentrations 30-fold higher than
their respective Ki or Kd values.
[6] The thermal stabili-
ty analysis (Figure 5B) revealed that the three inhibi-
tors 6AcCAS, PUGNAc and 2AcDNJ increased the
melting temperature (Tm) of wild-type CpGH89 by
6.21 8C, 3.76 8C, and 2.11 8C, respectively (Figure 5 C).
Among the products of the a-TGL, the best stabilis-
ing effect was produced by a-GlcNAc-N3 (DTm =
4.02 8C), while b-GlcNAc-N3 did not show any stabili-
sation of the wild-type CpGH89. This finding demon-
strates the importance of the configuration of the gly-
cosidic bond for binding, and as a potential factor in
Figure 5. Effect of the a-thioglycoligase products on
CpGH89 activity and stability. A : Effect by known inhibi-
tors and a-TGL products on the activity of wild type
CpGH89. Bars indicate the average value obtained from du-
plicate experiments; the error bars indicate the standard de-
viation. B : Denaturation curves followed by differential
scanning fluorimetry (DSF) of wild type CpGH89 in the ab-
sence of ligands (control) and in the presence of the
6AcCAS inhibitor and a-GlcNAc-N3 are shown as case ex-
amples. C : The increasing melting temperatures (Tm) of wild
type CpGH89 in the presence of the indicated ligands as de-
termined by DSF. Bars indicate the average value obtained
from triplicate experiments; the error bars indicate the stan-
dard deviation.
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establishing selectivity. GlcNAc, the product of the
hydrolysis reaction, also significantly improved the
thermal stability of the enzyme (DTm = + 3.38 8C)
compared to galactose (DTm = +0.70 8C), indicating
that the stabilising effect of a carbohydrate-derivative
molecule could be directly related to the donor 1
subsite.[16] It is worth noting that a-GlcNAc-N3, which
is the second-best PC after 6AcCAS, showed no in-
hibition of CpGH89 at 0.6 mM concentration (Fig-
ure 5A), a characteristic highly recommended in
second generation PCs as they can promote the cor-
rect folding of the defective target enzyme with no
detrimental effect on its activity in the lysosome.[3,24]
In addition, as already stated above, a-GlcNAc-N3
can be used as azide substrate in “click” reactions,
thus, showing interesting potential as lead for novel
a-linked PC molecules to test in pharmacological
chaperone therapies for MPS IIIB.
Conclusions
Stable a-linked analogues of GlcNAc glycosides hold
great potential for the development of new selective
therapies for a range of diseases, for example, com-
pounds that can act as inhibitors of the enzymes in-
volved in the biosynthesis of essential cofactors in
pathogenic organisms,.[25] or by stabilising the struc-
tures of defective mutant variants of key metabolic
enzymes whose deficiency lead to genetic diseases.[4,5]
However, such compounds are not easily obtained
through chemical means due to the requirement for
multistep synthesis with several protection/deprotec-
tion protocols. Here we have demonstrated that a-
GlcNAc-N3 and several a-GlcNAc thioglycosides can
be obtained by preparative scale biocatalysis using an
engineered mutant of the a-N-acetyl-glucosaminidase
from Clostridium perfringens (CpGH89) in which its
catalytically essential acid/base residue (Glu483) has
been replaced by alanine. The development of this a-
N-acetyl-thioglycosaminoligase lowers the barrier to
the access of a-linked GlcNAc glycoside analogues
significantly, and should facilitate the investigation of
such compounds as therapeutic agents. In this study
we highlight the potential scope for such compounds
by showing their ability to inhibit or stabilise the
wild-type form of CpGH89, a proxy for the NAGLU
enzyme whose deficiency causes mucopolysaccharido-
sis IIIB, or Sanfilippo syndrome.
Experimental Section
General Materials and Methods
The donor substrates 2- and 4-NP-a-GlcNAc were obtained
from Carbosynth (Compton, U.K.) while 2,4DNP-a-GlcNAc
was prepared by chemical synthesis using a previously pub-
lished protocol.[26] Methyl 4-deoxy-4-thioglucoside and
GlcNAc-S-(Me4-thioGlc) were prepared by chemical syn-
thesis as outlined in the Supporting Information. General
chemicals, reagents, and media were purchased from Sigma–
Aldrich or Merck Chemicals (Darmstadt, Germany) and
were of the highest purity. Solvents used for reactions were
Chromasolv HPLC grade solvents (Sigma–Aldrich), and the
ethyl acetate (EtOAc), methanol (MeOH) and water used
for purification were purchased from Merck Chemicals. Pro-
tein purifications were conducted on an kta Prime system
(GE Healthcare). Spectrophotometric assays were per-
formed on a Cary 100 Scan spectrophotometer (Varian, Aus-
tralia), coupled with a thermally controlled Peltier system.
High performance anionic exchange chromatography with
pulsed amperometric detection (HPAEC-PAD) was per-
formed on a Thermofisher Scientific system equipped with
a CarboPac PA200 Analytical (2 205 mm) column. Solid
phase extraction (SPE) columns (Phenomenex Strata)
were obtained from Separations (Cape Town, South Africa).
Cloning and Mutagenesis of CpGH89 Wild Type and
Mutants
The synthetic CpGH89 wild type and E601A mutant genes
were custom-made by GeneArt Gene Synthesis (Thermo-
fisher Scientific) in pET28a vector, with N-terminal 6  His
tag. The mutants E601G/S and E483G were prepared from
the pET28a-CpGH89wt by using the GeneTailor Site-Di-
rected Mutagenesis system (Invitrogen) with the following



















PCR-generated constructs were verified by sequencing.
Expression and Purification of CpGH89 Wild Type
and Its mutants
CpGH89 wild type and mutants were expressed in E. coli
strain JM109 (DE3) or BL21*(DE3). The cells transformed
with the appropriate construct were grown at 37 8C in 2 L of
Luria-Bertani (LB) broth supplemented with kanamycin
(50 mg.mL1). Gene expression was induced by the addition
of 1 mM IPTG when the culture reached an OD600 of 1.0.
Growth was allowed to proceed for 16 h, and cells were har-
vested by centrifugation at 5000 g. The resulting cell pellet
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was resuspended in 50 mM sodium phosphate buffer,
pH 8.0, 300 mM NaCl and 1% TRITON-X100 with a ratio
of 5 mL g1 cells, followed by incubation at 37 8C for 1 h
with 20 mg of lysozyme (Fluka) and 25 Ug1 cell of DNAseI
(SIGMA). Cells were lysed by 5 sonication cycles and cell
debris was removed by centrifugation at 12000 g for 30 min.
The cell free extract (CFE) was loaded on a HisTrap FF
column (GE-Healthcare) equilibrated with 50 mM sodium
phosphate buffer, pH 8.0, 300 mM NaCl (Buffer A). After
an initial wash-step (20 column volumes) with Buffer A, the
protein was eluted at 250 mM imidazole in Buffer A. The
active fractions were pooled, dialysed against 20 mM
sodium phosphate buffer, pH 7.3, 150 mM NaCl (PBS
buffer) and stored at 4 8C. The protein concentration was
determined with the Bradford assay (Bio-Rad). After this
procedure the enzymes were more than 95% pure by SDS-
PAGE, with an approximate final yield of 20 mgL1 of cul-
ture.
Comparative Structural Analysis
CD spectroscopy and thermal analysis were conducted using
a Photophysics Chirascan-plus spectrometer at 25 8C. The
samples contained 0.5 mgmL1 protein in 100 mM sodium
phosphate buffer (pH 7.3). The optimum wavelength for
analysis of thermal stability was determined by a CD ab-
sorption scan from 200–300 nm at 25 8C. The thermal stabili-
ty experiments were conducted by heating the samples from
25 8C to 100 8C and measuring the changes in CD absorption
at 220 nm.
CpGH89 Hydrolytic Activity Assay
Hydrolytic activity assays for CpGH89 wild type and mu-
tants at 25 8C were conducted using a microplate-based con-
tinuous spectrophotometric assay measuring the release of
the nitrophenolate from the respective donor that was used.
For assays conducted at 25 8C, reactions were performed in
triplicate in a final reaction volume of 250 mL. The assays
contained 2 mM enzyme, 100 mM sodium phosphate buffer
(pH 7.3), and substrate concentrations in a range varying be-
tween 0–2.5 mM. The liberation of the nitrophenolate ion
was monitored at 400 nm (e=1.8 mM1 cm1 and
13.3 mM1 cm1 for 2- and 4-nitrophenolate, respectively)
for 10 min. Assays conducted at 37 8C were performed in
a final reaction volume of 1 mL. The assays typically con-
tained 220 nM of wild type and 1.3–4.11 mM of mutant en-
zymes, in 100 mM sodium phosphate buffer (pH 7.3), and
substrate concentrations in a range varying between 0.5 mM
and 5 mM. The liberation of the nitrophenolate ion was
monitored at 405 nm (e=3.63 mM1 cm1,
16.39 mM1 cm1and 11.92 mM1 cm1 for 2-, 4- and 2,4-dini-
trophenol, respectively) for 10 min. The rates of product for-
mation were calculated using linear regression analysis of
the initial linear portions of the progress curves; these were
plotted against the substrate concentration to obtain the ac-
tivity profiles. The kinetic parameters kcat and KM were ob-
tained by performing a least squares fitting of the data to
the Michealis–Menten equation. One unit of enzyme activity
was defined as the amount of enzyme catalysing the hydrol-
ysis of 1 mmol of substrate in 1 min under the conditions de-
scribed. Blank mixtures, containing all the reagents but the
enzyme(s) were incubated at the same conditions and used
to subtract the spontaneous hydrolysis of the donor(s).
Chemical Rescue with Sodium Azide
The chemically rescued hydrolase activity of the four
CpGH89 acid/base mutants (E483A/S/Q/G) was measured
in 100 mM sodium phosphate buffer at pH 7.3 using 5 mM
2,4DNP-a-GlcNAc and increasing the concentrations of
sodium azide (between 50 mM and 1.5 M) at 37 8C. The spe-
cific activity was measured as described for the hydrolytic
activity assay above. Blank mixtures, containing all the re-
agents but the enzyme(s) were incubated at the same condi-
tions and used to subtract the spontaneous hydrolysis of the
donor(s). Aliquots of the reaction mixtures (20 mL) incubat-
ed for 16 h were analysed by thin layer chromatography
(TLC) as described previously.[27] Briefly, reaction mixtures
were loaded on a silica gel 60 F254 plate by using EtOAc/
MeOH/H2O (70:20:10 v/v) as eluent and were detected by
exposure to 10% sulphuric acid in methanol, followed by
charring at 170 8C. The efficiency of each mutant was evalu-
ated by HPAEC-PAD analysis at 35 8C using a flow rate
0.4 mL min1 and 16 mM sodium hydroxide (NaOH) as
eluent. For quantification, a calibration curve was created
with three different amounts (0.25, 0.75 and 1.5 nmol) of the
a-GlcNAc-N3, and cellobiose (0.75 nmol) was included as in-
ternal standard. The synthetic efficiency of the mutants was
determined assuming the amount of GlcNAc available in
2,4DNP-a-GlcNAc as 100%. All the samples were analysed
in duplicate.
Evaluating the a-Thioglycoligase Activity of
CpGH89–E483A/S with Selected Thiols
The a-thioglycoligase activities of the CpGH89–E483A/S
mutants were evaluated using 2NP-a-GlcNAc as the donor.
All thioglycoligase reactions were performed using 100 mM
sodium phosphate buffer, with pH ranging from 5.8–8.0
(values indicated in Table 2), 1.33 mM enzyme and 5 mM
2NP-a-GlcNAc in a final volume of 200 mL. The final thiol
concentration ranged from 2.5 mM to 100 mM. The reac-
tions were incubated at 37 8C, and the mixtures were ana-
lysed by TLC with ethyl acetate/methanol/water (EtOAc/
MeOH/H2O) (70:20:10 v/v) using UV light to detect the ni-
trophenol group, and staining with 10% sulphuric acid in
methanol, followed by incubation at 150 8C for 15 min, to
visualise all other components. For each reaction 4 5 mL of
the solution were spotted on the TLC.
Synthetic Efficiency of CpGH89–E483 Mutants with
Methyl and Ethyl Thioglycolate as Acceptor
To determine the synthetic efficiency of the four CpGH89
acid/base mutants (CpGH89–E483A/S/Q/G), reactions were
performed at 37 8C using 100 mM sodium phosphate buffer
(pH 8.0), 1.33 mM enzyme, 5 mM 2NP-a-GlcNAc as donor
and 106 mM methyl or ethyl thioglycolate as acceptor (sup-
plied with 17.9 mM DTT) in a final volume of 200 mL. At
time intervals (0–48 h) aliquots (10 mL) were withdrawn, di-
luted 1:100 with water and analysed by HPAEC-PAD at
35 8C using a flow rate of 0.4 mL. min1 and the following
elution program: [segment 1] 0–12’ isocratic 16 mM NaOH,
[segment 2] 12–42’ up to 96 mM NaOH, [segment 3] 42–52’
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step to 160 mM NaOH. The total amount of the expected
thioglycoside product was determined by using a calibration
curve with three different amounts (0.53, 1.06 and 2.12 nmol
of a-GlcNAc-S-CH2CO2Me and 0.25, 0.75 and 1.5 nmol of
a-GlcNAc-S-CH2CO2Et, respectively) of the product, and
cellobiose (0.73 nmol) as internal standard. The authentic
compounds used to obtain the calibration curves were ob-
tained by preparative scale biocatalysis as outlined below.
The synthetic efficiency of the mutants was determined as-
suming the amount of GlcNAc available in 2NP-a-GlcNAc
as 100%. All the samples were analysed in duplicate.
Preparative Scale Biocatalysis
Preparative scale a-TGL reactions were carried out in
15 mL of 100 mM sodium phosphate buffer (pH 8.0). 2NP-
a-GlcNAc (0.026 g, 0.076 mmol) was added as the donor,
followed by addition of thiol (20 equiv.) or 100 mM sodium
azide as the acceptor. DTT (0.160 mM, 0.370 mg,
0.0024 mmol,) was added as reducing agent to prevent disul-
phide bond formation in the case of the thiol acceptors. The
reaction was initiated by addition of the thioglycoligase cat-
alyst (1.33 mM of either CpGH89–E483A or CpGH89–
E483S) to the reaction mixture followed by incubation at
37 8C. Reaction progress was monitored and analysed by
TLC (EtOAc/MeOH/H2O; 70:20:10 v/v). Upon completion
(usually after overnight incubation), the reaction was fil-
tered through a syringe filter (13 mm GHP Acrodisc filter
with 0.2 mm GHP membrane) to remove the protein. The fil-
tered mixture was loaded onto an SPE column (Phenomen-
ex Strata C18-U, 55 mm, 70 A, 10 g/60 mL) and the crude
product was eluted with methanol. The fractions with the
crude product were pooled together and concentrated by
rotary evaporation. In the case of reactions with acceptors
that do not proceed close to completion (as in the case of
thiophenol), the crude product was treated with wild-type
CpGH89 for 72 h under standard conditions to hydrolyse
any residual donor that may be present. The enzyme was
subsequently removed as described above. The crude prod-
uct was purified by flash column chromatography on silica
(EtOAc/MeOH/H2O; 70:20:10 v/v). Any residual nitrophe-
nol was removed by passing the purified product through
Phenomenex Strata Phenyl (55mm 70 ) SPE column, elut-
ing with water. The final purified products were obtained
following by freeze drying for three days to remove any
water, and were fully characterised by 1H NMR, 13C NMR
and MS-ESI or HR-MS (see the Supporting Information for
data).
CpGH98 Wild Type Inhibition assay and Thermal
Stability
The inhibitory effects of the different compounds (0.6 mM
each) were assayed by measuring the specific activity of
CpGH89 wild type on 2NP-a-GlcNAc in 100 mM phosphate
buffer (pH 7.3) at 37 8C as reported above. Thermal stability
of CpGH89 wild type was measured by DSF as previously
reported[23] with some modifications. Briefly, CpGH89 wild
type (2.5 mg) was incubated in citrate phosphate buffer and
SYPRO Orange dye 5X, in a total volume of 25 mL in the
presence of the different compounds under test. Samples
were heated from 25 to 94 8C in a Real-Time Light Cycler
(Bio-Rad, Milan, Italy). Thermal stability scans were per-
formed at 0.2 8C min1 and the SYPRO Orange fluorescence
was normalised to maximum fluorescence value within each
scan to obtain relative fluorescence. All the measurements
were performed in triplicate. The Tm value represents the
flection point of the transition curve, as described by the
Boltzmann equation.[28]
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2.2 Additional information 
The following experiment was also conducted as part of the published study, but was 
not included in the manuscript. 
 2.2.1 Generation of S-GlcNAc 1-thioacetate through the use of an α-TGL  
2.2.1.1 Evaluation of potassium thioacetate as the thiol acceptor molecule  
We decided to test if potassium thioacetate can act as the thiol acceptor in an α-
TGL-catalyzed reaction because of its low pKa and because hydrolysis of the 
resulting thioester product would give 1-mercapto-α-GlcNAc, a useful starting 
material in several syntheses. The α-N-acetyl-thioglycosaminoligases CpGH89-
E483Ala/Ser/Gln were chosen as the α-TGL and 2NP/2,4DNP-α-GlcNAc as donors 
for these tests (Figure 2.1). The thioglycoligation reactions performed at different pH 
values (5.8-8.0) using 100 mM potassium thioacetate were evaluated using TLC 
analysis. A new spot (which could correspond to the expected product) was 
observed only in the presence of the α-TGLs (Figure 2.2). The spot was more visible 
in the reactions conducted at pH values between 5.8 and 7.3. The reactions 
performed with α-GlcNAc-DNP as donor showed more hydrolysis of the donor, 
especially with CpGH89-E483Gln, while those performed with α-GlcNAc-ONP still 
showed a lot of unreacted donor being present. This indicated that the reactions with 
α-GlcNAc-ONP required longer incubation than those with α-GlcNAc-DNP, 
especially when CpGH89-E483Gln is used as α-TGL, or CpGH89-E483Ala or 
CpGH89-E483Ser at pH 5.8-6.5.  
Fig. 2.1: The enzymatic reaction of α-N-acetyl-thioglycosaminoligases CpGH89-
E483Ala/Ser/Gln with 2NP/2,4DNP-α-GlcNAc as donors and potassium thioacetate 
as acceptor and the excepted product. R1, 2,4DNP/2NP-α-GlcNAc and R2, 
E483Ala/Ser/Gln 
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Fig. 2.2: TLC analysis of α-N-acetyl-thioglycosaminoligase reaction with 100 mM of 
potassium thioacetate as acceptor and 2,4DNP/2NP-α-GlcNAc as donors at 
increasing pH concentrations (pH 5.8-8.0). WT, CpGH89-wild type; A, CpGH89-
E483A; S, CpGH89-E483S; Q, CpGH89-E483Q and B, no enzyme. A, α-GlcNAc-
ONP, B α-GlcNAc-DNP.  
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2.2.1.2 Preparative scale biocatalytic preparation of S-GlcNAc 1-thioacetate 
using the α-TGLs CpGH89-E483Ala/Ser/Gln 
To establish if the spot observed in the TLC analysis of the small scale reactions 
done with potassium thioacetate as acceptor indeed corresponds to the expected 
product, preparative scale biocatalysis was performed to allow for isolation of the 
product. The biocatalysis reactions were performed using CpGH89–Glu483Ala 
and/or Ser using ~0.08 mmol 2NP--GlcNAc as donor, buffer with pH 7.3, and 20-
fold molar excess acceptor at 37°C. The reaction progress was monitored by TLC 
until completion, that is, until depletion of the donor. After the completion the enzyme 
was removed as described for the other preparative scale reactions. However, 
during purification process the new spot identified during the test reactions 
disappeared, with the signal of the by-product (GlcNAc) spot getting stronger. This 
suggested that during removal of the buffer components conditions changed such 
that the thioester bond of the expected product was cleaved, releasing 1-mercapto-
α-GlcNAc, which could have more or less running TLC condition as GlcNAc. 
Unfortunately, separation of the degradation product and GlcNAc the by-product 
proved to be very difficult, so that it was impossible to verify the structure of the 
degradation product. This led to investigation of reactions with potassium thioacetate 
as acceptor to be abandoned.  
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Chapter 3:  
Chemo-enzymatic synthesis of GlcNAc 
thioglycosides and ‘click’ adducts as 
alternative substrates or inhibitors of the 
deacetylases MshB and BshB  
3.1 Introduction 
The problem of antibiotic resistance in Staphylococcus aureus (S. aureus) and 
Mycobacterium tuberculosis (M. tuberculosis) is increasing rapidly [1-7], with millions 
of people dying every year as a result of infections by these pathogens. Additionally, 
very few new antibacterial drugs have been developed in the past decades. 
Consequently, the world is heading towards a post-antibiotics era [5]. 
The mycothiol (MSH) and bacillithiol (BSH) biosynthetic pathway enzymes and 
enzymes dependent on these metabolites are currently viewed as potential targets 
for the development of new antibacterial drugs against M. tuberculosis and S. 
aureus, respectively [8-11]. MSH and BSH are low molecular weight thiols that play 
several essential functions within their hosts [8, 10, 12-15]. Apart from the main 
function of maintaining the redox balance in the microorganism, they can also 
provide nutrients during starvation, or act as enzyme co-factors. In addition, they are 
utilised by the microorganisms in defensive reactions against xenobiotic agents, 
including antibiotics.  
The range of reactions are catalysed by different MSH-dependent enzymes which 
includes mycothiol S-transferase (MST), mycothiol disulphide reductase (Mtr), thiol 
peroxidase, mycothiol-S-nitrosoreductase/-formaldehyde dehydrogenase (MscR) 
and mycothiol S-conjugate amidase (Mca (Figure 3.1). The metabolic reactions of 
BSH are not yet fully characterized, but are assumed to occur in the same way as 
MSH [10, 12, 15]. For example, the BSH-dependent detoxification metabolism has 
been found to occur in the same way with MSH, including the involvement of 
enzymes such as bacillithiol S-transferase (BST), with exception of the additional 
acetylation by cysteinyl S-conjugate acetyltransferase (CAT) of the cysteinyl S-
conjugate released by the action of bacillithiol S-conjugate amidase (Bca) (compare 
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Figure 3.2 to Figure 3.1) [12, 15, 16]. Of the different MSH and BSH biosynthetic- 
and -dependent enzymes, the deacetylases BshB, MshB, Mca and Bca are 
specifically considered good potential targets for the development of new 
antimicrobial drugs. This is because their functions are interlinked and because 
compounds developed as inhibitors of MshB/Mca have been found to inhibit both 
enzymes. The enzymes are also interlinked because in the absence of the mshB 
and bshB genes, Mca and Bca allow for the synthesis of MSH and BSH. This was 
demonstrated by a gene knockout study in which the mshB gene was removed; the 
resulting strain was found to still produce MSH, even in the absence of mshB [8, 17]. 
Mca normally hydrolyses the glucosaminyl-amide bond of the MS-conjugated 
complex formed between MSH and a xenobiotic during the elimination of such 
xenobiotics; the result is a mercapturic acid derivative and glucosamine-inositol 
(GlcN-Ins), a product of MshB (Figure 3.1). The generated GlcN-Ins can then be 
recycled back to the MSH biosynthetic pathway to generate MSH, while the 
mercapturic acid derivative is excreted by the microorganism. The same reaction 
sequence is thought to occur with Bca (Figure 3.2). In addition, these 
metalloamidases have also been attributed to the development of drug resistance 
within the respective bacteria [8, 15, 16]. 
3.1.1 Functions of BshB, MshB, Bca and Mca 
BshB, MshB, Bca and Mca are enzymes that belong to the LmbE-like superfamily of 
metallohydrolases that catalyse the breakdown of several biological substrates in the 
presence of a metal ion such as zinc, cobalt, magnesium etc., with zinc usually being 
the preferred metal [11]. Mca and Bca are metalloamidases that hydrolyse the N-acyl 
group of compounds with an N-acylglucosamine core, while BshB and MshB are 
metallodeacetylases that hydrolyses substrates with an N-acetylglucosamine core 
[11, 15, 18]. Mca and Bca hydrolyse the glucosaminyl-amide bond of MS-S-
conjugate and Bs-S-conjugate, respectively to release mecapturic acid toxin and 
their relative GlcN-moiety: GlcN-Mal for Bca and GlcN-Ins for Mca which are 
recycled back into the biosynthetic pathway. BshB catalyses the second reaction of 
BSH biosynthetic pathway, while MshB catalyses the third reaction of MSH 
biosynthetic pathway. All four metallohydrolases reactions yield an N-glucosamine 
glycosides as products (Figure 3.1 and 3.2).  
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Fig. 3.1: The MSH biosynthesis pathway and the different metabolic reactions with 
the various MSH-dependent enzymes [8, 14, 19, 20]. The biosynthesis of MSH is 
represented in black, while the defensive reactions against xenobiotics are shown in 
blue, reaction in which MSH acts as a co-factor in green, and the degradation of 
MSH during nutrient starvation illustrated red. ROOH, reactive oxygen species; 
MSSM, mycothiol disulphide; NO, nitrogen reactive species; MSCH2OH, S-
hydroxymethyl-mycothiol; MSNO, nitrosomycothiol; MSNHOH, mycothiol-N-hydroxy-
sulfenamide and X, xenobiotics.  
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Fig. 3.2: The BSH biosynthesis pathway (black) and the detoxification reactions with 
the various BSH-dependent enzymes (blue) [12]. BST, bacillithiol S-tranferase; Bca, 
bacillithiol S-conjugate amidase; CAT, cysteinyl S-conjugate acetyltransferase and 
BSmB, bacillithiol-S-bimane.  
The crystal structures of BshB [21] and MshB [22-24] have been resolved with that of 
Bca and Mca still pending. MshB is also the enzyme for which its catalytic 
mechanism has been studied the best. MshB was found to utilise an acid-base 
mechanism (i.e. a carboxypeptidase-like mechanism) during the deacetylation of its 
N-acetylglucosamine substrate (Figure 3.3) [11, 25]. In this mechanism the metal is 
attached to Asp 16, His13 and His147 of MshB, with Asp15 and His144 acting as 
base and acid-residues during catalysis, respectively. The metal promotes the 
deprotonation of a water molecule by Asp15 to generate the nucleophile that attacks 
the acetamido group’s carbonyl oxygen. The resulting oxyanion intermediate is 
stabilized by interactions with the metal and with Tyr142. The His144 enables 
collapse of the tetrahedral intermediate, resulting in the deacetylation of the 
substrate. The catalytic mechanisms of Bca, Mca and BshB are not fully understood, 
but are assumed to be similar to MshB, since all four enzymes contain an N-acetyl-
D-glucosaminylphosphatidylinositol deacetylase domain within their active site [11]. 
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Fig. 3.3: The catalytic mechanism of MshB [25] 
3.1.2 Metallohydrolases as targets for drug development 
The original research on MSH biosynthetic or MSH-dependent enzymes as potential 
drug targets was done on Mca as this was the first of these enzymes to be 
discovered [26-29]. Mca was found to be inhibited by a number of bromotyrosine 
alkaloids from marine sources, as well as by synthetic compounds with the same 
scaffold as the natural products [27]. As a result of the lack of a Mca crystal structure 
most studies has since focussed on MshB for which crystal structures are available 
[22-24]. 
The first MshB inhibitor compounds were chemically synthesised in 2007 by 
Meteferia et al., wherein 23 analogues of MSH were generated and divided into 
three groups: sulphonamides, amides and heterocycles [30]. The heterocycles 
showed the most inhibition, with the same compounds also being found to inhibit 
Mca. Another three groups of MshB inhibitors were synthesised in 2010 by Gammon 
et al., namely thioglycosides, cyclohexyl-deoxy-2-C-alkyglucosides and redox cyclers 
consisting of plumbagin tethered with methylene carbons and an amide connected to 
phenyl-2-deoxy-2amino-1-thio-α-D-glucopyranoside [31]. Again, these compounds 
were found to inhibit both MshB and Mca, with redox cyclers being the most potent. 
As such one can anticipate that developing antimicrobial drugs against the one 
protein would also target the other one, i.e. hitting two birds with one stone. 
However, the problem with the inhibitor compounds that are currently available is 
that they inhibit the enzymes only at micromolar concentrations; this is not 
reasonable for the development of new anti-bacterial drugs. 
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The research on BSH biosynthetic- and -dependent enzymes has only been gaining 
more attention recently after the identification of BSH in 2009 by Newton et al as the 
other low molecular weight thiol found in S. aureus and Firmicutes such as Bacillius 
species and Clostridium amongst others [15, 32]. Gene knock-out studies of BSH 
biosynthetic enzymes showed that BSH is essential for the stress resistance, even 
though some of the bacteria have low molecular weight thiol such as cysteine and 
CoA, in the case of S. aureus [10, 15, 16]. The mutation of the bshA gene was found 
to delay the growth of the bacteria, while that of bshB and bshC genes resulted in 
loss of BSH production [12, 15, 33-36]. No studies on the inhibition of the BSH 
biosynthetic pathway enzymes or dependent enzymes have been reported to date.  
3.1.3 Problem identification and rationale  
The biggest challenge affecting the development of inhibitors of the MSH and BSH 
biosynthetic enzymes is the lack of availability of their natural substrates or 
alternative substrate in sufficient quantity to support inhibitor screening efforts. The 
natural substrate of MshB, α-N-acetyl-glucosamine-inositol (α-GlcNAc-Ins), is 
currently generated either by chemo-enzymatic manipulation or by chemical 
synthesis. The chemo-enzymatic process involves treatment of mycothiol-S-
conjugates isolated from natural sources with Mca to release GlcN-Ins [37], while the 
chemical synthetic process requires multiple steps [28, 31, 38-40]. The problem with 
both these methods is the low final yield of the product obtained after the lengthy 
preparation process. Consequently, several GlcNAc-based glycosides, GlcNAc and 
thioglycosides have been chemically synthesised and tested as alternative 
substrates of MshB [18, 31, 41-44]. However, these compounds often also require a 
lengthy process to be generated, give low yields for the final product and also have 
shown solubility problems in aqueous environments; examples include 2,4DNP-α-S-
GlcNAc and α-GlcNAc-SPh [31, 41]. Furthermore, the alternative substrates with 
high specific activity in relation to the natural substrate are the ones with amidase 
activity [18]. The problem with amidase activity is that it does not really mimic what 
happens with the natural substrate at the active site of MshB, since MshB natural 
activity is the deacetylase activity, as such one cannot really use them during 
inhibitor studies. Therefore GlcNAc itself is still the most used alternative MshB 
substrate, also because it is commercially available. However, is shows very low 
deacetylation activity [18, 37, 41].  
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On the other hand α-N-acetyl-glucosamine-malic acid (α-GlcNAc-Mal), natural 
substrate of BshB, is generated by chemical synthesis over several steps that 
involve the protection and deprotection of the intermediate compounds [13, 45]. 
Several compounds with the GlcNAc moiety have also been chemically synthesised 
and tested as alternative substrate of BshB [46]. Unfortunately these alternative 
substrates displayed low activity in relation to α-GlcNAc-Mal. The relatively recent 
discovery of BSH means that all its other biosynthetic enzymes still require more 
characterisation to best understand their respective functions. Also in their case the 
absence of substrates or suitable substrate analogues hinders such full 
characterisation, which also limits full inhibition studies. 
In a recent study by Tshililo et al. an α-N-acetylglucosaminidase (CpGH89) from 
Clostridium perfringens was converted into α-N-acetyl-thioglycosaminoligase which 
allowed the biocatalytic production of α-GlcNAc thioglycosides, as well as α-GlcNAc-
N3 on multimilligram scale [see publication reproduced as Chapter 2 of this 
dissertation]. This was achieved through the use of glycosyl donors such 2,4DNP-α-
GlcNAc and 2NP-α-GlcNAc and various thiol molecules or sodium azide as 
acceptors. In the current study, we set out to apply this biocatalyst in the chemo-
enzymatic synthesis of α-GlcNAc thioglycosides as alternative substrates of MshB 
and/or BshB. In addition, the α-GlcNAc-N3 prepared in the previous study was used 
as substrate in ‘Click’-chemistry reactions to generate several GlcNAc-linked 
triazoles. ‘Click’-chemistry describes a group of high yielding chemical reactions that 
are easily performed and that require no or minimal purification of the final product, 
among other factors [47]. Included among such reactions are alkyne/azide 
cycloaddition and nucleophilic ring-opening reactions, carbonyl chemistry of the non-
aldol type and additions of carbon multiple bonds. Of these four reactions 
alkyne/azide cycloadditions that leads to the formation 1,4-substituted 1,2,3-triazoles 
are the most widely used. Its mechanism has been described as an annealing step-
wise reaction which occurs through an intriguing six membered copper-containing 
intermediate III [47-49]. ‘Click’-chemistry has been mostly applied in the drug 
discovery, in the pharmaceutical industries, and in polymer science among other 
fields. In this study the alkyne/azide cycloaddition reaction was applied to chemically 
synthesise GlcNAc-linked triazoles as potential alternative substrates of MshB and 
BshB.  
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The α-GlcNAc-based glycosides together with the GlcNAc-linked triazole compounds 
and various inhibitor compounds generated by the Gammon group from the 
University of Cape Town, were subsequently characterised as either substrates or 
inhibitors of MshB from M. tuberculosis. 
3.2 Results and Discussion 
3.2.1 The assessment of α-N-acetyl-thioglycosaminoligases with several 
thiol-compounds  
In 2011, Almendros et al. found that the thioglycoligation reaction of 
furanothioglycoligase only took place with aryl thiols which had a pKa value between 
5.83 and 8.75, indicating that the pKa value of a thiol group influenced its ability to 
act as an acceptor during the reaction [50]. This was also observed by Tshililo et al., 
that is, only thiol-containing molecules with pKa values between 6.6 and 8.1 were 
able to act as thiol-acceptors during the thioglycoligation reaction catalysed by α-N-
acetyl-thioglycosaminoligases [Chapter 2]. Consequently, based on the precedent of 
these two studies, several thiolated compounds with pKa values between 3.49 and 
6.0 (Table 3.1) were chosen for this study for the evaluation as thiol-acceptors for the 
generation of α-GlcNAc thioglycosides that could potentially act as alternative 
substrates for MshB and/or BshB. Apart from being commercially available the aryl 
thiol compounds (entry 1-6) were chosen as acceptor owing to their low pKa values 
of the thiol group and because α-GlcNAc-SPh derivates have been found to act as 
alternative substrate for MshB [31, 41]. Mercaptosuccinic acid, entry 7-8, was 
chosen as an acceptor for the generation of α-N-acetyl-glucosamine-thio-malic acid 
(α-GlcNAc-SMal), an analog of BshB natural substrate α-GlcNAc-Mal. Meanwhile 
dimethyl mercaptosuccinate (entry 9-10) was chosen for the generation of S-(2-
acetamido-2-deoxy-α-D-glucopyranosyl) 2-thiosuccinate (α-GlcNAc-SMal (OMe)2) 
with the idea of chemically converting it into α-GlcNAc-SMal. No thiol sugar 
compounds were utilised due to the fact that they are not commercially available and 
it is challenging to chemically synthesis them. In addition, their thiol pKa values limits 
them to act as acceptor, that is, the pKa values of some thiol group of thio-sugar is 
greater than 8, which restricts the generation of thiolate anion. An example is that of 
thio-sugar methyl 4-deoxy-4-thioglucoside in Chapter 2. Thio-sugar methyl 4-deoxy-
4-thioglucoside was chemically synthesise through several chemical steps and in the 
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end it was unable to act as an acceptor due to its pKa value of greater than 8 
[Chapter 2]. The two α-N-acetyl-thioglycosaminoligases (CpGH89–E483A and 
CpGH89–E483A) with the best activity in large scale reactions as described in 
Chapter 2 were utilised for the assessment using the same reaction conditions used 
in the previous study. 
Table 3.1: Activity of CpGH89–E483A and CpGH89–E483S with various thiol-
containing molecules as acceptors and 2,4DNP/2NP-α-GlcNAc as donor in all 
entries 
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*Chemically synthesised, see materials and methods section.  
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indicated by dotted circles; other spots where visualized by staining with 10% 
sulphuric acid in methanol, followed by incubation at 150°C for 15 minutes. WT, 
CpGH89 wild type; A, CpGH89–E483A; S, CpGH89–E483S, B, blank (no enzyme), 
7.3 and 8.0 is the pH value. 
Mercaptosuccinic acid was also unable to promote thioglycoligation reaction nor 
hydrolysis at high concentration (100 mM), indicating inhibition of the enzymes 
(Figure 3.5A). However, when the concentration of mercaptosuccinic acid was 
reduced (i.e. from 100 mM to 5–30 mM) only hydrolysis of the donors was observed 
in the present of the enzymes (Figure 3.5B).  
In addition, altering the final concentration of the buffer (50-500mM) with the different 
low concentrations of mercaptosuccinic acid also resulted only in the hydrolysis of 
the donors. Consequently, the expected product (α-GlcNAc-SMal, see Table 3.1) 
was not formed under any of the tested conditions. The incapacity of 
mercaptosuccinic acid to act as an acceptor at low concentration is assumed to 
because that maybe the α-N-acetyl-thioglycosaminoligases do not prefer negative 
charged molecules in their active site. To test such theory the carboxylic acid groups 
of mercaptosuccinic acid were converted into an ester producing dimethyl 
mercaptosuccinate thiol compound (entry 9 and 10). 
The thioglycoligation reaction with 100 mM of dimethyl mercaptosuccinate thiol 
compound as an acceptor formed a new spot only in the presence of the two α-N-
acetyl-thioglycosaminoligases as observed through TLC analysis (Figure 3.6). The 
strong signal of a new spot as observed through human eyes was formed in the 
reactions in which 2NP-α-GlcNAc was used as donor. The signal of new spot of 
reactions with 2,4DNP-α-GlcNAc was weak in relation to 2NP-α-GlcNAc. In addition, 
the reaction with 2,4DNP-α-GlcNAc also resulted in high hydrolyse activity of the 
donor. The outstanding synthetic effectiveness of this reaction encouraged us to 
determine if the α-N-acetyl-thioglycosaminoligases activity would also translate to 
preparative scale, and allow the biosynthesis and purification of dimethyl S-(2-
acetamido-2-deoxy-α-D-glucopyranosyl) 2-thiosuccinate (α-GlcNAc-SMal(OMe)2). 
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analysed in the same manner as conducted by Tshililo et al. [see Chapter 2]. The 
NMR and MS spectra confirmed that the new observed spot is indeed α-GlcNAc-
SMal(OMe)2 (Figure 3.7). The generation of α-GlcNAc-SMal(OMe)2 is very beneficial 
since it can be demethylated for the generation of α-GlcNAc-SMal, an analogue of 
BshB natural substrate, α-GlcNAc-Mal (see section 3.2.3).
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Fig. 3.7: The analysis of α-GlcNAc-SMal(OMe)2 through NMR and MS. NMR analyses: All 1H (A) and 13C (B) NMR spectra were 
obtained using a 600 MHz Varian Unity Inova (150 MHz for 13C) instruments (Varian Inc., Palo Alto, CA, USA. All chemical shifts (δ) 
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were referenced to the reported values of Gottlieb [51] using the signal from the residual protonated solvent for 1H spectra, or to the 
13C signal from the deuterated solvent. Chemical shift  values for 1H and 13C spectra are reported in parts per million (ppm) relative 
to these referenced values. All 13C NMR spectra were recorded with complete proton decoupling. FID files were processed using 
MestraNova 6.0.2 (MestreLab Research). MS analysis (C): All high resolution mass spectrometry (HRMS) was performed on a 
Waters API Q-TOF Ultima spectrometer.  
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
71 
3.2.3 Chemical modification of α-GlcNAc thioglycosides obtained by 
biocatalysis 
Since attempts at preparing α-GlcNAc-SMal by enzymatic synthesis failed, we 
decided to prepare this potential alternative BshB substrate by chemical synthesis 
using the methyl ester (α-GlcNAc-SMal(OMe)2) that was successfully obtained as 
starting material. The same strategy was also applied to α-GlcNAc-SCH2CO2Me 
obtained by biocatalysis in a previous study (see chapter 2) to give a truncated BshB 
substrate analogue, α-GlcNAc-SCH2CO2H. 
Both esters were demethylated using methods previously published by White et al. 
and Corey et al. in yields of between 30 and 60% (Figure 3.8) [52, 53]. In both cases 
the polarity of the carboxylic acid groups made purification of the compounds by 
flash column chromatography challenging, and was the main cause of the low yields.  
 
 
Fig. 3.8: The chemical synthesis of α-GlcNAc based thioglycosides through 
demethylation of enzymatically-synthesized starting materials. Panel A, chemical 
synthesis of α-GlcNAc-SMal from α-GlcNAc-SMal(OMe)2 and panel B, chemical 
synthesis α-GlcNAc-SCH2CO2H from α-GlcNAc-SCH2CO2Me. THF, Tetrahydrofuran; 
RT, room temperature and LiOH, lithium hydroxide 
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3.2.4 Preparing GlcNAc-based “Click” adducts using α- and β-GlcNAc-N3 
as starting material 
An alternative strategy to obtain MshB and BshB substrate analogues or substrate 
mimicking inhibitors is to use the GlcNAc core structure as scaffold and to introduce 
a variety of substructures in the position normally occupied by inositol or malate in 
these enzyme’s native substrates. This can be done by using GlcNAc-N3 to generate 
N-GlcNAc-based glycosides through their reaction with alkyne compounds by means 
of “Click Chemistry”. Currently β-GlcNAc-N3 is commercially available; however, to 
maintain the correct anomeric configuration for recognition by MshB and BshB would 
require the use of α-GlcNAc-N3 instead. Fortunately, we have demonstrated that this 
compound can be generated by preparative scale biocatalysis from 2NP-α-GlcNAc- 
and NaN3 using the α-N-acetyl-thioglycosaminoligase CpGH89-E483A [Chapter 2], 
and it was therefore available for use in this study. For the Click reactions, two 
alkynes were chosen: propargyl alcohol and 1-ethynyl-1-cyclohexanol. The aryl 
alkynes were chosen base to resemble the inositol moiety of MshB and because α-
GlcNAc-aryl based glycosides have found to be better alternative for MshB [31, 41]. 
The alcohol alkynes were selected to generate GlcNAc-triazoles compounds with 
alcohol group to resemble those of the inositol and malic acid moiety. Furthermore, 
both alkynes were commercially available, meaning no chemical synthesis required. 
The reactions were performed with both α- and β-GlcNAc-N3 to investigate the 
importance of the anomeric configuration in the cycloaddition reaction, and 
subsequently in interaction with the enzymes. 
Two β-GlcNAc-triazoles were generated in the presence of copper sulphate with a 
yield of more than 50% using previously published chemical methods by Rostovtsev 
et al. (Figure 3.9A) [48]. On the other hand, the synthesis of the α-GlcNAc-triazoles 
were found to be much more challenging as demonstrated by the lower yields 
(between 38 and 43%) that were obtained (Figure 3.9B). Additionally, Click reactions 
with the α-anomer required long running times to reach completion and the addition 
of Tris [(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), a tertiary amine that 
stabilizes the copper catalyst [54]. The long reaction time and use of TBTA is 
assumed to be due to the steric hindrance that occurs as results of the position of 
the azide moiety in relation to the acetyl group at the second carbon of the GlcNAc 
moiety.  
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Fig. 3.9: The chemically synthesis of GlcNAc-triazoles through “Click chemistry”. (A) 
Generation of β-GlcNAc-triazole from β-GlcNAc-N3 by the method of Rostovtsev et 
al. [48](B) α-GlcNAc-triazoles obtained from α-GlcNAc-N3 following the method of 
Machida et al. [54]TBTA, Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine; CuSO4, 
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3.2.5 Evaluation of the GlcNAc-based glycosides as potential alternative 
substrates of MshB 
Several compounds have been chemically synthesised as alternative substrates for 
MshB [28, 31, 38-41]. However, the majority of them have low active in relation to 
the natural substrate. The chemically and enzymatically synthesised GlcNAc-based 
glycosides prepared in this study and previous study [Chapter 2], together with the 
commercial available compounds GlcNAc and β-GlcNAc-N3 were assessed for their 
ability to act as substrates for MshB. The compounds were evaluated for their 
deacetylation-specific activity, the effect of the type of glycosidic linkage and the 
anomeric configuration.  
A number of discontinuous assays are used to characterise MshB and BshB activity, 
only one continuous assay is used for characterisation of MshB activity. The 
discontinuous assays include 6-aminoquinolyl-N-hydroxysuccinimidly carbamate 
assay (AccQ-FluorTM) [18, 37], fluorescamine (FSA) [43] and naphthalene-2,3-
dicarboxaldehyde (NDA) [46] of which all utilise derivatization agents, while the 
continuous assay is called a 5,5-dithio-bis-2-nitrobenzoic acid (DTNB) base 
assay [41]. Due to several shortcoming of the others assays (more details in Chapter 
4) the fluorescamine (FSA) derivatization assay which modifies the deacetylated 
amine product to give a fluorescent product was selected for these evaluations. The 
assay was conducted in the same way as Huang et al. with some modifications [43]. 
Since standards could not be generated for all the anticipated reaction products, 
glucosamine was chosen as reference to generate a standard curve to determine the 
amount of free amino sugar produced during each reaction as described below.  
3.2.5.1 Standard curve 
The standard curve was generated from the fluorescence units detected from the 
increasing concentration of reaction mixtures of glucosamine. The increasing 
concentrations reaction mixtures of glucosamine with FSA were subsequently 
determined by fluorimetry (FSA excitation at 395 nm and emission at 485 nm). The 
resulting increasing fluorescence units from the different concentration of 
glucosamine together with the various concentrations of glucosamine were used to 
plot a standard curve through which a linear equation (y = mx + c) was fitted (Figure 
3.10). The linear equation was determined to be y = 0.9379x + 0.8821 (R2 = 0.9882), 
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and was used in all calculations to convert the fluorescence units detected into free 
amino groups produced during the reaction.  
 
[Glucosamine] in M

























Fig. 3.10: Glucosamine standard curve obtained by fitting a linear equation (y = mx 
+ x ) through the data. Each point represents the amount of the fluorescence units 
observed for a specific concentration of glucosamine. Each point was done in 
triplicate with the error bars representing the standard deviation. 
3.2.5.2 Evaluation of MshB deacetylation activity  
The specific activity of MshB with a variety of substrate analogues has been reported 
to be between 5–66% relative to its native substrate, GlcNAc-Ins [18, 31, 41]. 
However, in the case of some alternative substrates (2,4DNP-α-GlcNAc and α-
GlcNAc-SPh) for which MshB does show relatively high deacetylation activity, 
solubility under the assay conditions is a significant problem [31, 41]. In this study, 
the deacetylase activity of MshB was evaluated against compounds containing the 
GlcNAc moiety as shown in Table 3.2 including GlcNAc with anticipation to identify a 
compound(s) that can be potentially used as alternative substrates during inhibition 
studies. The compounds tested include GlcNAc linked with three types of glycosidic 
linkages (O-, S- and N-) and having different anomeric configurations (α- and β-). All 
compounds were tested at a final concentration of 5 mM with 1 µM of enzyme over a 
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period of 1 h. Since α-GlcNAc-Ins was not available in this study, the specific 
deacetylation activity of MshB was related to its activity towards GlcNAc, as it one of 
the most used alternative substrates (MshB has been found to be 87 fold less active 
with GlcNAc as substrate in relation to its natural substrate, α-GlcNAc-Ins [18]). The 
results of the activity assays are summarized in Figure 3.11.  
Table 3.2: Compounds synthesised as potential alternative substrates of MshB 
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Fig. 3.11: Specific deacetylase activity of MshB determined with various potential 
alternative substrates. The bars represent the average specific activity of the 
different compounds with error bars representing standard deviation. Activity assays 
were performed using 5 mM of the indicated compound and 1 μM MshB, in 
duplicate. Compounds are identified by the numbers as listed in Table 3.2. GlcNAc 
was used as reference compound for the specific deacetylase activity of MshB. 
Using the FSA assay, the specific deacetylase activity of MshB with GlcNAc (the 
chosen reference compound) was found to be 42.6±3.1 nmol/min/mg. Its α-methyl 
glycoside (1) was found to be a better substrate, with a specific activity of 65.2±3.2 
nmol/min/mg (a 1.53-fold increase). The BshB substrate α-GlcNAc-Mal (2), which 
was prepared by chemical synthesis, was not tested for MshB activity. 
Amongst the S-glycosides (compounds 3-5, 7-9) no MshB deacetylase activity was 
observed including α-GlcNAc-SMal (4), the thioglycoside analogue of the BshB 
natural substrate, α-GlcNAc-Mal. However, MshB showed the most activity towards 
its methyl ester (α-GlcNAc-SMal(OMe)2) (3), with a specific activity of 136±12.3 
nmol/min/mg. The MshB activity decreased towards the other S-glycosides 5, 7, 8, 
and 9 in relation to compounds 3, with activities of 18.3±4.12, 6.80±3.31 113±6.0 
and 9.24±2.91 nmol/min/mg, respectively (Figure 3.11). 
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MshB activity towards the GlcNAc triazoles and azide (N-glycoside) was only 
observed for compounds with an α-anomeric configuration. Of these triazole 13, 
which has a hydroxylated cyclohexane ring reminiscent of the inositol moiety of the 
MshB native substrate GlcNAc-Ins, showed the most deacetylase activity (217±6.7 
nmol/min/mg), 5.09-fold more compared to GlcNAc (Figure 3.11). It was followed by 
α-GlcNAc-N3 (12) and the triazole 14, with specific activities of 104±12.5 
nmol/min/mg and 44±4.4 nmol/min/mg, respectively. No deacetylase activity was 
observed with compounds having the β-glycosidic linkages (compounds 10, 11 and 
15) demonstrating that MshB has a strong preference for compounds with the 
glycosidic bond in the α-anomeric configuration.  
To determine if the observed activity was not due to the interaction of FSA with the 
tested compounds, the assay was repeated with compounds 1, 3, 5, 8, 9 and 12–15) 
in the absence of MshB. Although low levels of background fluorescence were 
observed in the case of some compounds, these levels are not sufficient to 
significantly influence the activity rates observed (Figure 3.12).  
Taken together, the results show that MshB clearly prefers the compounds with α-
anomeric glycosidic bond over the β ones. The type of the glycosidic bond 
apparently does not influence or affect the activity, as MshB activity was observed 
with compounds with all three different types of the glycosidic bonds. However, the 
type of the glycosidic bond is an important consideration during the development of 
inhibitor compounds, as it has been found that S-glycosidic bonds are more resistant 
to hydrolysis than their O-glycoside counterparts [55]. In contrast to the lack of effect 
of the glycoside linkage, the structure of the moiety attached to GlcNAc clearly 
impacts on the activity of MshB. This corresponds with the results of the docking 
studies reported by Huang et al. that showed that the moiety attached to the GlcNAc 
influences the binding of the substrate at the active site, thereby promoting the 
activity of MshB [42].  
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Fig. 3.12: Background fluorescence due to interaction of fluorescamine with the 
various potential alternative substrates. The bars represent average of the free 
amino sugar generated for the different compounds with error bars representing 
standard deviation. Activity assays were performed using 5 mM of the indicated 
compound and in present and absence of MshB, in duplicate. Compounds are 
identified by the numbers as listed in Table 3.2. Blanks were used as reference 
compound for the background fluorescence activity. 
3.2.5.3 Preliminary kinetic study of MshB activity towards alternative substrate 
candidates 
Next we set out to determine the kinetic parameters of MshB with α-GlcNAc-triazole 
compound 13 and α-GlcNAc-N3 12 to establish how these compare to the values 
previously obtained for the enzyme’s native substrate, GlcNAc-Ins. The 
thioglycosides 3 and 8 that also showed high levels of activity as MshB substrate 
were not included in these tests due to the limited availability of compounds. The 
kinetic studies were done with 1 µM of enzyme and substrate concentrations ranging 
from 0.1 mM to 5 mM in a time course over 50 minutes for each concentration tested 
using the FSA assay.  
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MshB exists as a dimer at normal ionic strength, while at low ionic strength two of 
these dimers combine to form tetrameric structures [18]. In addition, it also consists 
of a polar binding pocket distal from the GlcNAc binding site [18, 30], hence its ability 
to accommodate the inositol moiety of GlcNAc-Ins and likely the aglycone moieties 
of compounds 12 and 13. During the kinetic study the data obtained for compounds 
12 and 13 generated sigmoidal curves in both cases. This suggests the cooperative 
binding of the compounds by MshB. As such the kinetic parameters for both 
compounds were obtained by fitting the single substrate Hill equation 
(v=VmaxSn/(Ksn+Sn), where n = Hill number) to the data(Figure 3.13). The kinetic 
parameters of compound 12 were established to be as follows: n = 2.1, Ks = 1.62 ± 
0.104 mM, kcat of 2.29 ± 0.086 nmoles/min and kcat/Ks of 1.41 ± 0.105 M-1min-1, while 
that of compound 13 were as follows: n = 2.4, Ks = 1.74 ± 0.064 mM, kcat of 8.70 ± 
0.191 nmoles/min and kcat/Ks of 5.03 ± 0.217 M-1min-1 (Figure 3.12). The Ks values 
observed for these compounds were 5-fold higher in relation the natural substrate 
(GlcNAc-Ins, KM = 340 ± 80 µM as reported by Newton et al. [18]. However, it was 
much lower compared to the KM obtained for GlcNAc (KM 38 ± 4 mM) for M. 
smegmatis MshB by Huang et al. [43]. This suggests that both compounds (12 and 
13) are far better alternative substrates for MshB than GlcNAc. In addition, the 
finding that the Hill numbers are very close to two would agree with the previous 
finding that MshB exists as a dimer. However, we were concerned that the observed 
sigmoidal activity profiles might be an artefact of the FSA assay, as no activity was 
observed for compound 13 at low concentrations (below 100 µM), even after several 
repetitions of the reaction. This suggested that the assay used might not be sensitive 
enough to report activity at low substrate concentrations, leading to its sigmoidal 
shape. This potential issue with the FSA assay’s sensitivity was addressed in the 
work as described in chapter 4. 
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Fig. 3.13: Activity profiles for MshB with α-GlcNAc-N3 12 (Panel A) and α-GlcNAc-
triazole 13 (Panel B) The data represent the average rate of MshB with the different 
compounds at various concentration with error bars representing standard deviation. 
Activity assays were performed using a range of concentrations (0–5 mM) of the 
different compounds, in duplicate. A curve using the single substrate Hill kinetic 
equation (v=VmaxSn/(KMn+Sn) was fitted through the data.  
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3.2.6 Inhibition of MshB activity by substrate analogues  
Several compounds have been synthesised and tested as inhibitory compounds 
against MshB activity [30, 31]. However, they were found to inhibit the activity of the 
enzyme only at high concentrations, with IC50 values of between 2 and 7 µM. 
Consequently the need remains to find inhibitors with higher potency. 
Gammon and co-workers recently synthesized several potential MshB inhibitors 
(data not published) based on the naphthoquinones scaffold explored previously by 
the same group [31]. Previously, Gammon and co-workers in a preliminary study 
found that naphthoquinones with 2 to 5 carbons as spacer are better inhibitors 
compounds. As such they chemically synthesised plumbagin derivatives alone and 
plumbagin tethered derivate with 2 to 5 methylene carbons spacer linked to phenyl-
2-deoxy-2-amino-1 thio-α-D-glucopyranoside through amide bond (shown in Figure 
3.14) as potential inhibitory compounds. We therefore set out to test the inhibition 
potency of these compounds toward MshB activity. For these tests, we used the 
continuous MshB assay that was previously developed in our group (see Chapter 4) 
[41]. This assay uses α-GlcNAc-S-DNP as substrate; after deacetylation, the 
substrate undergoes a rearrangement reaction that reveals a free thiol group that 
can be tracked using 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB) also knowns 
as Ellman's Reagent. The use of FSA assay for the inhibition study was limited by 
two factors; lack of a good compound to use as alternative substrate and chances of 
the fluorescamine interaction with the free amino group within the structure of the 
compounds (Figure 3.14). The use of the NDA assay was not feasible because 
during the deacetylation activity characterisation of MshB NDA assay was also 
tested as an alternative assay, but yielded no results, that is, no activity could be 
detected.  
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Fig. 3.14: Structures of the putative MshB inhibitors synthesized by the Gammon 
group (UCT). 
Due to the limitations of the DTNB-based assay which will be discussed in chapter 4, 
section 4.2.5, the inhibition studies were done at two different inhibitor 
concentrations, i.e. 75 µM and 150 µM, using a substrate concentration of 150 µM. 
The observed activity in each case was normalized relative to a control reaction 
containing only DMSO which was set at 100% (Figure 3.15). Very few compounds 
showed more than 20% inhibition under these conditions. Only two compounds (RF 
3 and NM 4) showed the most inhibitory activity and had the longest methylene 
carbons spacer between plumbagin tethered and phenyl-2-deoxy-2-amino-1 thio-α-
D-glucopyranoside in relation to other compounds (Figure 3.14). Most inhibition 
activity for both compounds was observed with the highest concentration (150 µM) 
i.e. RF3 showed 71%, while NM4 showed 51% inhibition activity. The inhibition 
activity at 75 µM of both compounds (68% and 44% for RF3 and NM4, respectively) 
was 6 fold less to the one at 150 µM indicating that neither compound was an 
effective inhibitor compounds. This suggests that the maximum inhibition levels 
under the assay conditions have been reached. Interestingly, of the other inhibitory 
compounds, compound DNM2 was found to actually stimulate MshB activity, rather 
than inhibit it.  












































Fig. 3.15: Inhibition of MshB (3 μM) activity by the putative inhibitor compounds at 
either 75 µM (grey bars) or 150 µM (black bars) using 150 µM α-GlcNAc-S-DNP as 
substrate. The bars represent MshB deacetylation activity with α-GlcNAc-S-DNP as 
the alternative substrate in the presence of inhibitory compounds, with error bars 
representing standard deviation. The activity of the enzyme was normalised to a 
sample containing only DMSO, i.e. with no inhibitory compound present. 
3.2.7 Characterisation of BshB  
Although at the start of this study our intention was to perform all the tests described 
above for MshB with BshB (especially since some of the compounds prepared 
chemo-enzymatically are structurally very close analogues of this enzyme’s native 
substrate) we were unable to obtain active enzyme with which to perform these 
tests. BshB was expressed and purified twice at different times and the purified 
enzyme tested for deacetylase activity using GlcNAc or compounds 2, 3 and 4 as 
substrates. Both the FSA and NDA assays were used for these tests. In all cases no 
BshB activity could be detected. Previous studies have indicated that the loss of the 
enzyme’s metal cofactor is a likely cause for the loss of enzyme activity. However, 
even in cases where the enzyme was subsequently treated with Zn2+ (its preferred 
cofactor) no activity could be observed. We have therefore initiated a collaboration 
with the group that first characterized BshB activity to allow us to continue this part of 
the study. However, at the time of writing this had not been achieved as yet.  
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3.3 Summary and Conclusion 
The application of α-N-acetyl-thioglycosaminoligases as biocatalyst using the same 
strategy as in a previous study (see Chapter 2) allowed the generation of α-GlcNAc-
S-Mal (OMe)2 and through chemical modification of α-GlcNAc thioglycosides (α-
GlcNAc-SMal(OMe)2 and α-GlcNAc-SCH2CO2Me) obtained by these biocatalysis 
BshB analogues, α-GlcNAc-SCH2CO2H and α-GlcNAc-SMal were synthesised. In 
addition, α-GlcNAc-N3 also generated from these biocatalysts permitted the chemical 
synthesis of GlcNAc-triazoles through “Click chemistry”. This indicates that the α-N-
acetyl-thioglycosaminoligases are useful for synthesis of α-GlcNAc thioglycosides 
and through careful selection of thio-molecules as acceptor and reaction conditions 
many more α-GlcNAc thioglycosides of biomedical interest can be generated.  
Due to the lack of generating the excepted reaction product (GlcN-R) of the various 
GlcNAc-based glycosides (Table 4.2) tested as alternative substrate for MshB, 
glucosamine was used to generate the standard curve for the conversion of 
fluorescence units into concentration of GlcN-R producing the reaction. Despite this 
small problem the characterisation of MshB with several α-GlcNAc-based glycosides 
(Table 4.2) showed that the type of glycosidic bond does not influence the activity of 
MshB, while the anomeric configuration and GlcNAc moiety does. Looking at Figure 
3.11, compound 3, 8, 12 and 13 can be viewed as potential substrate for MshB, as 
they were way more active than GlcNAc. The preliminary kinetic study with 
compounds 12 and 13 also showed that these compounds are better alternative 
substrates than GlcNAc. Observing the data from the specific activity to the inhibition 
study, the lack of generating the standard reaction product and the lack of a good 
continuous assay to characterise MshB are the major problems. In addition, 
discontinuous assays are time consuming and they bring about human error which 
can really affect the final data leading to wrong conclusion. The development of a 
high throughput continuous assay will open many doors for characterisation of MshB 
and BshB with the generated α-GlcNAc-based glycosides.  
3.4 Materials and methods 
All the chemicals used were purchased from Sigma-Aldrich unless stated otherwise 
except, GlcNAc which was brought from Carbosynth. 2-(S)-(3,4,6-tri-O-acetyl-2-
azido-2-deoxy-α-D-glucopyranosyl)-butan-1,4-dioic acid dimethyl ester was obtained 
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3.4 Materials and methods 
All the chemicals used were purchased from Sigma-Aldrich unless stated otherwise 
except, GlcNAc which was brought from Carbosynth. 2-(S)-(3,4,6-tri-O-acetyl-2-
azido-2-deoxy-α-D-glucopyranosyl)-butan-1,4-dioic acid dimethyl ester was obtained 
as a present from Chris Hamilton group. The assays were done using Greiner Bio-
One polystyrene flat-bottomed 96-well plates, specifically clear plates for the DTNB 
assay and black plates for FSA assay. Varioskan multimode reader (Thermo 
Scientific) was used to measure the fluorometric and spectrophotometric readings. 
Enzyme expression and purification was done based on Newton et al for MshB [18] 
and based on Fang et al for BshB [46]. All cultures were grown until the optical 
density at 600 nm (OD600) reached 0.600, followed by induction with 0.10 mM 
isopropyl-1-thio-β-D-galactropyranoside (IPTG) for MshB and 5.8 mM of lactose for 
BshB followed by incubation of the cultures overnight at 22oC and 15oC, respectively. 
This was followed by the harvesting of cells by centrifugation at 17000×g for 20 
minutes at 10oC. The pelleted cells were stored at -20oC until use. Both enzymes 
were subject to disruption by sonication external cooling within their respective buffer 
before purification. The enzymes were purified with automated purification program 
on ÄKTAprime system (Amersham Bioscience) using the previously published 
described methods after the removal of the cell bris through centrifugation [18, 46]. 
SDS-PAGEs (12%) were used to check the purity of the proteins, while the Bradford 
method was used to determine the protein concentration. 
3.4.1 Generation of GlcNAc thioglycosides 
3.4.1.1 Enzymatic synthesis 
Dimethyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thiosuccinate (3): The 
same reaction conditions described in chapter 2 were for the 
enzymatic synthesis of 3. 1H NMR (600 MHz, d2o) δ 5.73 (d, 
J = 5.5 Hz, 1H), 5.62 (d, J = 5.4 Hz, 1H), 4.09 (td, J = 11.4, 
5.4 Hz, 1H), 3.98 (ddt, J = 13.4, 6.8, 5.1 Hz, 2H), 3.89 – 3.80 
(m, 2H), 3.79 (d, J = 0.8 Hz, 3H), 3.73 (d, J = 3.4 Hz, 3H), 
3.65 – 3.58 (m, 1H), 3.56 – 3.50 (m, 1H), 3.10 (ddd, J = 33.2, 17.1, 8.5 Hz, 1H), 2.95 
(ddd, J = 37.3, 17.1, 6.5 Hz, 1H), 2.05 (s, 3H). 13C NMR (150 MHz, d2o) δ 174.93 (s), 
174.83 (s), 174.57 (s), 174.43 (s), 173.72 (s), 84.45 (s), 83.50 (s), 73.78 (s), 73.68 
(s), 71.31 (s), 71.25 (s), 70.59 (s), 70.48 (s), 60.83 (s), 60.67 (s), 54.49 (s), 54.36 (s), 
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54.00 (s), 53.98 (s), 53.23 (s), 53.16 (s), 42.78 (s), 40.82 (s), 37.13 (s), 36.26 (s), 
22.36 (s). ESI-MS (m/z): [M+H]+ calcd. for C14H24NO9S 382.1167; found 382.1170. 
3.4.1.2 Chemical synthesis  
2-(R)-(2-acetamido-2-deoxy-α-D-glucopyranosyl)-oxy-succinic acid (2). 
Previously described methods by Sharma et al. were used to 
synthesise α-GlcNAc-O-Mal [13]: To 2-(S)-(3,4,6-tri-O-acetyl-
2-azido-2-deoxy-α-D-glucopyranosyl)-butan-1,4-dioic acid 
dimethyl ester group (0.123 g, 0.19 mmol) in dry ethyl acetate 
at 0°C was added 555 μL of acetic anhydride and 56 mg of 
10% Pd/C. This was followed by purging the reaction with 
nitrogen followed by addition of 285 µL triethylsilane drop wise over an hour. The 
reaction was allowed to warm up to room temperature and stirred overnight. This 
was followed by filtering the reaction mixture through a pad of Celite and washed 
with ethyl acetate. After the removal of solvent the mixture was co-evaporated with 
toluene three times. To the crude in dry methanol at 0°C was added 1 mL of 1M 
NaOCH3 and stirred for 2hrs. Dowex-H+ resin (200mg) was used to quench the 
reaction. After filtration of the resin the solvent was evaporated with the crude 
subjected to flash chromatography (10:1 to 1:1, ethyl acetate: methanol) to produced 
6.55 mg of α-GlcNAc-O-Mal as white powder, with 10% yield over two step. The 
NMR analyses gave spectra identical to those reported by Sharma et al [13]. 
 
S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thiosuccinic acid (4):α-GlcNAc-
SMal was generated from compound 3by removing the 
methyl group using the method of White et al. and Corey et al. 
[52, 53]. Dimethyl ester 3 (11.18 mg, 0.0293 mmol) was 
dissolved in THF: H2O (3:1) mixture at 0°C. This was followed 
by addition of lithium hydroxide (1.58 mg, 0.065 mmol) and 
stirred at room temperature until the starting material 
disappeared. The reaction mixture was concentrated under reduced pressure to 
remove all the solvents. The resulting residue was purified by flash column 
chromatography (61:33:6 DCM:methanol:water) to give a white powder (6.10 mg, 
59%). 1H NMR (600 MHz, D2O) δ 5.53 (t, J = 4.9 Hz, 1H), 4.12 (dt, J = 10.5, 5.2 Hz, 
1H), 4.09 – 4.02 (m, 1H), 3.92 – 3.80 (m, 2H), 3.72 – 3.60 (m, 2H), 3.50 (dd, J = 
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20.2, 10.1 Hz, 1H), 2.76 (ddd, J = 15.1, 6.2, 2.4 Hz, 1H), 2.48 (ddd, J = 36.0, 15.3, 
9.5 Hz, 1H), 2.06 (s, 3H). 13C NMR (150 MHz, D2O) δ 179.14 (s), 179.07 (s), 179.02 
(s), 179.01 (s), 174.35 (s), 135.22 (s), 83.99 (s), 82.53 (s), 72.56 (s), 72.52 (s), 71.09 
(s), 71.00 (s), 70.23 (s), 70.08 (s), 60.41 (s), 60.19 (s), 53.75 (s), 53.61 (s), 48.17 (s), 
46.04 (s), 41.24 (s), 40.48 (s), 21.87 (s), 21.86 (s). ESI-MS (m/z): [M+H]+ calcd. for 
C12H20NO9S 354.0854; found 354.0860 
 
S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetic acid (6): α-GlcNAc-S-
CH2-COOH was synthesised using the same methods used 
for α-GlcNAc-SMal above from compound 5 which was 
enzymatically synthesised in Chapter 2. Compound 5 (12.2 
mg, 0.039mmol) and lithium hydroxide (1.74 mg, 0.072 
mmol) gave 3.54 g of α-GlcNAc-S-CH2-COOH as white powder (31% yield). 1H NMR 
(400 MHz, D2O) δ 5.43 (d, J = 5.3 Hz, 1H), 4.11 (dd, J = 11.0, 5.3 Hz, 1H), 4.073 – 
4.073(m, 1H), 3.87 – 3.76 (m, 2H), 3.72 (dd, J = 10.9, 8.9 Hz, 1H), 3.49 (dd, J = 
12.1, 6.9 Hz, 1H), 3.35 – 3.18 (m, 2H), 2.04 (s, 3H). 13C NMR (100 MHz, D2O) δ 
178.05 (s), 175.10 (s), 84.37 (s), 73.13 (s), 71.60 (s), 70.89 (s), 61.01 (s), 54.41 (s), 
36.05 (s), 22.53 (s).  
 
N-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-4-(1-hydroxycyclohexyl)-1H-1,2,3-
triazole (10). Previously established synthetic method 
by Rostovtsev et al. was used for the synthesis of 
compound 10 [48]. To a solution of β-GlcNAc-N3 (50 
mg, 0.20 mmol) and 1-ethynyl-1-cyclohexanol (65 mg, 
0.52 mmol, 67 µL) in 1.7 mL mixture of water/tert-butyl alcohol/ACN /DMF (1:1:2:1) 
stirring at room temperature was added 186 µL of sodium ascorbate (0.26 mmol, 1.4 
M solution freshly prepared in water). This was followed by addition of 142 µL copper 
(II) sulfate pentahydrate (4.7 mg dissolved in water, 0.01882 mmol). The mixture was 
stirred overnight at room temperature. TLC was used to check for the complete 
consumption of the β-GlcNAc-N3. The reaction mixture was concentrated under 
reduced pressure to remove all the solvents. The resulting residue was purified by 
flash column chromatography (7:2:1 ethyl acetate:methanol:water) to give the 
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1H), 3.96 (dd, J = 12.5, 2.0 Hz, 1H), 3.91 – 3.67 (m, 4H), 2.14 (m, 2H), 1.87 – 1.76 
(m, 5H), 1.70 (m, 2H), 1.53 – 1.28 (m, 4H). 13C NMR (100 MHz, D2O) δ 174.57 (s), 
122.02 (s), 87.05 (s), 79.56 (s), 74.14 (s), 71.39 (s), 70.28 (s), 69.94 (s), 61.06 (s), 
56.05 (s), 37.61 (s), 37.58 (s), 25.37 (s), 22.67 (s), 22.63 (s), 22.19 (s). ESI-MS 
(m/z): [M+Na]+ calcd. for C14H26N4O6Na 393.1744; found 393.1754 
 
N-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-4-hydroxymethyl-1H-1,2,3-triazole  
(11): The same procedure as above was used to 
generate the title compound: β-GlcNAc-N3 (50 mg, 0.20 
mmol) and propargyl alcohol (29 mg, 0.52 mmol, 30 µL). 
The resulting residue was purified by flash column chromatography (7:2:1 ethyl 
acetate:methanol:water) to give the product as a whitish powder (38.73 mg, 64%). 
1H NMR (400 MHz, D2O) δ 8.20 (s, 1H), 5.87 (d, J = 9.7 Hz, 1H), 4.74 (s, 2H), 4.28 
(t, J = 9.9 Hz, 1H), 3.96 (dd, J = 12.5, 2.0 Hz, 1H), 3.89 – 3.81 (m, 2H), 3.81 – 3.75 
(m, 1H), 3.75 – 3.68 (m, 1H), 1.83 (s, 3H). 13C NMR (75 MHz, d2o) δ 174.82 (s), 
147.69 (s), 123.33 (s), 86.98 (s), 79.53 (s), 74.12 (s), 69.91 (s), 61.05 (s), 55.98 (s), 




triazole (13). The previously established synthetic method of 
Machida et al was used for the synthesis of compound 13 
[54]. To a solution water of α-GlcNAc-N3 (19.52 mg, 0.08 
mmol, 40mM) and copper(II) sulfate pentahydrate (0.016 
mmol, 4.0 mg) stirring on ice was added sodium ascorbate 
(0.16 mmol, 32 mg) and 600 μL of TBTA (8.5 mg, 0.016 mmol) dissolved in DMF: 
tert-butyl alcohol (1:1). This was followed by addition of 1-ethynyl-1-cyclohexanol 
(9.93m g, 0.08 mmol, 10 µL). The reaction was stirred on ice for 5 hrs followed by stir 
at room temperature overnight. TLC was used to check for the complete 
consumption of the α-GlcNAc-N3. After complete consumption of the α-GlcNAc-N3 
the reaction mixture was concentrated under high pressure to remove all the 
solvents. The final product was a white powder (11.17mg, 38%). 1H NMR (400 MHz, 
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the reaction mixture was concentrated under high pressure to remove all the 
solvents. The final product was a white powder (11.17mg, 38%). 1H NMR (400 MHz, 
d2o) δ 8.07 (s, 1H), 6.36 (d, J = 5.8 Hz, 1H), 4.58 – 4.50 (m, 1H), 4.42 (dd, J = 10.8, 
5.8 Hz, 1H), 3.82 – 3.63 (m, 4H), 2.17 – 2.07 (m, 2H), 1.90 – 1.79 (m, 5H), 1.76 – 
1.65 (m, 2H), 1.57 – 1.34 (m, 4H). 13C NMR (101 MHz, d2o) δ 175.37 (s), 134.14 (s), 
124.92 (s), 83.52 (s), 75.77 (s), 71.39 (s), 70.53 (s), 70.27 (s), 60.93 (s), 53.70 (s), 
37.64 (s), 37.55 (s), 25.36 (s), 22.59 (s), 22.55 (s), 22.07 (s). ). ESI-MS (m/z): 
[M+Na]+ calcd. for C14H27N4O6Na 371.1924; found 371.1933 
N-(2-acetamido-2-deoxy-α-D-glucopyranosyl)-4-hydroxymethyl-1H-1,2,3-triazole  
(14): The same procedure as above was used for the 
generation of compound 14: α-GlcNAc-N3 (14.22 mg, 0.06 
mmol), copper(II) sulfate pentahydrate (0.012 mmol, 3.0 mg), 
sodium ascorbate (0.12 mmol, 24 mg), TBTA (6.37 mg, 
0.012 mmol) and propargyl alcohol (3.36 mg, 0.06 mmol, 3.5 
μL). The resulting residue was purified by flash column chromatography (7:2:1 ethyl 
acetate: methanol: water) to give a whitish powder (7.73 mg, 43%). 1H NMR (400 
MHz, D2O) δ 8.09 (s, 1H), 6.37 (d, J = 5.8 Hz, 1H), 4.77 – 4.75 (m, 2H), 4.60 – 4.52 
(m, 1H), 4.46 (dd, J = 10.8, 5.8 Hz, 1H), 3.82 – 3.64 (m, 4H), 1.89 (s, 3H). 13C NMR 
(100 MHz, D2O) δ 175.42 (s), 147.22 (s), 126.29 (s), 83.61 (s), 75.68 (s), 71.52 (s), 
70.56 (s), 60.93 (s), 55.07 (s), 53.56 (s), 22.10 (s). ESI-MS (m/z): [M+Na]+ calcd. for 
C11H24N4O6Na 325.1118; found 325.1119. 
Dimethyl 2-mercaptosuccinate: The title compound was synthesised by shielding 
the carboxylic acid of mercaptosuccinic acid based on the methods by 
Kikionis et al. [56] . To a mixture of mercaptosuccinic acid (2.5 g, 
0.016 mol) in methanol (15 mL) at 0°C was added acetyl chloride (149 
µL) dropwise and left to reflux at 60°C for 6hrs. After completion the 
reaction mixture was concentrated under reduced pressure to remove all the 
solvents. The resulting liquid was purified by flash column chromatography (2:1 
hexane: ethyl acetate) to give a clear stinking liquid (2.06 g, 72%). 1H NMR (600 
MHz, CDCl3) δ 3.77 (s, 3H), 3.70 (s, 3H), 3.02 (dd, J = 17.0, 8.9 Hz, 1H), 2.77 (dd, J 
= 17.0, 5.9 Hz, 1H), 2.22 (d, J = 9.6 Hz, 1H), 1.59 (s, 1H). 13C NMR (150 MHz, 
CDCl3) δ 172.70 (s), 170.71 (s), 52.81 (s), 51.99 (s), 39.59 (s), 35.94 (s). ESI-MS 
(m/z): [M+Na]+ calcd. for C6H16O5SNa 201.0192; found 201.0195 
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3.4.2 The generation of the Standard curve 
The same experimental procedure for the FSA assay was used for the generation of 
the standard curve data. Different concentrations of glucosamine (0 – 1 mM) in the 
reaction buffer were added into 20% of 10 µL of Trichloroacetic acid (TCA) and 
subjected to centrifugation at 13000 xg for 10 minutes. After the centrifugation 
process 25 µL of the supernatant was added into a 96 well plate, wherein 75 µL of 
1M borate at pH 9.0 was added. The increasing concentrations reaction mixtures of 
glucosamine were reacted with 30 µL of 10 mM FSA dissolved in ACN. The FSA 
was allowed to react with the increasing concentrations reaction mixtures of 
glucosamine at room temperature for 10 minutes. The increasing concentrations 
reaction mixtures of glucosamine with FSA were subsequently determined by 
fluorimetry (FSA excitation at 395 nm and emission at 485 nm). 
3.4.3 Fluorescamine assay 
The MshB alternative substrate assays were done in assay buffer (50 mM HEPES, 
50 mM NaCl, 1 mM TCEP) with 1 µM of MshB (final concentration) in a 200 µL 
reaction mixture. The reactions were done in duplicate and were initiated by addition 
of MshB after equilibrating the reactions at 30oC for 10 minutes. The reactions were 
carried out at 30oC for 1h, with 30 µL aliquots removed at 0, 5, 10, 30 50 and 60 
minutes, followed by quenching with 10 µL of 20% TCA followed by removal of the 
precipitated enzymes by centrifuging at 13000g for 10 minutes. The supernatants 
(25 µL) were transferred to 96-well black plates, to which was added 75 µL of 1M 
borate buffer at pH 9.0. The free amino sugar product was detected by addition of 30 
µL 10mM FSA dissolved in acetonitrile followed by incubation in the dark for 10 
minutes. The adduct levels were subsequently determined by fluorimetry (FSA 
excitation at 395 nm and emission at 485 nm.  
3.4.4 DTNB continuous assay 
The DTNB assay was carried out in the same way as published by Lamprecht et al, 
except that 3 µM of MshB was used and the reactions were done in a total volume of 
150 µL [41]. 
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3.4.5 NDA assay 
The NDA assay was carried out in the same way as published by FANG et al., 
different concentration of BshB was used and the reaction was done in a total 
volume of 150 µL [46]. 
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Chapter 4: 
Studies towards the development of a high-
throughput continuous assay of the metallo-
deacetylases, MshB and BshB 
4.1 Introduction 
MshB and BshB are metal-containing deactylase enzymes that catalyse the third 
reaction of MSH biosynthesis pathway [1-4] and second reaction of BSH 
biosynthesis pathway, respectively [5-8]. Both reactions produce acetate and a free 
amino-sugar: MshB generates α-GlcN-Ins from α-GlcNAc-Ins, while BshB produces 
α-GlcN-Mal from α-GlcNAc-Mal (Figure 4.1). As stated previously, full 
characterization of MshB and BshB as well as the discovery of selective inhibitors 
targeting these enzymes are hampered by two factors. The first is the lack of 
availability of the natural substrates (or alternative compounds that can be used as 
substrates), especially in the case of MshB. This is mostly due to the challenge 
associated with the generation of the α-glycosidic bond in these compounds; a 
solution towards this is described in Chapter 3. The second factor is the lack of a 
high-throughput continuous assay that can be used for activity characterization and 
inhibitor screening. This is because neither substrates nor the amino-sugars 
generated from these reactions are UV-active, which makes it impossible to follow 
these reactions spectrophotometrically. Consequently, it becomes necessary to 
either derivatise the product to allow it to be quantified in a discontinuous manner, or 
for the formation of one of the products to be coupled to secondary enzyme 
reactions that can be assayed in continuous fashion. This part of the study describes 
the efforts that were made to develop such an assay for MshB and BshB. 


















































Fig. 4.1: The MshB (A) and BshB (B) reactions with their respective natural 
substrate and products 
4.2 Assays currently utilised for determining metallodeacetylase 
activity, and their shortcomings 
The majority of the assays that are currently used to characterise MshB and BshB 
activity are discontinuous assays that utilise derivatization agents such as 6-
aminoquinolyl-N-hydroxysuccinimidly carbamate (AccQ-FluorTM) [3, 4], 
fluorescamine (FSA) [2] and naphthalene-2,3-dicarboxaldehyde (NDA) [7]. These 
derivatization agents react with the free amine group of the product generating a 
complex that is either spectrophotometrically or fluorometrically active. In addition, 
our group was involved in the development of a DTNB-based continuous assay for 
characterisation of MshB activity [9]. These various assays and their respective 
shortcomings are described below. 
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4.2.1 The AccQ-FluorTM derivatization-based assay 
AccQ-Fluor is a highly stable fluorescent reagent that reacts with primary and 
secondary amino group to produce the corresponding an N-6-aminoquinolyl-urea 
and N-hydroxysuccinimide as side product (Figure 4.2) [10]. It was synthesised by 
Cohen and Michaud in 1993 to overcome shortcomings of other fluorescent 
derivatization agents such as o-phthalaldehyde (OPA), 9-
fluorenylmethylchloroformate etc [10]. These included lability, generation of 
numerous derivatives, and the inability to derivatise secondary amino groups. Amino 
groups derivatised with AccQ-Fluor can easily be analysed by High Performance 
Liquid Chromatography (HPLC) using reversed phase columns and fluorescence 
detection with excitation at 250 nm and emission at 395 nm. AccQ-Fluor has been 
found to work best under basic conditions, that is, it works well in solutions with a pH 
range from pH 8.3-10.0. The AccQ-Fluor derivatization-based assay is sold in kit-
format by Waters Corporation.  
 
Fig. 4.2: The reaction of AccQ-Fluor with the free amino sugar of MshB reaction 
product. 
The AccQ-Fluor kit has been used by Anderberg et al. in 1998 to investigate the 
formation of GlcN-Ins during MSH biosynthesis [11]. It was subsequently used in 
2000 by Newton et al. in the determination of GlcNAc-Ins as the natural substrate of 
MshB and in the identification of GlcNAc-Ins as the key intermediate within the MSH 
biosynthesis pathway [3]. Since then it has been used by several people to 
characterise MshB activity [4, 9, 12]. In 2010 it was also applied by Parsonage et al. 
Stellenbosch University  https://scholar.sun.ac.za
 
103 
in the discovery and characterisation of BshB involved the BSH biosynthesis 
pathway [13]. Apart from being a discontinuous assay, the use of AccQ-Fluor kit has 
its own shortcomings. It requires the use of HPLC to isolate and identify the 
derivatised product, which requires several hours for the analysis of multiple 
samples. In addition, the derivatization involves several steps that must occur before 
HPLC analysis, as required by the manufacture. 
4.2.2 The FSA derivatization-based assay 
FSA is a heterocyclic dione compound that is fluorescent once it reacts with a 
primary amine [14]. In 1972 Udenfriend et al. reported that FSA was synthesised by 
Weigele et al. as a substitute for fluorogenic ninhydrin reaction for the analysis of 
amino acids, primary amines and peptides [14]. FSA reacts with primary amines to 
form fluorophores that fluoresce when excited at 390 nm; the emission is at 475 mm. 
The best derivatization was found to occur at pH 9.0 [14, 15]. The first use of 
fluorescamine as a derivatizing reagent for MshB product formation was done by 
Huang et al. in 2011 (Figure 4.3) [2]. In this study the authors used GlcNAc as the 
substrate, and derivatised the GlcN product with FSA in 1M borate buffer at pH 9.0 
followed by determination of the fluorescence in a 96 well plate using a plate reader.  
 
Fig. 4.3: MshB reaction through analysis of FSA-derivatization-based assay.  
Apart from being a discontinuous assay, the FSA-derivatization-based assay 
requires generation of a standard curve using known standards of the expected 
reaction product to allow its quantification. With the MshB and BshB products this 
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can be very challenging due to the α-configuration of the glycoside that impedes 
access the free amine group on the 2-position.  
4.2.3 The NDA derivatization-based assay 
NDA is a fluorogenic derivatizing reagent that reacts with primary amines in the 
presence of a thiol or cyanide ion to produce an N-2-substituted-1-cyanobenz-[ƒ]-
isoindole, which is highly fluorescent (Figure 4.4) [16]. It was initially synthesised by 
Matuszewski and co-workers in 1986 as a replacement of OPA, a fluorogenic 
reagent which is very unstable at room temperature [17]. 
 
 
Fig. 4.4: The reaction of NDA with a primary amine in the presence of cyanide at 
room temperature [16]. 
Since then it has being used by many as the fluorogenic derivatising agent of choice 
for primary amines due to its improved stability and sensitivity compared to FSA and 
AccQ-Fluor [7, 14, 15]. Recently, NDA was used as the fluorogenic derivatising 
agent in the characterisation of BshB [7].  
The major issue with the NDA assay is that it is also a discontinuous assay, and like 
FSA it requires the generation of a standard curve using known standards of the 
expected reaction product to allow its quantification. In addition, it also requires the 
use of a toxic molecule, namely potassium cyanide. 
4.2.4 The DTNB-based continuous assay 
In 2012 Lamprecht et al. developed a DTNB-based continuous assay for the 
characterisation of MshB activity [9]. This assay depends on an intramolecular SN 
Smiles rearrangement that occurs after the deacetylation of 2,4DNP-α-S-GlcNAc (an 
alternative substrate) by MshB (Figure 4.5). The intramolecular SN Smiles 
rearrangement takes place in three steps which is highly dependent on the nature of 
the substituent(s) of the aromatic group. The first step involves reaction of the amine 
with the nitrogen of the GlcN moiety generated after the deacetylation of 2,4DNP-α-
Stellenbosch University  https://scholar.sun.ac.za
105 
S-GlcNAc with carbon 1 of phenyl ring to form the spiro-Meisenheimer intermediate. 
This is followed by its deprotonation to form a nucleophilic spiro-Meisenheimer 
intermediate. The last step involves the bond breaking between carbon 1 and the 
sulphur atom generating a thiolate anion which is then protonated to form a thiol 
group. Once the thiol is generated DTNB reacts with it to form NTB while forming a 
disulphide bond with the thiol group of the reaction product. NTB is UV-active and 
can be detected at 412 nm as it is released. 
 
 
Fig. 4.5: The MshB catalysed reaction as analysed by DTNB assay [9].  
The problem with this assay is the low solubility of the alternative substrate, 2,4DNP-
α-S-GlcNAc, which must be dissolved in DMSO. In addition, it is a poor substrate 
alternative, requiring high concentrations to show activity. This combination makes it 
impossible to use to conduct kinetic studies of MshB as the substrate concentration 
required to saturate the enzyme is too high and would require high levels of DMSO 
to keep it in solution. In addition, a lag period is observed during the initial stages of 
the reaction, assumed to be due to intramolecular SN Smiles rearrangement taking 
place. Consequently the assay cannot be used to determine the initial rates of 
activity accurately.  
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4.3 Motivation for this study 
The main aim of the study described in this chapter was to develop a continuous 
assay for the metallodeacetylases MshB and BshB that would be suited for use in 
kinetic characterization and inhibitor screening. Specifically, the goal was to establish 
a method whereby the acetate produced during the course of the reaction could be 
quantified by through coupling to enzymes that utilise acetate as a substrate. To 
achieve this, two enzymes that utilise acetate as natural substrate were chosen as 
possible candidates for the coupling enzyme: acetate kinase and acetyl-CoA 
synthase. In both cases, the reactions catalysed by these two enzymes can be 
linked to other enzymes that finally results in the consumption or production of 
NADH, which be followed spectrophotometrically. The amount of NADH consumed 
can then correlated to the amount of acetate produced. However, this can be done in 
several ways. 
In this study three different routes were investigated; these were based on previously 
published assays for other deacetylases [18-20]. The first route entails coupling to 
the enzyme acetyl-CoA synthetase (ACS), which is then linked to myokinase, 
pyruvate kinase (PK) and lactate dehydrogenase (LDH) (Figure 4.6) [19]. The 
second route couples to citrate synthase (CS) and malate dehydrogenase (MDH) 
(Figure 4.7) [20]. In the last route acetate production is coupled to acetate kinase 
(AK), and subsequently to phosphotransacetylase (PTA) and then to PK/LDH (Figure 
4.8) (PTA is added to prevent the forward reaction of AK, see Figure 4.12). Here we 
describe the results of our studies to establish the potential and utility of these 
various systems for application as a robust continuous assay for MshB and BshB 
activity by using the MshB reaction with GlcNAc as substrate as test case. 
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Fig. 4.6: The proposed continuous deacetylase assay based on the coupling of 
acetate production to acetyl-CoA synthetase and a subsequent cascade ending in 
the oxidation of NADH through myokinase [19].  
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Fig. 4.7 The proposed continuous deacetylase assay based on the coupling of 
acetate production to acetyl-CoA synthetase and a subsequent cascade ending in 
the oxidation of NADH through citrate synthetase [20].  
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Fig. 4.8: The proposed continuous deacetylase assay based on the coupling of 
acetate production to acetate kinase and a subsequent cascade ending in the 
oxidation of NADH. This assay is commercially available in kit form 
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4.4 Results and discussion 
4.4.1 Evaluation of a continuous assay with ACS, PK, LDH and 
myokinase as coupling enzymes 
The main physiological function of ACS is to activate acetate by forming AcCoA [18]. 
The first ACS that was discovered was the ADP-forming version (EC: 6.2.1.13) from 
Entamoeba histolytica, discovered in 1977 by Reeves et al.[21]. Since then, many 
ACS enzymes have been discovered from different microorganisms, such as 
Griardia lamblia, Pyroccus furiosus among others [22, 23]. The AMP–forming version 
of ACS (EC: 6.2.1.1) belongs to the acyl-adenylate-forming enzyme superfamily [23]. 
Its reaction occurs in two steps (Figure 4.9) and is assayed by the detection of 
unreacted CoA or the AMP produced as by-product [19, 24, 25]. The former is 
detected using DTNB (Ellman’s reagent) that is tracked examined 
spectrophotometrically at 420 nm [19, 24]. Detection by means of AMP-formation 
utilises the coupling of myokinase to PK and LDH which allows the reaction to be 
followed by the oxidation of NADH [19]. In the context of deacetylase assays, ACS 
was utilised by Wolfson et al. for the characterisation of histone deacetylase [20]. 
The same assay was used by Krämer et al. in 2016 to characterise the reaction of 
acetylpolyamine amidohydrolases [26].  
 
 
Fig. 4.9: The reaction catalysed by AMP-forming ACS enzymes [25]. 
In 1987 Patel et al. used PK, LDH and myokinase as coupling enzymes in an assay 
(Figure 4.7) of ACS from yeast in which various carboxylic acid compounds were 
screened as alternative substrates [19]. Several carboxylic acid compounds such as 
propanoic acid and 2-propanoic acid amongst other were identified as alternative 
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substrates for the enzyme. Using this report as starting point, we set out to establish 
if this assay could be used for determining MshB activity. Six test reactions were set 
up to ensure that the observed activity could be attributed to MshB, and not to 
background activity of one of the coupling enzymes (see Table 4.1 for the different 
reactions and expected result for each). The results of these tests are shown in 
Figure 4.10. This shows that even in the case of negative controls (i.e. in the 
absence of coupling enzymes), high levels of background activities were observed. 
The background activity was observed for all reactions containing ACS and 
myokinase (Blank, positive control, experiment and negative control 3). The amount 
of NADH in these reactions was very low in relation to the ones without ACS 
(negative control 1) or myokinase (negative control 2). This indicates that the 
coupling reactions had already occurred, depleting the NADH that was present in the 
master mix at the start of the reactions. For the reaction without ACS (negative 
control 1) the NADH level remained constant meaning that no reaction was taking 
place as expected. In the absence of myokinase (negative control 2) the NADH level 
decreased slowly indicating a slow background activity, most likely due to the 
presence of AMP in the ATP used in the reaction mix.  
Table 4.1: Test reactions for ACS-based MshB assay with expected results for each. 
Reaction types Content of the reaction  Expected results 
Blank Everything except GlcNAc No change in NADH 
Experiment MshB reactions Decrease of NADH 
Positive control No MshB, but AcOH added as 
substrate 
Decrease of NADH 
Negative control 1 Everything, except ACS No change in NADH 
Negative control 2 Everything, except myokinase No change in NADH 
Negative control 3 Everything, except MshB No  change in NADH 









































Fig. 4.10: The evaluation of the test reactions set up to evaluate the ACS-based 
MshB coupled assay (see Table 4.1 for reaction conditions). 
To establish the cause of the background activity, the various components of the 
reaction mixture was sequentially added. The initial test mixture contained buffer with 
LDH, PK, MgCl2, KCl, NADH and PEP (A). For the next reaction myokinase was 
added (B), followed ATP (C), and CoA (D). ACS was added last (E). The addition of 
C, ATP, results is a slight decrease which stabilised over time. This indicated that the 
ATP is contaminated with some trace of ADP, that is, some of ATP has been 
hydrolysed into ADP and Pi. The addition of ACS resulted (E) in an immediate 
decrease of NADH, even though no acetate was present the mixture (Figure 4.11). 
This clearly indicates that the ACS used in this assay is responsible for the 
background activity. This is most likely due to the commercial ACS preparation is not 
pure, that is, the ACS mixture might contain other enzymes in the mixture that are 
either promoting the PK reaction, LDH reaction or they can reduce NADH to NAD+. 
Since the further development of this assay required a high purity ACS preparation 
that was not accessible at this time, our attention moved to other options for 
continuous deacetylase assays. 
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Fig. 4.11: Identification of the background activity through sequential addition of the 
reaction reagents. A: buffer with LDH, PK, MgCl2, KCl, NADH and PEP; B: 
myokinase added to A; C: ATP added to B; D: CoA added to C; E: ACS added to D. 
4.4.2. Evaluation of a continuous assay with ACS, CS and MDH as 
coupling enzymes 
Wolfson et al. and Krämer et al. used an assay in which ACS is coupled to CS and 
MDH to characterise the reaction of histone deacetylase and acetylpolyamine 
amidohydrolases, respectively [20, 26]. In both cases they were able to detect the 
amount of the acetate released in a continuous manner. However, when the same 
assay was applied to determine the activity of MshB using the conditions reported in 
these studies, no activity could be observed even after several reactions, not even 
background activity. Subsequently several acetate compounds (such sodium 
acetate) were used in what would be positive control reactions. However, no activity 
was detected. Modifying the ratio of coupling enzymes within the assay also did not 
result in any activity. It was assumed that the no activity results could be associated 
with the linking enzymes (CS and MDH), that is, maybe they are inactive. Studies on 
evaluating the activity of CS and MDH were never done because if the problem 
could be resolved there was still the problem of the background activity of 
commercial ACS. Wolfson et al. indicated that a highly purified recombinants ACS is 
required for the use of such assay in order to decrease the background activity [20]. 
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The accessible of a highly purified recombinants ACS at this time was not feasible. 
Consequently the further investigation of this route was also terminated.  
4.4.3 Evaluation of a continuous assay with AK, PTA, PK, and LDH as 
coupling enzymes 
Acetate kinase is a reversible phosphoryl transfer enzyme that transfers and 
activated phosphoryl group to acetate to generate acetyl-phosphate and either ADP 
or Pi as a by-product [27]. The phosphoryl donor can either be diphosphate or ATP, 
with the reactions being catalysed by acetate kinase (EC: 2.7.2.12) and acetate 
kinase (EC: 2.7.2.1), respectively (Figure 4.12). Acetate kinase was discovered by 
Lipmann in 1944 [28] and is a member of the ASKHA (Acetate and Sugar Kinases; 
Hsp70, Actin) phosphotransferase superfamily [27, 29]. Its reaction is characterised 
either through the use of enzyme-coupled assays [30] or through the hydroxamate 
assay, with the latter being derived from the Lipmann-Tuttle and Rose methods [31, 
32]. The hydroxamate assay involves the use of hydroxylamine that reacts with 
acetyl-phosphate to form acetyl hydroxamate; this produces a coloured complex with 
ferric ions [27, 31-33]. The enzyme-coupled assay uses the PK and LDH enzymes to 
detect the ADP produced during the reaction. Currently, acetate kinase is utilised in 
the acetic acid kit from Megazyme to determine the amount of acetic acid in food. 
 
 
Fig. 4.12: The reversible reaction of AK [27]. 
Initial screening of the acetate kinase-based assay as a potential continuous assay 
for MshB deacetylase activity again involved inspection to determine any 
background activity or interference within the assay. GlcNAc was selected as the 
substrate, and was used in the assay at different concentration (0 - 250 mM) in the 
absence of MshB. All reactions except the one with no GlcNAc (0 mM) gave 
background activity (Figure 4.13). Moreover, the rate of NADH reduction was found 
to correlate with the GlcNAc concentration, that is, the higher the amount of GlcNAc 
used the faster the rate of NADH reduction was found to be. This suggested that the 
GlcNAc preparation contained acetic acid as contaminant. The GlcNAc preparation 
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was therefore subjected to several rounds of freeze drying in an attempt to remove 
the acetic acid, after which the test was repeated.  
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Fig. 4.13: Background activity of acetate kinase with GlcNAc as a substrate (in the 
absence of MshB). 
The rate of reduction of NADH was reduced dramatically in reactions in which freeze 
dried GlcNAc was used. GlcNAc was therefore subjected to a further round of freeze 
drying; the GlcNAc that was purified in this manner gave no background when tested 
at 250 mM (Figure 4.13). The successful removal of acetic acid from GlcNAc made it 
possible to investigate the acetate kinase-based assay for use as an MshB assay.  
The acetate kinase-based assay was evaluated by using it to determine the MshB 
kinetic parameters with GlcNAc as substrate, and to compare the results to 
published values. The kinetic study was done with the pure GlcNAc in a 
concentration range from 0–250 mM. The acetate kinase-based assay gave 
reasonable MshB activity profiles (Figure 4.14A), which were hyperbolic in nature, 
not showing the sigmoidal profiles previously observed for compounds 12 and 13 
when the FSA assay was used (see chapter 3). The kinetic parameters obtained by 
fitting the Michaelis-Menten equation to the data differed from the ones published by 
Huang et al., which was obtained using the FSA assay (Table 4.2) [2]. The KM 
obtained from the acetate kinase assay was five-fold higher compared to the 
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published value, while the kcat value was lower, although by a factor less than two. 
However, it should be pointed out that the data in the study by Huang et al. was 
obtained using the M. smegmatis MshB, while our studies were performed with the 
M. tuberculosis enzyme. 
To exclude the possibility that the low activity could due to the coupling enzymes, i.e. 
that one of these enzyme are rate limiting, the assay was performed with different 
concentrations of MshB (0.5 µM, 1.0 µM, 2.0 µM and 2.5 µM) at one concentration of 
GlcNAc (38 mM). The activity of MshB was found to increase linearly with the 
amount of enzyme used indicating that the coupling enzymes are not a limiting factor 
in the assay (Figure 4.15). A linear equation (y = mx + c) was fitted through the data 















































Fig. 4.14: Activity profiles for MshB with GlcNAc: Panel A is a continuous assay 
done through the AK-PTA-PK-LDH coupling-enzyme assay with a fit of R2 = 0.9800. 
Panel B is a discontinuous assay done through FSA derivatization-based assay with 
a fit of R2 0.9006 (The standard curve, Figure 3.10 in Chapter 3, was used to convert 
the fluorescence units into [GlcN]). The data represent average rate of MshB at 
various concentration of GlcNAc with the error bars representing standard deviation. 
Activity assays were performed using a range of concentrations (0 mM - 250 mM) of 
the different compounds and were in triplicate for FSA assay and duplicate for AK-
PTA-PK-LDH assay coupling-enzyme. The non-linear Michaelis-Menten equation 
(v=Vmax*S/(KM+S) was fitted through the data.  
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Table 4.2: Kinetic study of MshB with GlcNAc as substrate through different assays 





KM (mM) 38 ± 4.0 199 ± 38 213 ± 74 
kcat (min-1) 46 ± 2.2 25 ± 2.7 30 ± 6.2. 
kcat/KM (mM-1.min-1) 1.2 ± 0.08 0.125 ± 0.027 0.141 ± 0.057 


























Fig. 4.15: Activity profile of MshB at various concentration with GlcNAc constant at 
38mM. The activity was done through the AK-PTA-PK-LDH assay coupling-enzyme. 
The data represent average activity rate of MshB at various concentration with the 
error bars representing standard deviation. Activity assays were performed using a 
range of concentrations (0–2.5 mM) of the MshB and were done in triplicate. A linear 
equation (y = mx + x ) was fitted through the data. 
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As the coupling enzymes were excluded as a possible source of error, we 
considered that the difference between the kinetic parameters observed during this 
study and those reported by Huang et al. could be due to the FSA assay used in the 
previous studies. We therefore also obtained an MshB activity profile using the FSA 
assay as described by Huang et al. (Figure 4.14B). The kinetic parameters obtained 
in this manner agreed very well with those from the acetate kinase-based assay 
(Table 4.2). This suggested that the difference in the kinetic parameters reported for 
MshB by Huang et al. and those obtained here is likely due to the difference in 
source of the enzymes, as the published data was from the Mycobacterium 
smegmatis enzyme [2], while the M. tuberculosis MshB was used in this study. 
Taken together, the results seemed to indicate that the acetate kinase-based assay 
could be used to characterise MshB activity with any substrate as long as there is no 
trace of acetic acid is present. To evaluate such claim α-GlcNAc-OMe was used as 
substrate in reactions with MshB, and the deacetylase activity tracked using both the 
acetate kinase-based and FSA assays for direct comparison. 
Activity profiles for MshB with α-GlcNAc-OMe using the acetate kinase-based and 
FSA assays were obtained without any problems (Figure 4.16). The fit of the non-
liner Michaelis-Menten equation through the FSA assay data was not a good fit (R2 = 
0.8795) in relation to the AK-PTA-PK-LDH coupling assay (R2 = 0.9813), hence the 
large difference between the kinetic parameters (Table 4.3). The kinetic parameters 
obtained from FSA assay active profiles are very inconclusive due to the large error 
margin. If one has to take the error into account FSA has a high kcat and low KM in 
relation to acetate kinase-based assay; however such account cannot be done 
because the error margin is so large. The data scatted of the FSA assay could be 
assumed to be due to the inaccessibility of the free amine group of the reaction 
product by the FSA, that is, the α-anomeric configuration of α-GlcN-OMe might be 
producing steric hindrance at the anomeric centre making it difficult for the FSA to 
reach the amine group (amine group and methyl group are facing the same 
direction) or because the standard curve used to convert the fluorescence units into 
α-GlcN-OMe concentration was generated from glucosamine and not α-GlcN-OMe. 
To prove such assumption a standard curve generated from α-GlcN-OMe would be 
required of which it is very challenging due to the formation of the α-configuration of 
the glycoside that impedes access the free amine group on the 2-position.  
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Looking at the activity profiles (Figure 4.14 and 4.16) of MshB with the different 
substrates (α-GlcNAc-OMeand α-GlcNAc) it is clear from both profiles that AK-PTA-
PK-LDH coupling assay seem to the best assay to characterise MshB reaction 
compared to FSA assay. Unlike FSA assay, the AK-PTA-PK-LDH coupling assay 
relies on the acetate produced during the reaction without the need of generating a 
standard curve or concerns about the possibility of steric hindrance interfering in the 
association between the derivatization agent and the reaction product. As such the 
AK-PTA-PK-LDH coupling assay can be applied to wider range of substrate.  
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Fig. 4.16: Activity profiles for MshB with α-GlcNAc-OMe: Panel A is a continuous 
assay done through the AK-PTA-PK-LDH coupling-enzyme assay with a fit of R2 
0.9813. Panel B is a discontinuous assay done through FSA derivatization-based 
assay with a fit of R2 0.8795 (The standard curve, Figure 3.10 in Chapter 3, was 
used to convert the fluorescence units into [α-GlcN-OMe]). The data represent the 
average rate of MshB at various concentration of α-GlcNAc-OMe with the error bars 
representing standard deviation. Activity assays were performed using a range of 
concentrations (0–250 mM) of the different compounds and were in triplicate for FSA 
assay and duplicate for AK-PTA-PK-LDH assay coupling-enzyme. The non-liner 
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Table 4.3. Kinetic study of MshB with α-GlcNAc-OMe through different assays 
Kinetic parameters AK-PTA-PK-LDH 
coupling assay 
FSA assay 
KM (mM) 227 ± 61 903 ± 837 
kcat (min-1) 32 ± 4.9 186 ± 143 
kcat/KM (mM-1.min-1) 0.14 ± 0.043 0.20 ± 0.24 
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4.5 Summary and conclusion 
Three different continuous deacetylase assays that is, ACS-PK-LDH-myokinase, 
ACS-CS-MDH and AK-PTA-PK-LDH were tested as potential candidates for 
characterisation of MshB activity. Of the three, ACS-PK-LDH-myokinase assay 
showed background activity as a result of the main coupling enzyme (ACS), while 
the ACS-CS-MDH assay show no activity at all. The AK-PTA-PK-LDH assay showed 
that MshB reaction can be followed through the detection of the acetate produced 
during the reaction, as long as there is no trace of acetate/acetic acid in the 
substrate being used. AK-PTA-PK-LDH assay was also found to be a better assay in 
relation to the FSA assay, that is, looking at the activity profiles for MshB with 
GlcNAc and α-GlcNAc-OMe through the two assays (Figure 4.15 and Figure 4.16) it 
clearly shows that acetate kinase-based assay is a better assay compared to the 
FSA assay. The data points of the acetate kinase-based assay had small error 
margin to those of FSA assay and the non-liner Michaelis-Menten equation was a 
better fit through the data. The initial rate can be determined without any problem, 
since AK-PTA-PK-LDH assay is a continuous assay which depends on the acetate 
formation and not the amine group, which means no standard of the reaction, is 
required for the generation of the standard curve. 
Looking at the kinetic parameters of AK-PTA-PK-LDH assay and FSA assay 
especially that of the α-GlcNAc-OMe it is clear that FSA assay is not the best assay 
to characterise reactions wherein α-GlcNAc-based glycosides are used as 
alternative substrate. This might explain the undetectable activity of MshB with α-
GlcNAc-N3 and α-GlcNAc-CyCOH (Figure 3.13 in Chapter 3) at low concentrations 
and the apparent cooperative kinetic behaviour that was observed, that is the 
observed cooperativity was due to the assay used and not due to substrate. Due to 
low amount of α-GlcNAc-N3 and α-GlcNAc-CyCOH the activity of MshB with these 
compounds could not be tested. Lastly AK-PTA-PK-LDH assay is a better 
continuous assay than the DTNB-based assay because does not require the 
substrate to dissolve in DMSO or the formation of any secondary product (Smiles-
rearrangement). In conclusion a continuous assay for metallo-deacetylase enzyme 
was found which allowed the characterisation of the reaction as it occurs through the 
determination of the acetate produced during the reaction.  
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4.6 Material and methods 
All the chemicals used were purchased from Sigma-Aldrich unless stated otherwise 
except, GlcNAc which was brought from Carbosynth and α-GlcNAc-OMe chemical 
synthesised using the previously described method by Gao et al. [34] and Neuberger 
et al. [35]. The assays were done using Greiner Bio-One polystyrene flat-bottomed 
96-well plate, that is clear plate for the different routes assay (ACS-PK-LDH-
myokinase; ACS-CS-MDH and AK-PTA-PK-LDH) and black plates were for FSA 
assay. Varioskan multimode reader (Thermo Scientific) was used to measure the 
fluorometric and spectrophotometric readings. All enzymes were purchased from 
Sigma-Aldrich, with exception to the ones used within the acetic kit from Megazyme 
and MshB. MshB was expressed and purified according to Newton et al for [4]. The 
cultures were grown until the optical density at 600nm (OD600) reached 0.600 and 
induced with 0.10mM of isopropyl-1-thio-β-D-galactropyranoside (IPTG) for MshB 
followed by incubation of the cultures overnight at 22oC. This was followed by cell 
harvest by centrifugation at 17600×g for 20 minutes at 10oC. The pellets cells were 
stored at -20oC until use. The enzymes was purified with automated purification 
program on ÄKTAprime system (Amersham Bioscience) using the previously 
described methods. SDS-PAGE was used to check the purity of the protein, while 
Bradford was used to determine the protein concentration. 
4.6.1. Studies toward the development of a potential high throughput 
continuous assay 
4.6.1.1. Evaluation of a continuous assay with ACS, PK, LDH and myokinase as 
coupling enzymes 
The use of ACS, PK, LDH and myokinase as coupling enzymes was inspired and 
conducted in the same way as Patel et al. with some modification to it [19]. The 
reaction mixture (master mix) containing reaction buffer (50mM HEPES, 50mM 
NaCl, pH 7.5) together with or without coupling enzymes or MshB, see Table 4.1, 
were incubated at 30°C for 2 minutes. The reaction was initiated by adding reaction 
mixture into the substrate or water in the case of blank already in a 96 well 
microplate. The decreasing absorbance of NADH was monitored at 340nm for 
several minutes.  
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4.6.1.2 Evaluation of a continuous assay with ACS, CS and MDH as coupling 
enzymes  
The successful application of ACS by Wolfson et al. to assay the histone 
deacetylase reaction with ACS, CS and MDH as coupling enzymes motivated us to 
utilised ACS, CS and MDH as coupling enzymes for the metallodeacetylase reaction 
[20]. The same produce used by Wolfson et al. was used to characterise MshB 
reaction with some modification to it for the development of a continuous assay [20]. 
The reaction mixture (master mix) containing reaction buffer (50mM HEPES, 50mM 
NaCl, pH 7.5) together with coupling enzymes and MshB was incubated at room 
temperature for 30 minutes for the equilibration. The reaction was initiated by adding 
reaction mixture into the substrate or water in the case of blank already in a 96 well 
microplate. The increasing absorbance of NADH was monitored at 340nm for 
several minutes at 30°C.  
4.6.1.3 Evaluation of a continuous assay with AK, PTA, PK, and LDH as 
coupling enzymes  
The AK, PTA, PK, and LDH as coupling enzymes were done using the acetic kit from 
Megazme and conducted as per manual state, with some modification to it 
[megazyme]. All reagents were added together including MshB and they were 
incubated at 30°C for 2 minutes before adding reaction mixture into the substrate or 
water in the case of blank already in a 96 well microplate. The decreasing 
absorbance of NADH was monitored at 340nm for several minutes at 30°C.  
4.6.2 FSA assay 
FSA was done in the same as in Chapter 3, see section 3.3.2 of Chapter 3. 
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Conclusion and Future work 
5.1 Summary of results achieved 
In this study various α-thioglycoligases that were derived from the CpGH89 α-N-
acetylglucosaminidase were characterised for their suitability as biocatalysts in the 
preparation of α-GlcNAc-based glycosides. Several α-GlcNAc-based glycosides 
were biosynthesised using these α-thioglycoligases and they were tested as small 
molecule chaperones (to determine their potential in the treatment of Sanfilippo 
syndrome) and as alternative substrates or inhibitors of the metallodeacetylase 
MshB. Finally, a new continuous assay for the metallodeacetylases MshB and BshB 
was developed. The specific objectives that were outlined in Chapter 1 to achieve 
this were accomplished as follows:  
5.1.1 Objective 1: Characterisation of α-thioglycoligases derived from 
the α-N-acetylglucosaminidase CpGH89 for the biocatalytic preparation 
of α-GlcNAc-based glycosides  
Although several glycosidase enzymes have been converted into thioglycoligases, 
only a few of them promote the formation of the α-thioglycosidic bond [1]. In addition, 
none of them promote the formation of α-N-acetyl-thioglycosides. We generated α-N-
acetyl-thioglycosides using α-thioglycoligases derived from an α-N-acetyl-
glucosaminidase. The chemical rescue of the α-thioglycoligases with sodium azide 
not only showed that the activity of these mutant glycosidases can be restored by the 
addition of an external nucleophile, but also for the first time allowed for the 
synthesis of α-GlcNAc-N3. The enzymes’ α-thioglycoligase activity was evaluated 
with various donors (2,4DNP-α-GlcNAc, 4NP-α-GlcNAc and 2NP-α-GlcNAc) and 
several thiol molecules as acceptors. No thioglycoligation reactions were observed 
with 4NP-α-GlcNAc as donor with any of the α-thioglycoligases tested, while 
2,4DNP-α-GlcNAc promoted thioglycoligation reactions with some of them. However, 
2,4DNP-α-GlcNAc was also found to be more susceptible to hydrolysis due to the 
stability of its leaving group. We found that the thioglycoligation reaction was best 
promoted with 2NP-α-GlcNAc as glycosyl donor and with thiol molecules containing 
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a thiol group having pKa values ranging between 3 and 8. In addition, specific α-
thioglycoligases, especially CpGH89-E438A and CpGH89-E438S, also promoted the 
thioglycoligation reaction on a preparative scale, which allowed the purification and 
characterisation of the enzymatic reaction products (Table 2.2). The generated α-
GlcNAc-based thioglycosides and α-GlcNAc-N3 were tested for their inhibition and 
stabilization of CpGH89. Of the tested glycosides, GlcNAc-S-CH2CO2Me and 
GlcNAc-S-CH2CO2Et showed the highest inhibition with 79% and 62% of residual 
activity respectively. No inhibition was observed with α-GlcNAc-N3. However, during 
the stabilization study α-GlcNAc-N3 showed the best stabilizing effect. This 
demonstrated that this compound could be a lead in the development of potential 
small molecule chaperones for the treatment of Sanfilippo syndrome since it does 
not inhibit the activity of the wild type enzyme, but increases its stability.  
5.1.2 Objective 2: Chemo-enzymatic synthesis and characterization of 
GlcNAc-based glycosides as alternative substrates or inhibitors of MshB 
and/or BshB 
Several GlcNAc-based thioglycosides that could potentially act as alternative 
substrates of MshB and/or BshB were synthesized chemo-enzymatically (Table 3.2). 
Chemical modification of the biosynthesised α-GlcNAc-based thioglycosides α-
GlcNAc-SMal(OMe)2 and α-GlcNAc-S-CH2CO2Me allowed for the synthesis of the 
BshB substrate analogues α-GlcNAc-SMal and α-GlcNAc-SCH2CO2H. In addition, α-
GlcNAc triazoles were generated from biocatalytically prepared α-GlcNAc-N3 through 
“Click” chemistry. These α-GlcNAc triazoles and α-GlcNAc-N3 were found to show 
higher MshB deacetylation activity than the best alternative substrates currently in 
use (Figure 3.11). The preliminary kinetic study also indicated that an α-GlcNAc 
triazole (compound 12) and α-GlcNAc-N3 (13) are better alternative substrates than 
GlcNAc. Unfortunately, the BshB deacetylation activity against various compounds 
couldn’t be tested since active BshB could not be prepared in this study. 
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5.1.3 Objective 3: Development of a continuous assay suitable for the 
characterization of the metallo-deacetylases, MshB and BshB  
With the exception of one assay described by Lamprecht et al. [2], all the assays that 
are currently available and used to characterise BshB and MshB activity are 
discontinuous assays [3-7]. However, such assays are less than ideal since all of 
them make use of derivatizing reagents which adds complexity, while some utilise 
compounds that are classified as toxic. Moreover, as they are all endpoint assays 
the progress of the reactions cannot be followed without performing an assay for 
each time point. On the other hand, the continuous assay reported by Lamprecht et 
al. utilizes as substrate a compound that shows relatively low activity, and it can only 
be dissolved DMSO, thus, the concentration range of substrate that can be used is 
limited.  
In our attempts to develop a continuous assay suitable for use in high-throughput 
screens we evaluated several potential coupled enzyme systems, including the ACS-
PK-LDH-myokinase [8], ACS-CS-MDH [9] and AK-PTA-PK-LDH 
[www.megazyme.com: K-ACETRM] systems for their potential and suitability as 
continuous assays for MshB’s deacetylation activity with GlcNAc as substrate. Of the 
three different systems investigated only the AK-PTA-PK-LDH system gave 
reproducible results. The background activity observed with the ACS-PK-LDH-
myokinase system was too high and no activity was observed with ACS-CS-MDH 
system, leading to these systems not be considered any further. Using the newly 
developed assay, we were able to characterise MshB activity with GlcNAc and α-
GlcNAc-OMe as substrates. In addition, the activity profile of MshB with different 
substrates was better when using the AK-PTA-PK-LDH coupled assay compared to 
the discontinuous end-point assay that relies on fluorescamine to react with the free 
amine of such as compound. The AK-PTA-PK-LDH system is thus a good candidate 
for utilization as an assay for the characterization of this particular metallo-
deacetylase.  
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5.2 Conclusion 
Overall the main goal of this project was attained through the vigilant evaluation of 
the available thioglycoligase enzymes under several reaction conditions. The α-
GlcNAc-based glycosides generated in this manner have some potential for 
development of small molecular chaperones for the treatment of Sanfilippo 
syndrome. In addition, the AK-PTA-PK-LDH continuous assay system was shown to 
be a viable method for characterizing MshB activity.  
This project opened the door in the search for other α-N-acetylglucosaminidases that 
can also be converted into α-thioglycoligases with other acceptor specificities, and 
which can therefore be used for the generation a different variety of α-GlcNAc-based 
thioglycosides. Furthermore, we developed a way to synthesize α-GlcNAc-N3 easily 
using the α-thioglycoligase CpGH89 as biocatalyst, making it available so that its use 
in other applications can be explored further. 
5.3 Future work 
5.3.1 Engineering and development of and α-thioglycoligase and 
conditions suitable for thioglycoligation using a larger scope of 
acceptors  
The α-thioglycoligases developed in this study only promote the thioglycoligation 
reaction with thio-molecules that had a pKa value below 8. Thio-molecules with a 
thiol groups having pKa values higher than 8 were unable to act as thio-acceptors 
since a thiolate anion could not be generated under the reaction conditions used. 
Future work involves finding reaction conditions that may allow thioglycoligation with 
thiol-molecules that have thiol group with higher pKa values, and without hydrolysis 
of the glycosyl donor. 
5.3.2 Preliminary characterisation of MshB with the newly chemo-
enzymatic synthesised α-GlcNAc-based glycosides 
The several α-GlcNAc-based glycosides prepared for the first time in this study using 
the reported biocatalytic method were tested as alternative substrates of MshB using 
the FSA assay. Of the tested compounds, compounds 3, 8, 12 and 13 were found to 
have higher deacetylation activity with MshB than GlcNAc, the alternative substrate 
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mostly used in current studies (Figure 3.11). In addition, a preliminary kinetic study of 
MshB using compounds 12 and 13 suggested that they are better alternative 
substrates for the enzyme than GlcNAc. Future studies will involve generating more 
of the α-GlcNAc-based thioglycosides and azides/triazoles that showed high MshB 
deacetylation activity by using the methods that were developed as described in 
Chapter 2. These compounds will be characterised with the newly validated AK-PTA-
PK-LDH-based assay of deacetylases, such MshB. This will allow the full kinetic 
characterisation of the activity of MshB and/or BshB towards such compounds; this 
will aid in the identification of alternate MshB substrates other than GlcNAc. Lastly, 
further studies will be conducted to isolate the BshB enzyme in its active form so that 
it too can be characterised with the different α-GlcNAc-based glycosides prepared in 
this study to date. 
5.3.3 The validation of the newly developed continuous deacetylase 
assay for use in inhibitor screening and characterization 
The availability of a new continuous assay for the deactylases MshB and BshB 
allows for more accurate determination of the initial rates of the reactions catalyzed 
by these enzymes. It also greatly facilitates any inhibitor screening and 
characterization processes. Future work will involve using the AK-PTA-PK-LDH 
assay identified as the best alternative for characterisation of MshB activity with the 
various GlcNAc-based glycosides, azides and triazoles produced in others studies 
(including those described in this thesis). It will also be used to establish if the 
system is suitable for inhibitor screening, as this would facilitate efforts to identify a 
new MshB and/or BshB inhibitor from existing compound libraries.  
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Appendix 
Supplementary information supplied in support of publication reproduced in Chapter 
2. 
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SUPPLEMENTAL FIGURES  
 
Figure S1. CpGH89 structure-based stability. A: CD absorption spectra of the buffer, wild type enzyme and its 
E601 mutants at 25°C showing that all the proteins have similar shapes. B: As for A, but for the E483 mutants. 
 
Figure S2. Chemical rescue of CpGH89–E483A/S/Q/G mutants in the presence of sodium azide. HPAEC-PAD 
chromatogram of the reactions performed by the mutants (1.33 M). The mixtures contained 100 mM sodium 
phosphate buffer at pH 7.3, 5 mM 2,4DNP--GlcNAc, and 250 mM sodium azide. Blank mixtures, containing 
all the reagents but the enzymes were incubated at the same conditions and used to test the spontaneous 
hydrolysis of the donor. Reactions were incubated for 16h at 37°C. Cellobiose was used as internal standard. 
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Figure S3. Thioglycoligase activity of CpGH89-derived acid/base mutants. HPAEC-PAD chromatograms of 
the reactions performed by the CpGH89–E483A mutant are shown as case examples. The mixtures contained 
100 mM sodium phosphate buffer at pH 8.0, 5 mM 2NP--GlcNAc, and 106 mM of either methyl 
thioglycolate (Me) or ethyl thioglycolate (Et) acceptors. Blank mixtures, containing all the reagents but the 
enzyme were incubated at the same conditions and used to test the spontaneous hydrolysis of the donor. 
Reactions were incubated for 48h at 37°C. No side-products could be observed but only unreacted donor. 
Cellobiose was used as internal standard. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
1. NMR and MS analysis methods 




C NMR spectra were obtained using a 300 MHz Varian VNMRS (75 MHz for 
13
C), 400 MHz Varian Unity Inova (100 MHz for 
13
C) or 600 MHz Varian Unity Inova (150 MHz for 
13
C) 
instruments (Varian Inc., Palo Alto, CA, USA) at the Central Analytical Facility (CAF) of Stellenbosch 
University. All chemical shifts (δ) were referenced to the reported values of Gottlieb (Gottlieb, et al., 1997) 
using the signal from the residual protonated solvent for 
1
H spectra, or to the 
13
C signal from the deuterated 




C spectra are reported in parts per million (ppm) relative to these 
referenced values, and multiplicities are abbreviated as s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br = broad. All 
13
C NMR spectra were recorded with complete proton decoupling. FID files were 
processed using MestraNova 6.0.2 (MestreLab Research). 
MS analyses: All high resolution mass spectrometry (HRMS) was performed on a Waters API Q-TOF Ultima 
spectrometer (Waters, Milford, MA, USA) at the MS unit of CAF.   
 
2. Preparative scale biocatalytic reactions: Characterization data  
 
Phenyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside [Table 2, Entry 1; 
Reaction with CpGH89–E483A, 2NP-α-GlcNAc as donor and thiophenol as 
acceptor]. Obtained as light yellow solid (4.3 mg, 18%).  TLC (silica gel, 15% 
MeOH in DCM): Rf = 0.41; 
1
H NMR (600 MHz, D2O) δ 7.48 (dd, J = 8.2, 1.2 
Hz, 2H), 7.31–7.24 (m, 3H), 5.68 (d, J = 5.2 Hz, 1H), 4.10–4.06 (m, 2H), 3.80 
(dd, J = 12.1, 2.5 Hz, 1H), 3.75 (dd, J = 12.1, 5.0 Hz, 1H), 3.65 (dd, J = 11.1, 
8.7 Hz, 1H), 3.43 (dd, J = 9.8, 8.8 Hz, 1H), 2.00 (s, 3H). NMR data are in 
agreement with those previously published (Gammon, D.W. et al., 2010). 
HRMS (m/z): [M+H]
+




[Table 2, Entry 3; Reaction with CpGH89–E483A, 2NP-α-GlcNAc as donor 
and 2,2,2-trifluoroethanethiol as acceptor]. Obtained as a white solid (3.7 mg, 
15%). TLC (silica gel, EtOAc/MeOH/H2O, 7:2:1 v/v): Rf = 0.77; 
1
H NMR (600 
MHz, D2O) δ 5.60 (d, J = 5.4 Hz, 1H), 4.13 (dd, J = 11.1, 5.4 Hz, 1H), 4.01 
(ddd, J = 10.1, 5.1, 2.3 Hz, 1H), 3.88 (dd, J = 12.4, 2.3 Hz, 1H), 3.83 (dd, J = 
12.5, 5.2 Hz, 1H), 3.71 (dd, J = 11.1, 8.9 Hz, 1H), 3.43–3.55 (m, 2H), 3.34 (dq, 
J = 15.7, 10.4 Hz, 1H), 2.06 (s, 3H). 
13
C NMR (150 MHz, D2O) δ 175.22, 
84.52, 73.53, 71.14, 70.79, 61.02, 54.44, 32.24, 32.00, 22.41. HRMS (m/z): 
[M+H]
+
 calcd. for C10H17F3NO5S 320.0780; found 320.0780. 
 
 
Methyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate [Table 2, 
Entry 5; Reaction with CpGH89–E483A, 2NP-α-GlcNAc as donor and methyl 
thioglycolate as acceptor]. Obtained as a white solid (19.6 mg, 83%). TLC 
(silica gel, EtOAc/MeOH/H2O, 7:2:1 v/v): Rf = 0.54; 
1
H NMR (400 MHz, D2O) 
δ 5.55 (d, J = 5.4 Hz, 1H), 4.11 (dd, J = 11.0, 5.4 Hz, 1H), 3.96–4.01 (m, 1H), 
3.82–3.84 (m, 2H), 3.76 (s, 3H), 3.67–3.74 (m, 1H), 3.56 (d, J = 15.7 Hz, 1H), 
3.53 (dd, J = 12.2, 6.7 Hz, 1H), 3.42 (d, J = 15.7 Hz, 1H), 2.06 (s, 3H). 
13
C 
NMR (100 MHz, D2O) δ 175.07, 173.87, 84.56, 73.40, 71.29, 70.73, 60.88, 
54.39, 53.77, 32.50, 22.45. HRMS (m/z): [M-H]
-
 calcd. for C11H18NO7S 
308.0804; found 308.0797. 
 
 
Methyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate [Table 2, 
Entry 6; Reaction with CpGH89–E483S, 2NP-α-GlcNAc as donor and methyl 
thioglycolate as acceptor]. Obtained as white solid (11.5 mg, 49%). 
Characterization data as above. 
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Ethyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate [Table 2, 
Entry 7; Reaction with CpGH89–E483A, 2NP-α-GlcNAc as donor and ethyl 
thioglycolate as acceptor]. Obtained as white solid (11.1 mg, 46%).  TLC (silica 
gel, EtOAc/MeOH/H2O, 7:2:1 v/v): Rf = 0.62; 
1
H NMR (400 MHz, D2O) δ 5.56 
(d, J = 5.4 Hz, 1H), 4.22 (q, J = 7.2 Hz, 2H), 4.11 (dd, J = 11.0, 5.4 Hz, 1H), 
3.97–4.02 (m, 1H), 3.81–3.85 (m, 2H), 3.67–3.74 (m, 1H), 3.49–3.56 (m, 2H), 
3.35–3.42 (m, 1H), 2.06 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H). 
13
C NMR (100 MHz, 
D2O) δ 176.98, 175.32, 86.37, 75.34, 73.23, 72.68, 65.44, 62.84, 56.33, 34.49, 
24.38, 15.81. HRMS (m/z): [M-H]
-




Ethyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate [Table 2, 
Entry 8; Reaction with CpGH89–E483S, 2NP-α-GlcNAc as donor and ethyl 
thioglycolate as acceptor]. Obtained as white solid (8.0 mg, 33%).  




2-Acetamido-2-deoxy-α-D-glucopyranosyl azide [Table 2, Entry 15; Reaction 
with CpGH89–E483A, 2NP-α-GlcNAc as donor and sodium azide as acceptor]. 
Obtained as white solid (14.7 mg, 79%).  TLC (silica gel, EtOAc/MeOH/H2O, 
7:2:1 v/v): Rf = 0.59; 
1
H NMR (300 MHz, CD3OD) δ 5.47 (d, J = 4.1 Hz, 1H), 
3.92 (dd, J = 10.6, 4.2 Hz, 1H), 3.84–3.88 (m 1H), 3.65–3.75 (m, 2H), 3.56 (dd, 
J = 10.6, 8.8 Hz, 1H), 3.33–3.41 (m, 1H), 2.00 (s, 3H). 
13
C NMR (75 MHz, 
CD3OD) δ 89.98, 76.11, 72.09, 71.80, 62.39, 54.81, 22.46. HRMS (m/z): [M-
H]
-
 calcd. for C8H13N4O5 245.0886; found 245.0879.  
 
3. Chemical syntheses: 
3.1 Synthesis of methyl 4-thio-α-D-glucopyranoside 
Methyl 4-thio-α-D-glucopyranoside was synthesized by modification of a previously reported method (Chen et 
al., 2010) as described below. 
Methyl 4-S-acetyl-2,3,6-tri-O-benzoyl-4-thio-α-D-glucopyranoside. Under a stream of 
argon, Tf2O (1.93 mL, 11.50 mmol, 2.3 equiv) was added in three portions to a solution of 
methyl 2,3,6-tri-O-benzoyl-α-D-galactopyranoside (2.50 g, 4.94 mmol) (Carbosynth) in 
dry DCM ( 42 mL) and dry pyridine (9.7 mL) at 0°C. After 1 h of stirring the reaction 
mixture under these conditions, 75 mL of DCM was added. The mixture was washed 
sequentially with 50 mL of ice cold 1M HCl, 50 mL of cold saturated NaHCO3 and 50 mL of cold brine, dried 
over MgSO4 and the solvent evaporated under diminished pressure to give a yellow residue. The resulting 
residue was purified by flash column chromatography (4:1 hexane/EtOAc) to give the triflate (1.43g, 45%) as a 
white powder. To the triflate (0.90 g, 1.40 mmol) was added 10 mL DMPU (1,3-dimethyl-3,4,5,6-tetra-hydro-
2(1H)-pyrimidinone) and KSAc (0.48 g, 4.20 mmol, 3.0 equiv), and the suspension was stirred at room 
temperature for 1.5 h. The reaction mixture was diluted with 100 mL of a 1:1 mixture of n-hexane and EtOAc, 
subsequently washed with water (550 mL) and brine (50 mL), and dried over MgSO4. The solvent was 
evaporated under diminished pressure to give a yellow residue, which was purified by flash column 
chromatography (4:1 and 2:1 hexane/EtOAc) to give the product (0.51 g, 65%) as a white powder. Rf 0.53 (2:1 
Hexane/EtOAc).
 1
H NMR (400 MHz, CDCl3) δ 8.09–8.16 (m, 2H), 7.91–8.00 (m, 4H), 7.56–7.63 (m, 1H), 7.49 
(ddd, J = 4.7, 3.5, 3.0 Hz, 4H), 7.36 (td, J = 7.8, 2.7 Hz, 4H), 5.94 (dd, J = 10.9, 9.6 Hz, 1H), 5.20–5.29 (m, 
2H), 4.65 (dd, J = 12.1, 2.2 Hz, 1H), 4.56 (dd, J = 12.1, 5.1 Hz, 1H), 4.29 (ddd, J = 11.6, 5.0, 2.0 Hz, 1H), 
4.09–4.22 (m, 1H), 3.44 (s, 3H), 2.21 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ 192.64, 169.64, 166.40, 165.92, 
165.84, 133.44, 133.34, 133.30, 130.04, 129.91, 129.89, 129.37, 129.20, 128.59, 128.51, 128.49, 97.36, 97.13, 
73.26, 72.04, 70.71, 69.41, 68.85, 68.73, 67.64, 63.98, 55.71, 44.28, 30.79, 20.73. ESI-MS (m/z): [M+Na]
+
 
calcd. for C30H32NO9SNa 587.1346; found 582.1351.  
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Methyl 4-thio-α-D-glucopyranoside. Argon was bubbled through a suspension of the 
thioacetate (0.50 g, 0.886 mmol) in 18 mL of dry methanol for 0.5 h at room temperature, 
after which sodium methoxide solution (0.25 mL, 5.4 M, 2.57 mmol, 2.9 equiv) was 
added. The reaction mixture was left stirring at room temperature under argon for 48 h, 
followed by addition of IR-120(H
+
) ion exchange resin (0.50 g). The resin-containing 
mixture was stirred for 0.5 h at room temperature, after which the resin was filtered and washed with dry 
methanol. The combined filtrates were concentrated in vacuo until 3 mL of solvent remained. A solution of 
DTT (0.36 g in 15 mL distilled water) was added to the remaining solvent while stirring. Argon was bubbled 
through the reaction mixture for 0.5 h, which was then left stirring under argon overnight. The solvent was 
evaporated under reduced pressure to give a white residue, which was purified by flash column 
chromatography (15:1 and 9.1, DCM: CH3OH) to give the product as a white powder (170 mg, 91%). Rf 0.14 
(15:1 DCM: CH3OH). 
1
H NMR (400 MHz, CD3OD) δ 4.73 (d, J = 4.7 Hz, 1H), 3.81 (dd, J = 12.0, 3.5 Hz, 2H), 
3.58 (ddd, J = 10.8, 4.6, 2.4 Hz, 1H), 3.51 (dd, J = 12.6, 6.8 Hz, 1H), 3.43 – 3.37 (m, 4H), 2.72 (t, J = 10.4 Hz, 
1H). 
13
C NMR (100 MHz, CD3OD) δ 101.35, 75.51, 74.97, 74.33, 63.12, 55.56, 43.37. ESI-MS (m/z): [M-H]
-
 
calcd. for C7H13O5S 209.0484; found 209.0485. 
 
3.2 Synthesis of methyl 4-S-(2-acetamido-2-deoxy-α-D-glucopyranosyl)-4-thio-α-D-glucopyranoside. 
The title compound was synthesized by modification of the method reported above, using 2-acetamido-3,4,6-
tri-O-acetyl-2-deoxy-1-thio-α-D-glucopyranose instead of thioacetate as nucleophile in the displacement 
reaction. 
Methyl 4-S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-gluco-pyrano-
syl)-4-thio-3,4,6-tri-O-benzoyl-α-D-glucopyranoside. A solution of 2-
acetamido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-α-D-glucopyranose (0.563 g, 1.54 
mmol) (Knapp, S. et al., 2001) in 3 mL of dry N,N-dimethylformamide (DMF) 
was treated with 0.058 g (1.53 mmol) of sodium borohydride while stirring 
under nitrogen. After 30 minutes, the triflate prepared as described above 
(1.53 g, 2.31 mmol, 1.5 equiv) was added and the reaction was stirred at room 
temperature for 4 h. The reaction mixture was neutralized by addition of glacial acetic acid (44 µL), followed 
by dilution with 50 µL of ethyl acetate. The reaction mixture was washed with water (450 mL) and dried over 
Na2SO4. The solvent was removed under diminished pressure to give a yellowish residue that was purified by 
flash column chromatography (hexane/EtOAc/acetone, 4:3:1) to give the product (0.315 g, 24%) as a white 
powder. Rf 0.35 (5% MeOH in DCM). 
1
H NMR (400 MHz, CDCl3) δ 8.08–8.11 (m, 2H), 7.89–7.96 (m, 4H), 
7.61 (t, J = 7.4 Hz, 1H), 7.51 (dt, J = 11.4, 7.4 Hz, 4H), 7.36 (dt, J = 11.6, 7.8 Hz, 4H), 6.04 (t, J = 10.4 Hz, 
1H), 5.54 (d, J = 5.3 Hz, 1H), 5.44 (d, J = 9.5 Hz, 1H), 5.19 (d, J = 3.5 Hz, 1H), 5.06–5.15 (m, 2H), 4.87 (ddd, 
J = 11.9, 9.1, 5.8 Hz, 2H), 4.60 (dd, J = 11.9, 5.8 Hz, 1H), 4.47 (ddd, J = 11.2, 9.6, 5.3 Hz, 1H), 4.18–4.33 (m, 
3H), 4.04 (d, J = 10.4 Hz, 1H), 3.44 (s, 3H), 3.30 (t, J = 11.0 Hz, 1H), 2.08 (s, 3H), 1.99 (s, 3H), 1.93 (s, 3H), 
1.61 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ 171.28, 170.70, 169.53, 169.24, 166.32, 165.93, 165.64, 133.85, 
133.53, 130.01, 129.87, 129.78, 129.69, 129.01, 128.89, 128.85, 128.74, 128.53, 97.2, 86.82, 73.27, 72.06, 
71.30, 69.72, 68.89, 67.69, 64.25, 61.67, 55.82, 51.76, 47.91, 22.48, 20.83, 20.70, 20.68. ESI-MS (m/z): 
[M+H]
+
 calcd. for C42H46NO6S 852.2537; found 852.2549. 
 
Methyl 4-S-(2-acetamido-2-deoxy-α-D-glucopyranosyl)-4-thio-α-D-gluco-
pyranoside. To a solution of methyl 4-S-(2-acetamido-3,4,6-tri-O-acetyl-2-
deoxy-α-D-glucopyranosyl)-4-thio-3,4,6-tri-O-benzoyl-α-D-glucopyranoside 
(0.315 g, 0.370 mmol) in 5 mL of dry methanol was added sodium methoxide 
solution (0.770 g in 5 mL dry methanol) and the mixture left to stir at room 
temperature overnight (Bengtsson, M. et al, 1998). This was followed by 
neutralization by addition of 0.5 g of IR-120(H
+
) ion exchange resin, which was 
stirred for 0.5h at room temperature. The resin was filtered and washed with dry methanol followed by removal 
of the solvent from the combined filtrates in vacuo. The resulting residue was purified using flash column 
chromatography (61:33:6, DCM/MeOH/H2O) to give the product as a white powder (70 mg, 46%). Rf 0.42 
(61:33:6, DCM/MeOH/H2O). 
1
H NMR (600 MHz, D2O) δ 5.66 (d, J = 5.4 Hz, 1H), 4.87 (d, J = 3.7 Hz, 1H), 
4.12 – 4.05 (m, 2H), 3.97 (dd, J = 12.1, 2.2 Hz, 1H), 3.94 – 3.89 (m, 2H), 3.89 – 3.78 (m, 3H), 3.64 (dd, J = 
11.1, 8.8 Hz, 1H), 3.57 (dd, J = 9.5, 3.7 Hz, 1H), 3.49 (dd, J = 9.8, 9.0 Hz, 1H), 3.43 (s, 3H), 3.37 (s, 1H), 2.79 
(t, J = 10.9 Hz, 1H), 2.08 (s, 3H). 
13
C NMR (150 MHz, D2O) δ 174.94, 100.04, 84.30, 73.84, 73.07, 72.21, 
71.50, 71.45, 70.85, 62.08, 61.09, 55.71, 54.75, 48.22, 22.46. ESI-MS (m/z): [M+H]
+
 calcd. for C15H28NO10S 
414.1434; found 414.1426. 
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Original spectra of compounds prepared by preparative scale biocatalysis (in order): 
1
H NMR spectrum of phenyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside.  
ESI-TOF (positive mode) spectrum of phenyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside.
 
1
H NMR spectrum of 2,2,2-trifluoroethyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside.  
13
C NMR spectrum of 2,2,2-trifluoroethyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside.  
ESI-TOF (positive mode) spectrum of 2,2,2-trifluoroethyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyrano-side.  
1
H NMR spectrum of methyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate.  
13
C NMR spectrum of methyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate.  
ESI-TOF (negative mode) spectrum of methyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate. 
1
H NMR spectrum of ethyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate.  
13
C NMR spectrum of ethyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate.  
ESI-TOF (negative mode) spectrum of ethyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate. 
1
H NMR spectrum of 2-acetamido-2-deoxy-α-D-glucopyranosyl azide.  
13
C NMR spectrum of 2-acetamido-2-deoxy-α-D-glucopyranosyl azide. 
ESI-TOF (negative mode) spectrum of 2-acetamido-2-deoxy-α-D-glucopyranosyl azide. 
 
 
Original spectra of compounds prepared by chemical synthesis (in order): 
1
H NMR spectrum of methyl 4-S-acetyl-2,3,6-tri-O-benzoyl-4-thio-α-D-glucopyranoside. 
13
C NMR spectrum of methyl 4-S-acetyl-2,3,6-tri-O-benzoyl-4-thio-α-D-glucopyranoside. 
ESI-TOF (positive mode) spectrum of methyl 4-S-acetyl-2,3,6-tri-O-benzoyl-4-thio-α-D-glucopyranoside. 
1
H NMR spectrum of methyl 4-thio-α-D-glucopyranoside. 
13
C NMR spectrum of methyl 4-thio-α-D-glucopyranoside. 
ESI-TOF (negative mode) spectrum of methyl 4-thio-α-D-glucopyranoside. 
1
H NMR spectrum of methyl 4-S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-gluco-pyranosyl)-4-thio-3,4,6-tri-O-
benzoyl-α-D-glucopyranoside. 
13
C NMR spectrum of methyl 4-S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-gluco-pyranosyl)-4-thio-3,4,6-tri-O-
benzoyl-α-D-glucopyranoside. 
ESI-TOF (positive mode) spectrum of methyl 4-S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-gluco-pyranosyl)-4-
thio-3,4,6-tri-O-benzoyl-α-D-glucopyranoside. 
1
H NMR spectrum of methyl 4-S-(2-acetamido-2-deoxy-α-D-glucopyranosyl)-4-thio-α-D-glucopyranoside. 
13
C NMR spectrum of methyl 4-S-(2-acetamido-2-deoxy-α-D-glucopyranosyl)-4-thio-α-D-glucopyranoside. 
ESI-TOF (positive mode) spectrum of methyl 4-S-(2-acetamido-2-deoxy-α-D-glucopyranosyl)-4-thio-α-D-
glucopyranoside. 
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Phenyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside: 
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m/z
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2,2,2-Trifluoroethyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside: 
1
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2,2,2-Trifluoroethyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranoside: 
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m/z
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Methyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate: 
1
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Methyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate: 
13
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mass spectrum (ESI-TOF-) 
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Ethyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate: 
1
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Ethyl S-(2-acetamido-2-deoxy-α-D-glucopyranosyl) 2-thioacetate: 
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m/z





















mass spectrum (ESI-TOF-) 
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2-Acetamido-2-deoxy-α-D-glucopyranosyl azide: 
1
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2-Acetamido-2-deoxy-α-D-glucopyranosyl azide: 
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MN24
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Methyl 4-S-acetyl-2,3,6-tri-O-benzoyl-4-thio-α-D-glucopyranoside: 
1
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Methyl 4-S-acetyl-2,3,6-tri-O-benzoyl-4-thio-α-D-glucopyranoside: 
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NM013
m/z



























638.2069 644.1729 652.2246 685.2053
664.2437
688.2216
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Methyl 4-thio-α-D-glucopyranoside: 
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Methyl 4-thio-α-D-glucopyranoside: 
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Methyl 4-S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-gluco-pyranosyl)-4-thio-3,4,6-tri-O-benzoyl-α-D-glucopyranoside: 
1
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Methyl 4-S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-gluco-pyranosyl)-4-thio-3,4,6-tri-O-benzoyl-α-D-glucopyranoside: 
13
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m/z
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Methyl 4-S-(2-acetamido-2-deoxy-α-D-glucopyranosyl)-4-thio-α-D-glucopyranoside: 
1
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Methyl 4-S-(2-acetamido-2-deoxy-α-D-glucopyranosyl)-4-thio-α-D-glucopyranoside: 
13
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NM017
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